{
  "meta": {
    "id": "test5",
    "title": "Hematology & Tranfusion",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "A patient with blood type A requires a blood transfusion. Which of the following blood types could they safely receive?",
      "options": [
        {
          "label": "A",
          "text": "A and AB",
          "correct": false
        },
        {
          "label": "B",
          "text": "A and O",
          "correct": true
        },
        {
          "label": "C",
          "text": "A, B, and AB",
          "correct": false
        },
        {
          "label": "D",
          "text": "Only A",
          "correct": false
        }
      ],
      "correct_answer": "B. A and O",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) A and O</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. A and AB: Type AB blood contains B antigens, which would react with the recipient's anti-B antibodies, leading to a transfusion reaction.</li><li>\u2022 Option A. A and AB:</li><li>\u2022 Option C. A, B, and AB: Type B blood would also react with the recipient's anti-B antibodies.</li><li>\u2022 Option C. A, B, and AB:</li><li>\u2022 Option D. Only A: While type A blood is compatible, type O is also safe for transfusion to a person with type A blood.</li><li>\u2022 Option D. Only A:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Understanding ABO compatibility is crucial for safe blood transfusions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b207cefc",
      "audio": ""
    },
    {
      "text": "Which of the following genetic modifications on chromosome 9 leads to the formation of the B antigen?",
      "options": [
        {
          "label": "A",
          "text": "Addition of N-acetylgalactosamine (GalNAc) to the H antigen",
          "correct": false
        },
        {
          "label": "B",
          "text": "Addition of galactose (Gal) to the H antigen",
          "correct": true
        },
        {
          "label": "C",
          "text": "Removal of fucose from the H antigen",
          "correct": false
        },
        {
          "label": "D",
          "text": "Absence of both GalNAc and Gal on the H antigen",
          "correct": false
        }
      ],
      "correct_answer": "B. Addition of galactose (Gal) to the H antigen",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Addition of galactose (Gal) to the H antigen</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Addition of N-acetylgalactosamine (GalNAc) to the H antigen: This modification results in the formation of the A antigen.</li><li>\u2022 Option A. Addition of N-acetylgalactosamine (GalNAc) to the H antigen:</li><li>\u2022 Option C. Removal of fucose from the H antigen: While removal of fucose is a step in the formation of both A and B antigens, it's not the final step for the B antigen.</li><li>\u2022 Option C. Removal of fucose from the H antigen:</li><li>\u2022 Option D. Absence of both GalNAc and Gal on the H antigen: This results in the O blood group, where neither A nor B antigens are present.</li><li>\u2022 Option D. Absence of both GalNAc and Gal on the H antigen:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The A and B antigens are formed by modifications of the H antigen.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a78bcb7",
      "audio": ""
    },
    {
      "text": "Which of the following Rh antigens is the most immunogenic, leading to the highest risk of alloimmunization in Rh-negative individuals?",
      "options": [
        {
          "label": "A",
          "text": "C antigen",
          "correct": false
        },
        {
          "label": "B",
          "text": "E antigen",
          "correct": false
        },
        {
          "label": "C",
          "text": "c antigen",
          "correct": false
        },
        {
          "label": "D",
          "text": "D antigen",
          "correct": true
        }
      ],
      "correct_answer": "D. D antigen",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) D antigen</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. C antigen: While the C antigen can be immunogenic, it is less so than the D antigen. Anti-C antibodies are relatively common, but they usually cause milder reactions than anti-D antibodies.</li><li>\u2022 Option A. C antigen:</li><li>\u2022 Option B. E antigen: Similar to the C antigen, the E antigen is immunogenic but less so than the D antigen. Anti-E antibodies are less common than anti-C antibodies and generally cause less severe reactions.</li><li>\u2022 Option B. E antigen:</li><li>\u2022 Option C. c antigen: The c antigen is the most common Rh antigen (80% of the population expresses it). However, it is considered weakly immunogenic, and anti-c antibodies are relatively rare.</li><li>\u2022 Option C. c antigen:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The D antigen is the most immunogenic, posing the highest risk of alloimmunization in Rh-negative individuals. Understanding the Rh system and its genetic basis is crucial for safe blood transfusions and preventing complications like hemolytic disease of the newborn.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f5ba8a6c",
      "audio": ""
    },
    {
      "text": "A patient with blood type AB positive requires a plasma transfusion. Which of the following blood types could be safely used as a source of fresh frozen plasma (FFP)?",
      "options": [
        {
          "label": "A",
          "text": "Only O",
          "correct": false
        },
        {
          "label": "B",
          "text": "Only AB",
          "correct": true
        },
        {
          "label": "C",
          "text": "A, B, AB, and O - all types",
          "correct": false
        },
        {
          "label": "D",
          "text": "Only A and B",
          "correct": false
        }
      ],
      "correct_answer": "B. Only AB",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Only AB</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5e265d4e",
      "audio": ""
    },
    {
      "text": "In a trauma setting where blood typing is not immediately available, which blood type is typically used for emergency transfusion?",
      "options": [
        {
          "label": "A",
          "text": "AB negative",
          "correct": false
        },
        {
          "label": "B",
          "text": "A positive",
          "correct": false
        },
        {
          "label": "C",
          "text": "B positive",
          "correct": false
        },
        {
          "label": "D",
          "text": "O negative",
          "correct": true
        }
      ],
      "correct_answer": "D. O negative",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) O negative</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. AB negative: AB negative blood contains both A and B antigens, which could cause a serious reaction if the recipient has antibodies against either of these antigens.</li><li>\u2022 Option A. AB negative:</li><li>\u2022 Option B. A positive: A positive blood contains A antigens and the Rh factor, both of which could trigger a transfusion reaction in a recipient without these antigens.</li><li>\u2022 Option B. A positive:</li><li>\u2022 Option C. B positive: B positive blood contains B antigens and the Rh factor, making it unsuitable for transfusion to individuals who lack these antigens.</li><li>\u2022 Option C. B positive:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 O negative blood is the universal red blood cell donor, making it the preferred choice for emergency transfusions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "54cacddd",
      "audio": ""
    },
    {
      "text": "A 30-year-old woman with blood type B negative requires an emergency blood transfusion due to severe hemorrhage. Which of the following blood types could be safely administered?",
      "options": [
        {
          "label": "A",
          "text": "B positive and B negative",
          "correct": false
        },
        {
          "label": "B",
          "text": "AB negative and O negative",
          "correct": false
        },
        {
          "label": "C",
          "text": "B negative and O positive",
          "correct": false
        },
        {
          "label": "D",
          "text": "Only B negative",
          "correct": true
        }
      ],
      "correct_answer": "D. Only B negative",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Only B negative</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. B positive and B negative: B positive blood has the RhD antigen, which the recipient could develop antibodies against, leading to potential complications in future transfusions or pregnancies.</li><li>\u2022 Option A. B positive and B negative:</li><li>\u2022 Option B. AB negative and O negative: AB negative blood contains A antigens, which would react with the recipient's anti-A antibodies.</li><li>\u2022 Option B. AB negative and O negative:</li><li>\u2022 Option C. B negative and O positive: O positive blood contains the RhD antigen, which the recipient could develop antibodies against.</li><li>\u2022 Option C. B negative and O positive:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 It is crucial to match both ABO and Rh blood groups to ensure safe transfusions, especially in emergency situations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ebaec015",
      "audio": ""
    },
    {
      "text": "A patient experiences a delayed hemolytic transfusion reaction (DHTR) 5 days after a blood transfusion. Which of the following blood group systems is most likely responsible?",
      "options": [
        {
          "label": "A",
          "text": "Kell",
          "correct": false
        },
        {
          "label": "B",
          "text": "Kidd",
          "correct": true
        },
        {
          "label": "C",
          "text": "MNS",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lewis",
          "correct": false
        }
      ],
      "correct_answer": "B. Kidd",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Kidd</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Kell: While Kell antibodies can cause severe hemolytic reactions, these are typically acute rather than delayed.</li><li>\u2022 Option A. Kell:</li><li>\u2022 Option C. MNS: MNS antibodies can cause delayed hemolytic transfusion reactions, but they are relatively rare compared to Kidd antibodies.</li><li>\u2022 Option C. MNS:</li><li>\u2022 Option D. Lewis: Lewis antibodies are naturally occurring and typically of the IgM isotype, which are generally not considered clinically significant in transfusions.</li><li>\u2022 Option D. Lewis:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Kidd antibodies are typically IgG and can cause severe delayed reactions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "95e579c7",
      "audio": ""
    },
    {
      "text": "Which of the following blood group antigens can be acquired by donor red blood cells (RBCs) soon after transfusion?",
      "options": [
        {
          "label": "A",
          "text": "Duffy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Kidd",
          "correct": false
        },
        {
          "label": "C",
          "text": "MNS",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lewis",
          "correct": true
        }
      ],
      "correct_answer": "D. Lewis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Lewis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Duffy: Duffy antigens are also integral membrane proteins of red blood cells and are not passively acquired.</li><li>\u2022 Option A. Duffy:</li><li>\u2022 Option B. Kidd: Kidd antigens are similarly integral membrane proteins and are not acquired from the plasma.</li><li>\u2022 Option B. Kidd:</li><li>\u2022 Option C. MNS: MNS antigens are part of the red blood cell glycophorin complex and are not acquired from the plasma.</li><li>\u2022 Option C. MNS:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Lewis antigens are not intrinsic to RBCs but are acquired from the plasma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5cabc4d1",
      "audio": ""
    },
    {
      "text": "Which of the following antigen is resistant to P. vivax/knowlesi?",
      "options": [
        {
          "label": "A",
          "text": "K/k",
          "correct": false
        },
        {
          "label": "B",
          "text": "DARC (Duffy Antigen Receptor for Chemokines)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Lewis Ag",
          "correct": false
        },
        {
          "label": "D",
          "text": "A antigen",
          "correct": false
        }
      ],
      "correct_answer": "B. DARC (Duffy Antigen Receptor for Chemokines)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) DARC (Duffy Antigen Receptor for Chemokines)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. K/k: Kell antigens are a group of antigens found on red blood cells. They are not involved in malaria resistance.</li><li>\u2022 Option A. K/k:</li><li>\u2022 Option C. Lewis Ag: Lewis antigens are present in body fluids and can be adsorbed onto red blood cells. They do not play a role in malaria resistance.</li><li>\u2022 Option C. Lewis Ag:</li><li>\u2022 Option D. A antigen: The A antigen is part of the ABO blood group system and determines blood type. It has no relationship to malaria susceptibility.</li><li>\u2022 Option D. A antigen:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The Duffy antigen receptor for chemokines (DARC) is essential for P. vivax and P. knowlesi malaria parasites to invade red blood cells. Individuals without this receptor are naturally resistant to these types of malaria.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6d76ab14",
      "audio": ""
    },
    {
      "text": "What is the primary goal of a blood crossmatch?",
      "options": [
        {
          "label": "A",
          "text": "Determine the blood type of the donor",
          "correct": false
        },
        {
          "label": "B",
          "text": "Determine the blood type of the recipient",
          "correct": false
        },
        {
          "label": "C",
          "text": "Detect unexpected antibodies in the recipient's serum",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ensure compatibility between donor red blood cells and recipient serum",
          "correct": true
        }
      ],
      "correct_answer": "D. Ensure compatibility between donor red blood cells and recipient serum",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Ensure compatibility between donor red blood cells and recipient serum</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Determine the blood type of the donor: Blood typing is a separate test performed prior to crossmatching to determine the donor's ABO and Rh blood group.</li><li>\u2022 Option A. Determine the blood type of the donor:</li><li>\u2022 Option B. Determine the blood type of the recipient: Similar to donor typing, recipient blood typing is done prior to crossmatching.</li><li>\u2022 Option B. Determine the blood type of the recipient:</li><li>\u2022 Option C. Detect unexpected antibodies in the recipient's serum: While crossmatching can detect unexpected antibodies, this is primarily the purpose of an antibody screen, a separate test performed before crossmatching.</li><li>\u2022 Option C. Detect unexpected antibodies in the recipient's serum:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Crossmatching is essential for ensuring safe blood transfusions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f00a9f64",
      "audio": ""
    },
    {
      "text": "A patient's blood sample is mixed with Anit-A/B/D and the findings are shown below. What is the patient's blood type?",
      "options": [
        {
          "label": "A",
          "text": "A+",
          "correct": false
        },
        {
          "label": "B",
          "text": "B+",
          "correct": true
        },
        {
          "label": "C",
          "text": "AB+",
          "correct": false
        },
        {
          "label": "D",
          "text": "O-",
          "correct": false
        }
      ],
      "correct_answer": "B. B+",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/01/screenshot-2024-08-01-103344.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) B+</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c593a786",
      "audio": ""
    },
    {
      "text": "A patient's blood sample is mixed with Anit-A/B/D and the findings are shown below. What is the patient's blood type?",
      "options": [
        {
          "label": "A",
          "text": "A+",
          "correct": false
        },
        {
          "label": "B",
          "text": "B-",
          "correct": false
        },
        {
          "label": "C",
          "text": "AB-",
          "correct": false
        },
        {
          "label": "D",
          "text": "O-",
          "correct": true
        }
      ],
      "correct_answer": "D. O-",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/01/screenshot-2024-08-01-103851.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) O-</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c593a786",
      "audio": ""
    },
    {
      "text": "What is the maximum storage duration for PRBCs at 2-6\u00b0C?",
      "options": [
        {
          "label": "A",
          "text": "21 days",
          "correct": false
        },
        {
          "label": "B",
          "text": "35 days",
          "correct": false
        },
        {
          "label": "C",
          "text": "42 days",
          "correct": true
        },
        {
          "label": "D",
          "text": "56 days",
          "correct": false
        }
      ],
      "correct_answer": "C. 42 days",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 42 days</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8b987ea6",
      "audio": ""
    },
    {
      "text": "A patient with acute blood loss and a hemoglobin (Hb) of 7 g/dL is in need of a blood transfusion. How many units of PRBCs should be transfused to raise the Hb to approximately 10 g/dL?",
      "options": [
        {
          "label": "A",
          "text": "1 unit",
          "correct": false
        },
        {
          "label": "B",
          "text": "2 units",
          "correct": false
        },
        {
          "label": "C",
          "text": "3 units",
          "correct": true
        },
        {
          "label": "D",
          "text": "4 units",
          "correct": false
        }
      ],
      "correct_answer": "C. 3 units",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 3 units</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e715c5f6",
      "audio": ""
    },
    {
      "text": "A 45-year-old patient is admitted to the ICU with acute coronary syndrome (ACS) and a hemoglobin level of 8.5 g/dL. What is the most appropriate transfusion threshold for this patient?",
      "options": [
        {
          "label": "A",
          "text": "7 g/dL",
          "correct": false
        },
        {
          "label": "B",
          "text": "8 g/dL",
          "correct": false
        },
        {
          "label": "C",
          "text": "8-10 g/dL",
          "correct": true
        },
        {
          "label": "D",
          "text": "10 g/dL",
          "correct": false
        }
      ],
      "correct_answer": "C. 8-10 g/dL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 8-10 g/dL</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. 7 g/dL: This is too low of a threshold for a patient with acute coronary syndrome (ACS). Transfusing at this level might not be necessary and could expose the patient to unnecessary risks associated with blood transfusion.</li><li>\u2022 Option A. 7 g/dL:</li><li>\u2022 Option B. 8 g/dL: While this could be considered in some cases, it might not be optimal for all ACS patients, especially those with ongoing ischemia or hemodynamic instability.</li><li>\u2022 Option B. 8 g/dL:</li><li>\u2022 Option D. 10 g/dL: This is a higher threshold typically used for stable patients or those without significant cardiac comorbidities. In ACS, a slightly lower threshold is often preferred to ensure adequate oxygen delivery to the heart.</li><li>\u2022 Option D. 10 g/dL:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Transfusion thresholds for ACS patients may be individualized within a recommended range.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a0658bdb",
      "audio": ""
    },
    {
      "text": "Which blood additive provides the longest shelf life for stored red blood cells?",
      "options": [
        {
          "label": "A",
          "text": "ACD (Acid citrate dextrose)",
          "correct": false
        },
        {
          "label": "B",
          "text": "CPD (Citrate phosphate dextrose)",
          "correct": false
        },
        {
          "label": "C",
          "text": "CP2D (Citrate phosphate double dextrose)",
          "correct": false
        },
        {
          "label": "D",
          "text": "SAGM (Saline adenine glucose mannitol)",
          "correct": true
        }
      ],
      "correct_answer": "D. SAGM (Saline adenine glucose mannitol)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) SAGM (Saline adenine glucose mannitol)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. ACD (Acid citrate dextrose): This was one of the earliest preservatives and has a relatively short shelf life (21 days). The citrate acts as an anticoagulant, while dextrose provides energy for the red blood cells.</li><li>\u2022 Option A. ACD (Acid citrate dextrose):</li><li>\u2022 Option B. CPD (Citrate phosphate dextrose): This is an improvement over ACD due to the addition of phosphate, which acts as a buffer to maintain pH. However, it still has a relatively short shelf life (21 days).</li><li>\u2022 Option B. CPD (Citrate phosphate dextrose):</li><li>\u2022 Option C. CP2D (Citrate phosphate double dextrose): This has double the amount of dextrose compared to CPD, providing more energy for the red blood cells and extending the shelf life slightly (28 days).</li><li>\u2022 Option C. CP2D (Citrate phosphate double dextrose):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 SAGM is the additive that provides the longest shelf life for stored red blood cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "023f9f0e",
      "audio": ""
    },
    {
      "text": "The addition of adenine to CPD (CPDA-1) results in:",
      "options": [
        {
          "label": "A",
          "text": "Increased red blood cell survival due to enhanced glycolysis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Improved pH buffering capacity",
          "correct": false
        },
        {
          "label": "C",
          "text": "Prevention of osmotic lysis of red blood cells",
          "correct": false
        },
        {
          "label": "D",
          "text": "Provision of ATP for extended red blood cell survival",
          "correct": true
        }
      ],
      "correct_answer": "D. Provision of ATP for extended red blood cell survival",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Provision of ATP for extended red blood cell survival</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increased red blood cell survival due to enhanced glycolysis: Adenine doesn't directly enhance glycolysis (the breakdown of glucose for energy). Glucose in the additive solution is the primary energy source for red blood cells during storage.</li><li>\u2022 Option A. Increased red blood cell survival due to enhanced glycolysis:</li><li>\u2022 Option B. Improved pH buffering capacity: The phosphate in CPD and CPDA-1 acts as the primary buffer to maintain a stable pH during storage. Adenine does not have a significant buffering effect.</li><li>\u2022 Option B. Improved pH buffering capacity:</li><li>\u2022 Option C. Prevention of osmotic lysis of red blood cells: Osmotic lysis is primarily prevented by maintaining the correct balance of electrolytes and osmotic pressure in the solution, not by adenine.</li><li>\u2022 Option C. Prevention of osmotic lysis of red blood cells:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Adenine improves the quality of stored red blood cells by providing ATP.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "821b60b2",
      "audio": ""
    },
    {
      "text": "What is the main advantage of single-donor platelets (SDPs) over random-donor platelets (RDPs)?",
      "options": [
        {
          "label": "A",
          "text": "Lower cost",
          "correct": false
        },
        {
          "label": "B",
          "text": "Reduced risk of alloimmunization",
          "correct": true
        },
        {
          "label": "C",
          "text": "Higher platelet increment",
          "correct": false
        },
        {
          "label": "D",
          "text": "Longer shelf life",
          "correct": false
        }
      ],
      "correct_answer": "B. Reduced risk of alloimmunization",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Reduced risk of alloimmunization</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Lower cost: SDPs are typically more expensive to produce than RDPs because they require apheresis, a specialized blood collection procedure.</li><li>\u2022 Option A. Lower cost:</li><li>\u2022 Option C. Higher platelet increment: While some studies have shown slightly higher platelet increments with SDPs, the difference is not always clinically significant, and the overall efficacy in preventing bleeding is similar between SDPs and RDPs.</li><li>\u2022 Option C. Higher platelet increment:</li><li>\u2022 Option D. Longer shelf life: Both SDPs and RDPs have similar shelf lives, typically around 5 days when stored properly.</li><li>\u2022 Option D. Longer shelf life:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 SDPs are preferred to reduce the risk of alloimmunization in patients who may require multiple transfusions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8cca6c13",
      "audio": ""
    },
    {
      "text": "Which of the Following is not a contraindication for platelet transfusion?",
      "options": [
        {
          "label": "A",
          "text": "TTP (Thrombotic Thrombocytopenic Purpura)",
          "correct": false
        },
        {
          "label": "B",
          "text": "HUS (Hemolytic Uremic Syndrome)",
          "correct": false
        },
        {
          "label": "C",
          "text": "ITP (Immune Thrombocytopenia)",
          "correct": true
        },
        {
          "label": "D",
          "text": "HELLP Syndrome",
          "correct": false
        }
      ],
      "correct_answer": "C. ITP (Immune Thrombocytopenia)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) ITP (Immune Thrombocytopenia).</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. TTP (Thrombotic Thrombocytopenic Purpura): Platelet transfusion is contraindicated in TTP because it can worsen the microvascular thrombosis, which is the primary cause of organ damage in this condition.</li><li>\u2022 Option A. TTP (Thrombotic Thrombocytopenic Purpura):</li><li>\u2022 Option B. HUS (Hemolytic Uremic Syndrome): Similar to TTP, platelet transfusion can exacerbate the thrombotic process in HUS and is generally avoided.</li><li>\u2022 Option B. HUS (Hemolytic Uremic Syndrome):</li><li>\u2022 Option D. HELLP Syndrome: Platelet transfusion is typically reserved for severe thrombocytopenia (<20,000/\u00b5L) or active bleeding in HELLP syndrome, as it doesn't address the underlying cause of the condition.</li><li>\u2022 Option D. HELLP Syndrome:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Platelet transfusion is generally contraindicated in conditions where it could worsen thrombosis (TTP, HUS) but may be considered in specific situations like life-threatening bleeding in ITP.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "23954dd3",
      "audio": ""
    },
    {
      "text": "A patient receiving platelet transfusions shows a corrected count increment (CCI) of 3,500/\u00b5L one hour after transfusion and 2,500/\u00b5L at 20 hours. Which of the following is the most likely cause of this refractoriness?",
      "options": [
        {
          "label": "A",
          "text": "Sepsis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fever",
          "correct": false
        },
        {
          "label": "C",
          "text": "Immune thrombocytopenic purpura (ITP)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hypersplenism",
          "correct": false
        }
      ],
      "correct_answer": "C. Immune thrombocytopenic purpura (ITP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Immune thrombocytopenic purpura (ITP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Sepsis and Option B. Fever: While sepsis and fever can cause increased platelet consumption, they typically don't result in such a low CCI at both time points. Additionally, the patient's clinical presentation would likely provide clues to these conditions.</li><li>\u2022 Option A. Sepsis</li><li>\u2022 Option B. Fever:</li><li>\u2022 Option D. Hypersplenism: Hypersplenism, an enlarged spleen, can sequester platelets, leading to thrombocytopenia. However, it usually doesn't cause the rapid decline in platelet count seen in ITP, where active immune-mediated destruction is occurring.</li><li>\u2022 Option D. Hypersplenism:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Platelet refractoriness with low CCI at 1 and 20 hours suggests immune-mediated platelet destruction.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "715a1207",
      "audio": ""
    },
    {
      "text": "A patient with severe liver disease presents with a prolonged prothrombin time (PT) and is scheduled for an invasive procedure. Which of the following is the most appropriate blood product for correcting their coagulopathy?",
      "options": [
        {
          "label": "A",
          "text": "Cryoprecipitate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prothrombin complex concentrate (PCC)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fresh frozen plasma (FFP)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Platelet concentrate",
          "correct": false
        }
      ],
      "correct_answer": "C. Fresh frozen plasma (FFP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Fresh frozen plasma (FFP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Cryoprecipitate: While cryoprecipitate is a source of fibrinogen and factor VIII, it would not address the multiple coagulation factor deficiencies commonly seen in liver disease.</li><li>\u2022 Option A. Cryoprecipitate:</li><li>\u2022 Option B. Prothrombin Complex Concentrate (PCC): PCC contains vitamin K-dependent clotting factors (II, VII, IX, and X), but patients with liver disease may also have deficiencies in other factors not included in PCC.</li><li>\u2022 Option B. Prothrombin Complex Concentrate (PCC):</li><li>\u2022 Option D. Platelet concentrate: Platelets are used to treat thrombocytopenia (low platelet count), not coagulation factor deficiencies. While liver disease can cause thrombocytopenia, it is not the primary concern in this scenario where the patient has a prolonged PT.</li><li>\u2022 Option D. Platelet concentrate:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 FFP is the preferred blood product for correcting coagulopathy in liver disease due to its comprehensive coagulation factor content.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d11d86b",
      "audio": ""
    },
    {
      "text": "What is the typical percentage increase in clotting factor levels expected after one unit of FFP transfusion?",
      "options": [
        {
          "label": "A",
          "text": "10%",
          "correct": false
        },
        {
          "label": "B",
          "text": "20%",
          "correct": false
        },
        {
          "label": "C",
          "text": "30%",
          "correct": true
        },
        {
          "label": "D",
          "text": "40%",
          "correct": false
        }
      ],
      "correct_answer": "C. 30%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 30%</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. 10%: This is too low of an increase. FFP contains a significant amount of clotting factors, and a single unit typically raises levels by more than 10%.</li><li>\u2022 Option A. 10%:</li><li>\u2022 Option B. 20%: This is also too low of an increase. The expected increase is generally closer to 30%.</li><li>\u2022 Option B. 20%:</li><li>\u2022 Option D. 40%: This is an overestimation of the increase. While FFP does contain clotting factors, the volume transfused and the recipient's plasma volume will affect the overall percentage increase.</li><li>\u2022 Option D. 40%:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 FFP provides a moderate increase in clotting factor levels and is suitable for most coagulopathies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "af8b9f9c",
      "audio": ""
    },
    {
      "text": "A patient with von Willebrand disease (vWD) is experiencing a bleeding episode. Which of the following blood products is most appropriate for managing this patient's bleeding?",
      "options": [
        {
          "label": "A",
          "text": "Fresh frozen plasma (FFP)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prothrombin complex concentrate (PCC)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cryoprecipitate",
          "correct": true
        },
        {
          "label": "D",
          "text": "Platelets",
          "correct": false
        }
      ],
      "correct_answer": "C. Cryoprecipitate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Cryoprecipitate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Fresh frozen plasma (FFP): While FFP contains vWF and factor VIII, the concentrations are lower than in cryoprecipitate. Thus, a larger volume of FFP would be needed to achieve the same therapeutic effect, potentially increasing the risk of volume overload.</li><li>\u2022 Option A. Fresh frozen plasma (FFP):</li><li>\u2022 Option B. Prothrombin complex concentrate (PCC): PCC contains vitamin K-dependent clotting factors (II, VII, IX, and X) but does not contain vWF or factor VIII. It is not indicated for vWD.</li><li>\u2022 Option B. Prothrombin complex concentrate (PCC):</li><li>\u2022 Option D. Platelets: Platelets are primarily used to treat thrombocytopenia (low platelet count), not deficiencies in vWF or factor VIII. While vWD can affect platelet function, the primary defect is in vWF, which is necessary for platelet adhesion and aggregation</li><li>\u2022 Option D. Platelets:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Cryoprecipitate is the preferred treatment for bleeding in vWD due to its high concentration of vWF and factor VIII.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7bfc3199",
      "audio": ""
    },
    {
      "text": "What is the recommended minimum irradiation dose for the center of a blood product bag to prevent TA-GVHD?",
      "options": [
        {
          "label": "A",
          "text": "15 Gy",
          "correct": false
        },
        {
          "label": "B",
          "text": "25 Gy",
          "correct": true
        },
        {
          "label": "C",
          "text": "35 Gy",
          "correct": false
        },
        {
          "label": "D",
          "text": "50 Gy",
          "correct": false
        }
      ],
      "correct_answer": "B. 25 Gy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 25 Gy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. 15 Gy: This dose is insufficient to reliably inactivate all donor lymphocytes in the blood product, which is necessary to prevent TA-GVHD.</li><li>\u2022 Option A. 15 Gy:</li><li>\u2022 Option C. 35 Gy and Option D. 50 Gy: While these higher doses would effectively prevent TA-GVHD, they are unnecessary and could cause excessive damage to red blood cells, potentially compromising their functionality and lifespan.</li><li>\u2022 Option C. 35 Gy</li><li>\u2022 Option D. 50 Gy:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The irradiation dose for blood products is standardized to ensure effective prevention of TA-GVHD while minimizing damage to blood components.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "df20dea2",
      "audio": ""
    },
    {
      "text": "What is the optimal timing for leukoreduction?",
      "options": [
        {
          "label": "A",
          "text": "Immediately before transfusion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Within 3-5 days of blood collection",
          "correct": true
        },
        {
          "label": "C",
          "text": "After 5 days of blood collection",
          "correct": false
        },
        {
          "label": "D",
          "text": "The timing of leukoreduction does not matter",
          "correct": false
        }
      ],
      "correct_answer": "B. Within 3-5 days of blood collection",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Within 3-5 days of blood collection</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "16c00034",
      "audio": ""
    },
    {
      "text": "A patient with a history of severe febrile non-hemolytic transfusion reactions (FNHTR) is scheduled for surgery and requires a red blood cell (RBC) transfusion. The blood bank is unable to provide leukoreduced RBCs due to limited supply. Which of the following alternative methods could be considered to potentially reduce the risk of FNHTR in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Irradiation of RBCs",
          "correct": false
        },
        {
          "label": "B",
          "text": "Washing of RBCs",
          "correct": false
        },
        {
          "label": "C",
          "text": "UVB-treated RBCs",
          "correct": true
        },
        {
          "label": "D",
          "text": "Plasmapheresis of RBCs",
          "correct": false
        }
      ],
      "correct_answer": "C. UVB-treated RBCs",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) UVB-treated RBCs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Irradiation of RBCs: Irradiation is primarily used to prevent transfusion-associated graft-versus-host disease (TA-GVHD) in immunocompromised patients. It does not specifically address the risk of FNHTR.</li><li>\u2022 Option A. Irradiation of RBCs:</li><li>\u2022 Option B. Washing of RBCs: Washing RBCs can remove some plasma proteins and antibodies, which may be helpful in preventing allergic reactions. However, it is not as effective as leukoreduction in preventing FNHTR, which is primarily caused by cytokines released from white blood cells.</li><li>\u2022 Option B. Washing of RBCs:</li><li>\u2022 Option D. Plasmapheresis of RBCs: Plasmapheresis is a procedure that separates plasma from blood cells and is not relevant to reducing the risk of FNHTR.</li><li>\u2022 Option D. Plasmapheresis of RBCs:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 UVB-treated RBCs may be considered as an alternative to leukoreduced RBCs in situations where leukoreduction is not feasible or unavailable. However, the efficacy of UVB treatment in preventing FNHTR is still under investigation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b9fc309e",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman presents with a history of recurrent bacterial infections and is found to have low IgG levels. Which of the following is the most appropriate treatment option for her condition?",
      "options": [
        {
          "label": "A",
          "text": "Plasmapheresis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Corticosteroids",
          "correct": false
        },
        {
          "label": "C",
          "text": "Intravenous immunoglobulin (IVIG)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Rituximab",
          "correct": false
        }
      ],
      "correct_answer": "C. Intravenous immunoglobulin (IVIG)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Intravenous immunoglobulin (IVIG)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Plasmapheresis: This is used to remove harmful substances from blood and is not indicated in this case.</li><li>\u2022 Option A. Plasmapheresis:</li><li>\u2022 Option B. Corticosteroids: While corticosteroids have immunomodulatory effects, they are not the first-line treatment for hypogammaglobulinemia.</li><li>\u2022 Option B. Corticosteroids:</li><li>\u2022 Option D. Rituximab: This is a monoclonal antibody targeting CD20-positive B cells and is not indicated for primary immunodeficiency.</li><li>\u2022 Option D. Rituximab:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 IVIG is a crucial therapy for patients with primary immunodeficiencies, providing passive immunity by supplementing IgG levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b5e5da7f",
      "audio": ""
    },
    {
      "text": "A patient with Waldenstr\u00f6m macroglobulinemia (WM) presents with hyperviscosity syndrome. Which of the following is the most appropriate initial therapeutic intervention?",
      "options": [
        {
          "label": "A",
          "text": "Plasmapheresis",
          "correct": true
        },
        {
          "label": "B",
          "text": "Corticosteroids",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rituximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Splenectomy",
          "correct": false
        }
      ],
      "correct_answer": "A. Plasmapheresis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Plasmapheresis</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4ff18327",
      "audio": ""
    },
    {
      "text": "In a standard TPE procedure, what is the recommended plasma volume that has to be exchanged?",
      "options": [
        {
          "label": "A",
          "text": "0.5-1",
          "correct": false
        },
        {
          "label": "B",
          "text": "1-1.5",
          "correct": true
        },
        {
          "label": "C",
          "text": "2-3",
          "correct": false
        },
        {
          "label": "D",
          "text": "3-5",
          "correct": false
        }
      ],
      "correct_answer": "B. 1-1.5",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 1-1.5</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "77559ae8",
      "audio": ""
    },
    {
      "text": "According to the Advanced Trauma Life Support (ATLS) definition, massive transfusion is defined as:",
      "options": [
        {
          "label": "A",
          "text": "Transfusion of >5 units of packed red blood cells (PRBCs) in 24 hours",
          "correct": false
        },
        {
          "label": "B",
          "text": "Transfusion of >10 units of PRBCs in 24 hours",
          "correct": true
        },
        {
          "label": "C",
          "text": "Transfusion of any amount of PRBCs in a patient with hemorrhagic shock",
          "correct": false
        },
        {
          "label": "D",
          "text": "Transfusion of PRBCs, platelets, and plasma in a 1:1:1 ratio",
          "correct": false
        }
      ],
      "correct_answer": "B. Transfusion of >10 units of PRBCs in 24 hours",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Transfusion of >10 units of PRBCs in 24 hours</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "850e13fe",
      "audio": ""
    },
    {
      "text": "A patient with a history of liver disease receives a massive blood transfusion. Which complication should be monitored closely due to the presence of citrate in transfused blood?",
      "options": [
        {
          "label": "A",
          "text": "Hypothermia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hyperkalemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hypocalcemia and metabolic alkalosis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Thrombocytopenia",
          "correct": false
        }
      ],
      "correct_answer": "C. Hypocalcemia and metabolic alkalosis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Hypocalcemia and metabolic alkalosis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Hypothermia: Hypothermia can be a complication of massive transfusion, but it's primarily caused by the rapid infusion of cold blood products, not the citrate preservative.</li><li>\u2022 Option A. Hypothermia:</li><li>\u2022 Option B. Hyperkalemia: While hyperkalemia can occur during massive transfusion, it's usually due to the breakdown of red blood cells releasing potassium, not the citrate itself.</li><li>\u2022 Option B. Hyperkalemia:</li><li>\u2022 Option D. Thrombocytopenia: Thrombocytopenia (low platelet count) can occur due to dilution from massive transfusion or consumption of platelets in trauma or sepsis. It's not directly related to citrate.</li><li>\u2022 Option D. Thrombocytopenia:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Patients with liver disease are at increased risk for hypocalcemia and metabolic alkalosis following blood transfusion due to impaired citrate metabolism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8777aaf3",
      "audio": ""
    },
    {
      "text": "A patient receiving a massive transfusion develops bleeding and prolonged PT/aPTT/ increased INR. Which of the following is the most likely cause?",
      "options": [
        {
          "label": "A",
          "text": "Citrate toxicity",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypothermia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hyperkalemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dilution of clotting factors",
          "correct": true
        }
      ],
      "correct_answer": "D. Dilution of clotting factors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Dilution of clotting factors</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Citrate toxicity: While citrate, used as an anticoagulant in blood products, can bind calcium and potentially affect coagulation, it's less likely to be the primary cause of bleeding and prolonged clotting times in massive transfusion. Citrate toxicity usually manifests with hypocalcemia (low calcium levels), tingling sensations, and muscle cramps.</li><li>\u2022 Option A. Citrate toxicity:</li><li>\u2022 Option B. Hypothermia: Hypothermia can exacerbate coagulopathy, but it's more likely to slow down enzymatic reactions and platelet function rather than directly causing a deficiency in clotting factors.</li><li>\u2022 Option B. Hypothermia:</li><li>\u2022 Option C. Hyperkalemia: Hyperkalemia (high potassium levels) can occur in massive transfusion due to the breakdown of red blood cells. However, it primarily affects cardiac function and does not directly cause coagulopathy.</li><li>\u2022 Option C. Hyperkalemia:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Dilution of clotting factors is a common complication of massive transfusion and requires close monitoring and appropriate intervention.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "abe7d0e1",
      "audio": ""
    },
    {
      "text": "A patient develops fever, chills, flank pain, and hypotension after starting a red blood cell transfusion. Urine output is significantly reduced, and the urine appears dark. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Febrile non-hemolytic transfusion reaction (FNHTR)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Transfusion-related acute lung injury (TRALI)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Allergic transfusion reaction",
          "correct": false
        },
        {
          "label": "D",
          "text": "Acute hemolytic transfusion reaction (AHTR)",
          "correct": true
        }
      ],
      "correct_answer": "D. Acute hemolytic transfusion reaction (AHTR)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Acute hemolytic transfusion reaction (AHTR)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Febrile non-hemolytic transfusion reaction (FNHTR): While FNHTR is the most common transfusion reaction, it typically presents with fever and chills but not hypotension, flank pain, or dark urine.</li><li>\u2022 Option A. Febrile non-hemolytic transfusion reaction (FNHTR):</li><li>\u2022 Option B. Transfusion-related acute lung injury (TRALI): TRALI is characterized by acute respiratory distress (e.g., dyspnea, hypoxemia) and non-cardiogenic pulmonary edema, which are not present in this case.</li><li>\u2022 Option B. Transfusion-related acute lung injury (TRALI):</li><li>\u2022 Option C. Allergic transfusion reaction: Allergic reactions usually manifest with urticaria (hives), itching, and sometimes bronchospasm. They typically do not cause flank pain, dark urine, or significant hypotension.</li><li>\u2022 Option C. Allergic transfusion reaction:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 AHTR is a life-threatening emergency requiring immediate recognition and intervention.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e3c1618f",
      "audio": ""
    },
    {
      "text": "Which of the following is the most common cause of acute hemolytic transfusion reactions (AHTR)?",
      "options": [
        {
          "label": "A",
          "text": "ABO incompatibility",
          "correct": true
        },
        {
          "label": "B",
          "text": "Rh incompatibility",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti-Kell antibodies",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti-Jka antibodies",
          "correct": false
        }
      ],
      "correct_answer": "A. ABO incompatibility",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) ABO incompatibility</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Rh incompatibility: While Rh incompatibility can cause hemolytic disease of the newborn (HDN) and delayed hemolytic transfusion reactions, it is less common as a cause of acute hemolytic reactions compared to ABO incompatibility.</li><li>\u2022 Option B. Rh incompatibility:</li><li>\u2022 Option C. Anti-Kell antibodies: Anti-Kell antibodies can cause severe hemolytic transfusion reactions, both acute and delayed, but they are much rarer than ABO incompatibility.</li><li>\u2022 Option C. Anti-Kell antibodies:</li><li>\u2022 Option D. Anti-Jka antibodies: Anti-Jka antibodies (part of the Kidd blood group system) can cause delayed hemolytic transfusion reactions, but they are less common than ABO incompatibility as a cause of acute reactions.</li><li>\u2022 Option D. Anti-Jka antibodies:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Careful pre-transfusion testing for ABO compatibility is crucial for preventing AHTR.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "95bf41d7",
      "audio": ""
    },
    {
      "text": "Which of the following is the primary mechanism behind febrile non-hemolytic transfusion reactions (FNHTR)?",
      "options": [
        {
          "label": "A",
          "text": "Recipient antibodies reacting with donor white blood cells (WBCs)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Recipient antibodies reacting with donor red blood cells (RBCs)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cytokines released from donor WBCs during storage",
          "correct": false
        },
        {
          "label": "D",
          "text": "Both A and C",
          "correct": true
        }
      ],
      "correct_answer": "D. Both A and C",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Both A and C</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Recipient antibodies reacting with donor red blood cells (RBCs): This mechanism would lead to a hemolytic transfusion reaction, not FNHTR. Hemolytic reactions are more serious and involve the destruction of red blood cells.</li><li>\u2022 Option B. Recipient antibodies reacting with donor red blood cells (RBCs):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 FNHTR has both immunologic and non-immunologic causes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6593f7f8",
      "audio": ""
    },
    {
      "text": "A patient is receiving a blood transfusion. What is the approximate percentage of patients who experience a minor allergic reaction during or shortly after a transfusion?",
      "options": [
        {
          "label": "A",
          "text": "0.1-1%",
          "correct": false
        },
        {
          "label": "B",
          "text": "1-3%",
          "correct": true
        },
        {
          "label": "C",
          "text": "5-10%",
          "correct": false
        },
        {
          "label": "D",
          "text": "10-20%",
          "correct": false
        }
      ],
      "correct_answer": "B. 1-3%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 1-3%</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d2fdf633",
      "audio": ""
    },
    {
      "text": "A patient with a history of recurrent allergic reactions to blood transfusions presents for a scheduled surgery. Which of the following tests is most appropriate to assess their risk of anaphylaxis?",
      "options": [
        {
          "label": "A",
          "text": "Direct antiglobulin test (DAT)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Serum IgA levels",
          "correct": true
        },
        {
          "label": "C",
          "text": "HLA antibody screening",
          "correct": false
        },
        {
          "label": "D",
          "text": "Platelet aggregation studies",
          "correct": false
        }
      ],
      "correct_answer": "B. Serum IgA levels",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Serum IgA levels</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Direct antiglobulin test (DAT): The DAT detects antibodies or complement proteins bound to red blood cells. While it is useful in diagnosing certain types of transfusion reactions (like hemolytic reactions), it doesn't directly assess the risk of IgA-mediated anaphylaxis.</li><li>\u2022 Option A. Direct antiglobulin test (DAT):</li><li>\u2022 Option C. HLA antibody screening: HLA antibodies are directed against human leukocyte antigens (HLA) on white blood cells. While these antibodies can cause transfusion reactions, they are not the primary culprit in IgA deficiency-related anaphylaxis.</li><li>\u2022 Option C. HLA antibody screening:</li><li>\u2022 Option D. Platelet aggregation studies: These tests assess platelet function and are primarily used to investigate bleeding disorders. They are not relevant to the diagnosis of IgA deficiency or the assessment of anaphylaxis risk.</li><li>\u2022 Option D. Platelet aggregation studies:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Serum immunoglobulin levels are essential for diagnosing IgA deficiency in patients with a history of transfusion reactions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9eb14fbb",
      "audio": ""
    },
    {
      "text": "Which of the following is the most appropriate initial treatment for a patient experiencing anaphylaxis during a blood transfusion?",
      "options": [
        {
          "label": "A",
          "text": "Antihistamines",
          "correct": false
        },
        {
          "label": "B",
          "text": "Corticosteroids alone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Epinephrine + Corticosteroids",
          "correct": true
        },
        {
          "label": "D",
          "text": "Intravenous fluids",
          "correct": false
        }
      ],
      "correct_answer": "C. Epinephrine + Corticosteroids",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Epinephrine + Corticosteroids</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Antihistamines: Antihistamines like diphenhydramine can help with allergic symptoms like hives and itching, but they are not sufficient to treat anaphylaxis and should not be used alone.</li><li>\u2022 Option A. Antihistamines:</li><li>\u2022 Option B. Corticosteroids alone: While corticosteroids are important, they do not provide the immediate, life-saving effects of epinephrine in anaphylaxis.</li><li>\u2022 Option B. Corticosteroids alone:</li><li>\u2022 Option D. Intravenous fluids: IV fluids are used to support blood pressure in anaphylaxis, but they are not the primary or initial treatment.</li><li>\u2022 Option D. Intravenous fluids:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Epinephrine is essential for managing anaphylactic transfusion reactions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "146cb766",
      "audio": ""
    },
    {
      "text": "A patient develops acute respiratory distress, fever, and hypotension within 2 hours of receiving a blood transfusion. On examination, there was no rise in JVP/pedal edema Chest X-ray reveals bilateral pulmonary infiltrates. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute hemolytic transfusion reaction (AHTR)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Transfusion-associated circulatory overload (TACO)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Transfusion-related acute lung injury (TRALI)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Anaphylactic transfusion reaction",
          "correct": false
        }
      ],
      "correct_answer": "C. Transfusion-related acute lung injury (TRALI)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Transfusion-related acute lung injury (TRALI)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Acute hemolytic transfusion reaction (AHTR): While AHTR can also cause fever and hypotension, it typically presents with additional symptoms like flank pain, hemoglobinuria (dark urine), and signs of hemolysis (increased bilirubin, decreased haptoglobin).</li><li>\u2022 Option A. Acute hemolytic transfusion reaction (AHTR):</li><li>\u2022 Option B. Transfusion-associated circulatory overload (TACO): TACO is characterized by signs of fluid overload, such as hypertension, elevated jugular venous pressure (JVP), and peripheral edema. Patients with TACO may also have respiratory distress due to pulmonary edema, but it is usually not associated with fever or hypotension.</li><li>\u2022 Option B. Transfusion-associated circulatory overload (TACO):</li><li>\u2022 Option D. Anaphylactic transfusion reaction: Anaphylactic reactions typically manifest with urticaria (hives), angioedema, and bronchospasm. While hypotension can occur, it is usually accompanied by other allergic symptoms not present in this case.</li><li>\u2022 Option D. Anaphylactic transfusion reaction:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 TRALI is a serious complication of transfusion characterized by acute lung injury.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ef9e8442",
      "audio": ""
    },
    {
      "text": "What is the first step in the management of a suspected TRALI reaction?",
      "options": [
        {
          "label": "A",
          "text": "Administer diuretics",
          "correct": false
        },
        {
          "label": "B",
          "text": "Start broad-spectrum antibiotics",
          "correct": false
        },
        {
          "label": "C",
          "text": "Initiate mechanical ventilation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Stop the transfusion",
          "correct": true
        }
      ],
      "correct_answer": "D. Stop the transfusion",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Stop the transfusion</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Administer diuretics: While pulmonary edema is a hallmark of TRALI, it is non-cardiogenic (not due to heart failure). Diuretics, which help remove excess fluid in cardiogenic edema, are not effective in TRALI and could worsen the condition.</li><li>\u2022 Option A. Administer diuretics:</li><li>\u2022 Option B. Start broad-spectrum antibiotics: TRALI is an immune-mediated reaction, not an infection. Antibiotics would not be helpful in this situation.</li><li>\u2022 Option B. Start broad-spectrum antibiotics:</li><li>\u2022 Option C. Initiate mechanical ventilation: While mechanical ventilation may be necessary if the patient's respiratory distress worsens, the first priority is to stop the transfusion, which is the source of the problem. Mechanical ventilation can be initiated later if needed.</li><li>\u2022 Option C. Initiate mechanical ventilation:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Stopping the transfusion is the first and most crucial step in managing TRALI.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8cc9c352",
      "audio": ""
    },
    {
      "text": "A 75-year-old woman with a history of congestive heart failure receives 2 units of packed red blood cells (PRBCs) over 2 hours. Shortly after the transfusion, she develops dyspnea, orthopnea, and cough. Her blood pressure is 150/90 mmHg, and her jugular venous pressure (JVP) is elevated. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute hemolytic transfusion reaction (AHTR)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Transfusion-related acute lung injury (TRALI)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Transfusion-associated circulatory overload (TACO)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Allergic transfusion reaction",
          "correct": false
        }
      ],
      "correct_answer": "C. Transfusion-associated circulatory overload (TACO)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Transfusion-associated circulatory overload (TACO)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Acute hemolytic transfusion reaction (AHTR): While AHTR can cause dyspnea and hypotension, it typically presents with fever, chills, flank pain, and hemoglobinuria (dark urine), which are not present in this case.</li><li>\u2022 Option A. Acute hemolytic transfusion reaction (AHTR):</li><li>\u2022 Option B. Transfusion-related acute lung injury (TRALI): TRALI also causes respiratory distress, but it typically presents with fever and hypotension within 6 hours of transfusion and is not associated with elevated JVP or hypertension.</li><li>\u2022 Option B. Transfusion-related acute lung injury (TRALI):</li><li>\u2022 Option D. Allergic transfusion reaction: Allergic transfusion reactions usually manifest with mild symptoms like urticaria (hives), itching, and flushing. They do not typically cause the severe respiratory distress and cardiovascular symptoms seen in TACO.</li><li>\u2022 Option D. Allergic transfusion reaction:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 TACO is a complication of transfusion caused by fluid overload, and its symptoms can mimic congestive heart failure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d5035910",
      "audio": ""
    },
    {
      "text": "A patient develops jaundice, fever, and a gradual drop in hemoglobin levels one week after receiving a blood transfusion. The pre-transfusion antibody screen was negative. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute hemolytic transfusion reaction (AHTR)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Febrile non-hemolytic transfusion reaction (FNHTR)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Transfusion-related acute lung injury (TRALI)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Delayed hemolytic transfusion reaction (DHTR)",
          "correct": true
        }
      ],
      "correct_answer": "D. Delayed hemolytic transfusion reaction (DHTR)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Delayed hemolytic transfusion reaction (DHTR)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Acute hemolytic transfusion reaction (AHTR): AHTR typically presents with rapid onset (within hours) of fever, chills, flank pain, and hemoglobinuria. It is usually caused by ABO incompatibility, which would have been detected in the pre-transfusion testing.</li><li>\u2022 Option A. Acute hemolytic transfusion reaction (AHTR):</li><li>\u2022 Option B. Febrile non-hemolytic transfusion reaction (FNHTR): FNHTR is the most common type of transfusion reaction and usually presents with fever and chills within a few hours of transfusion. It is not associated with jaundice or a drop in hemoglobin levels.</li><li>\u2022 Option B. Febrile non-hemolytic transfusion reaction (FNHTR):</li><li>\u2022 Option C. Transfusion-related acute lung injury (TRALI): TRALI presents with acute respiratory distress, hypotension, and pulmonary edema shortly after transfusion. It does not typically cause jaundice or a delayed drop in hemoglobin.</li><li>\u2022 Option C. Transfusion-related acute lung injury (TRALI):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 DHTRs are typically delayed and caused by undetected antibodies against minor blood group antigens.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "32837173",
      "audio": ""
    },
    {
      "text": "Which of the following antibodies is most commonly implicated in the pathogenesis of Post-Transfusion Purpura (PTP)?",
      "options": [
        {
          "label": "A",
          "text": "Anti-RhD",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-Kell",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti-HPA-1a",
          "correct": true
        },
        {
          "label": "D",
          "text": "Anti-Fya",
          "correct": false
        }
      ],
      "correct_answer": "C. Anti-HPA-1a",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Anti-HPA-1a</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c36decee",
      "audio": ""
    },
    {
      "text": "Which of the following heparin products is associated with the lowest risk of heparin-induced thrombocytopenia (HIT)?",
      "options": [
        {
          "label": "A",
          "text": "Unfractionated heparin (UFH)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Low molecular weight heparin (LMWH)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fondaparinux",
          "correct": true
        },
        {
          "label": "D",
          "text": "Bivalirudin",
          "correct": false
        }
      ],
      "correct_answer": "C. Fondaparinux",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Fondaparinux</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Unfractionated heparin (UFH): UFH has the highest risk of HIT.</li><li>\u2022 Option A. Unfractionated heparin (UFH):</li><li>\u2022 Option B. Low molecular weight heparin (LMWH) : LMWH has a lower risk than UFH but can still cause HIT.</li><li>\u2022 Option B. Low molecular weight heparin (LMWH)</li><li>\u2022 Option D. Bivalirudin : Bivalirudin is a direct thrombin inhibitor and does not cause HIT, but it is not a heparin product.</li><li>\u2022 Option D. Bivalirudin</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Fondaparinux is the safest heparin product for patients with a history of or suspected HIT.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "26330d78",
      "audio": ""
    },
    {
      "text": "A 35-year-old female presents with fever, petechiae, confusion, and acute kidney injury. Her peripheral blood smear shows schistocytes and thrombocytopenia. Which of the following tests is MOST LIKELY to confirm the diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Coombs test",
          "correct": false
        },
        {
          "label": "B",
          "text": "ADAMTS13 activity level",
          "correct": true
        },
        {
          "label": "C",
          "text": "Bone marrow biopsy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serum haptoglobin level",
          "correct": false
        }
      ],
      "correct_answer": "B. ADAMTS13 activity level",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) ADAMTS13 activity level</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Coombs test is used to diagnose immune-mediated hemolytic anemias.</li><li>\u2022 Option A. Coombs test</li><li>\u2022 Option C. Bone marrow biopsy is not indicated in the initial workup of TTP.</li><li>\u2022 Option C. Bone marrow biopsy</li><li>\u2022 Option D. Serum haptoglobin level is low in hemolysis, but it is not specific for TTP.</li><li>\u2022 Option D. Serum haptoglobin level</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 ADAMTS13 deficiency is the hallmark of TTP and its measurement is crucial for diagnosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f4d01a6b",
      "audio": ""
    },
    {
      "text": "A patient with a history of systemic lupus erythematosus (SLE) presents with anemia, jaundice, and spherocytes on the peripheral smear. Which of the following is the most likely cause of the anemia?",
      "options": [
        {
          "label": "A",
          "text": "Autoimmune hemolytic anemia (AIHA)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Microangiopathic hemolytic anemia (MAHA)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vitamin B12 deficiency",
          "correct": false
        },
        {
          "label": "D",
          "text": "Aplastic anemia",
          "correct": false
        }
      ],
      "correct_answer": "A. Autoimmune hemolytic anemia (AIHA)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Autoimmune hemolytic anemia (AIHA)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Microangiopathic hemolytic anemia (MAHA): MAHA is characterized by schistocytes, not spherocytes, on the peripheral smear.</li><li>\u2022 Option</li><li>\u2022 B. Microangiopathic hemolytic anemia (MAHA):</li><li>\u2022 Option C. Vitamin B12 deficiency: Vitamin B12 deficiency causes megaloblastic anemia with hypersegmented neutrophils and macro-ovalocytes.</li><li>\u2022 Option</li><li>\u2022 C. Vitamin B12 deficiency:</li><li>\u2022 Option D. Aplastic anemia: Aplastic anemia is characterized by pancytopenia and hypocellular bone marrow.</li><li>\u2022 Option</li><li>\u2022 D. Aplastic anemia:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 SLE is a common cause of secondary AIHA, and spherocytes are a hallmark of this condition.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d330b7e8",
      "audio": ""
    },
    {
      "text": "A 55-year-old male with a recent diagnosis of chronic lymphocytic leukemia (CLL) presents with fatigue, easy bruising, and petechiae. His platelet count is 20,000/\u00b5L. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Primary immune thrombocytopenia (ITP)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Drug-induced thrombocytopenia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Heparin-induced thrombocytopenia (HIT)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Secondary ITP associated with CLL",
          "correct": true
        }
      ],
      "correct_answer": "D. Secondary ITP associated with CLL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Secondary ITP associated with CLL</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Primary immune thrombocytopenia (ITP): While ITP presents with isolated thrombocytopenia, the presence of CLL suggests a secondary cause in this case.</li><li>\u2022 Option</li><li>\u2022 A. Primary immune thrombocytopenia (ITP):</li><li>\u2022 Option B. Drug-induced thrombocytopenia: There is no mention of recent medication use to suggest this diagnosis.</li><li>\u2022 Option</li><li>\u2022 B. Drug-induced thrombocytopenia:</li><li>\u2022 Option C. Heparin-induced thrombocytopenia (HIT): HIT is an immune-mediated reaction to heparin, which is not mentioned in the patient's history.</li><li>\u2022 Option C.</li><li>\u2022 Heparin-induced thrombocytopenia (HIT):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Secondary ITP can be caused by various underlying conditions, including lymphoproliferative disorders like CLL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "11c527ba",
      "audio": ""
    },
    {
      "text": "A 68-year-old woman on unfractionated heparin (UFH) for a deep vein thrombosis (DVT) develops a platelet count of 90,000/\u00b5L on day 3 of therapy. Her baseline platelet count was 250,000/\u00b5L. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Type I heparin-induced thrombocytopenia (HIT)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Type II HIT",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pseudothrombocytopenia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Drug-induced thrombocytopenia (DITP)",
          "correct": false
        }
      ],
      "correct_answer": "A. Type I heparin-induced thrombocytopenia (HIT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Type I heparin-induced thrombocytopenia (HIT)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Type II HIT : Type II HIT is an immune-mediated condition that usually occurs later (5-10 days) and is associated with a higher risk of thrombosis.</li><li>\u2022 Option B. Type II HIT</li><li>\u2022 Option C. Pseudothrombocytopenia : This is a lab artifact where platelets clump in the test tube, but the patient's smear does not show clumping.</li><li>\u2022 Option C. Pseudothrombocytopenia</li><li>\u2022 Option D. DITP : This is less likely given the temporal association with heparin initiation.</li><li>\u2022 Option D. DITP</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Early, mild thrombocytopenia in a patient on heparin is most likely Type I HIT, which is usually benign and does not require heparin discontinuation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2fed2366",
      "audio": ""
    },
    {
      "text": "A patient with a history of malignant hypertension presents with MAHA, thrombocytopenia, and acute kidney injury. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "TTP",
          "correct": false
        },
        {
          "label": "B",
          "text": "HUS",
          "correct": false
        },
        {
          "label": "C",
          "text": "DIC",
          "correct": false
        },
        {
          "label": "D",
          "text": "TMA",
          "correct": true
        }
      ],
      "correct_answer": "D. TMA",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) TMA</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. TTP (Thrombotic Thrombocytopenic Purpura): While TTP can present with MAHA, thrombocytopenia, and acute kidney injury, it is typically associated with a deficiency of the ADAMTS13 enzyme. This patient's history of malignant hypertension makes TMA a more likely diagnosis.</li><li>\u2022 Option</li><li>\u2022 A. TTP (Thrombotic Thrombocytopenic Purpura):</li><li>\u2022 Option B. HUS (Hemolytic Uremic Syndrome): HUS is often associated with Shiga-toxin producing E. coli infection and commonly presents with bloody diarrhea. The patient's history does not suggest this.</li><li>\u2022 Option</li><li>\u2022 B. HUS (Hemolytic Uremic Syndrome):</li><li>\u2022 Option C. DIC (Disseminated Intravascular Coagulation): DIC is a consumptive coagulopathy triggered by a systemic illness (e.g., sepsis, malignancy). While it can cause MAHA and thrombocytopenia, it would typically present with abnormal coagulation parameters (prolonged PT/PTT, low fibrinogen) which are not mentioned in this scenario.</li><li>\u2022 Option</li><li>\u2022 C. DIC (Disseminated Intravascular Coagulation):</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 It's important to consider secondary causes of TMA, such as malignant hypertension, in patients with relevant risk factors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "04575a9a",
      "audio": ""
    },
    {
      "text": "A 5-year-old child presents with bloody diarrhea, pallor, and decreased urine output after eating undercooked meat at a family barbecue. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "HUS D+",
          "correct": true
        },
        {
          "label": "B",
          "text": "HUS D-",
          "correct": false
        },
        {
          "label": "C",
          "text": "TTP",
          "correct": false
        },
        {
          "label": "D",
          "text": "IgA nephropathy",
          "correct": false
        }
      ],
      "correct_answer": "A. HUS D+",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) HUS D+</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. HUS D : This form is not typically associated with bloody diarrhea and is usually caused by complement dysregulation.</li><li>\u2022 Option B.</li><li>\u2022 HUS D</li><li>\u2022 Option C. TTP : TTP is characterized by severe ADAMTS13 deficiency and does not typically present with bloody diarrhea.</li><li>\u2022 Option C. TTP</li><li>\u2022 Option D. IgA nephropathy : This condition typically presents with hematuria after an upper respiratory infection.</li><li>\u2022 Option D. IgA</li><li>\u2022 nephropathy</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 HUS D+ is a serious condition that can occur in children after consuming contaminated food</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1030008b",
      "audio": ""
    },
    {
      "text": "Which of the following genetic mutations is NOT typically associated with familial atypical HUS?",
      "options": [
        {
          "label": "A",
          "text": "CFH",
          "correct": false
        },
        {
          "label": "B",
          "text": "CFI",
          "correct": false
        },
        {
          "label": "C",
          "text": "CD46",
          "correct": false
        },
        {
          "label": "D",
          "text": "STXBP5",
          "correct": true
        }
      ],
      "correct_answer": "D. STXBP5",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) STXBP5</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. CFH, Option B. CFI and Option C. CD46: These genes all encode complement regulatory proteins, and mutations in them can lead to familial aHUS.</li><li>\u2022 Option</li><li>\u2022 A. CFH, Option</li><li>\u2022 B. CFI</li><li>\u2022 Option</li><li>\u2022 C. CD46:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Familial atypical HUS is a genetically heterogeneous disorder with mutations in several complement regulatory genes. Recognizing the role of these genes is essential for accurate diagnosis, genetic counseling, and potential targeted therapies. While STXBP5 mutations are more commonly associated with a neurological disorder and are not typically seen in familial cases.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "07d812ed",
      "audio": ""
    },
    {
      "text": "A patient with suspected TTP has a severely reduced ADAMTS13 activity level. Which of the following treatments is the cornerstone of management?",
      "options": [
        {
          "label": "A",
          "text": "Platelet transfusion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Corticosteroids",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rituximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Plasma exchange",
          "correct": true
        }
      ],
      "correct_answer": "D. Plasma exchange",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Plasma exchange</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Platelet transfusion: Platelet transfusions are contraindicated in TTP as they can worsen thrombosis.</li><li>\u2022 Option A.</li><li>\u2022 Platelet transfusion:</li><li>\u2022 Option B. Corticosteroids: Corticosteroids can be used as adjunctive therapy but are not the primary treatment.</li><li>\u2022 Option B.</li><li>\u2022 Corticosteroids:</li><li>\u2022 Option C. Rituximab: Rituximab can be used in refractory or relapsing TTP but is not the first-line therapy.</li><li>\u2022 Option C.</li><li>\u2022 Rituximab:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Plasma exchange is the most effective treatment for TTP and should be initiated promptly.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "df425da0",
      "audio": ""
    },
    {
      "text": "A 30-year-old woman presents to the clinic with a two-week history of easy bruising and pinprick red spots on her lower legs. She denies any recent injuries or medication use. On examination, she has multiple petechiae on her skin and mucous membranes. Blood investigations except low platelet count, imagings turned out to be normal. What's the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Aplastic anemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Immune thrombocytopenia (ITP)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Myelodysplastic syndrome (MDS)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thrombotic microangiopathy (TMA)",
          "correct": false
        }
      ],
      "correct_answer": "B. Immune thrombocytopenia (ITP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Immune thrombocytopenia (ITP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Aplastic anemia : While it can cause thrombocytopenia, it also affects other cell lines (red blood cells and white blood cells).</li><li>\u2022 Option A. Aplastic anemia</li><li>\u2022 Option C. Myelodysplastic syndrome (MDS) : MDS can cause thrombocytopenia, but it is more common in older adults and often presents with other cytopenias.</li><li>\u2022 Option C. Myelodysplastic syndrome (MDS)</li><li>\u2022 Option D. Thrombotic microangiopathy (TMA) : TMA causes thrombocytopenia through a different mechanism (platelet consumption in microvascular thrombi).</li><li>\u2022 Option D. Thrombotic microangiopathy (TMA)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 ITP is a diagnosis of exclusion, meaning other causes of thrombocytopenia need to be ruled out.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "40e992c2",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman presents with fatigue, jaundice, and petechiae. Her blood work shows anemia, thrombocytopenia, and a positive direct Coombs test (DCT). Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Autoimmune hepatitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Evans syndrome",
          "correct": true
        },
        {
          "label": "C",
          "text": "Systemic lupus erythematosus (SLE)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thrombotic thrombocytopenic purpura (TTP)",
          "correct": false
        }
      ],
      "correct_answer": "B. Evans syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Evans syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Autoimmune hepatitis : While it can cause jaundice, it doesn't typically cause thrombocytopenia or a positive DCT.</li><li>\u2022 Option A. Autoimmune hepatitis</li><li>\u2022 Option C. Systemic lupus erythematosus (SLE) : SLE can cause a variety of hematologic abnormalities, but the combination of findings is more specific for Evans syndrome.</li><li>\u2022 Option C. Systemic lupus erythematosus (SLE)</li><li>\u2022 Option D. Thrombotic thrombocytopenic purpura (TTP) : TTP is a thrombotic microangiopathy that typically doesn't cause a positive DCT.</li><li>\u2022 Option D. Thrombotic thrombocytopenic purpura (TTP)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Evans syndrome is a rare but serious condition that requires prompt diagnosis and treatment. Recognizing the combination of ITP and AIHA is crucial.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "521101a5",
      "audio": ""
    },
    {
      "text": "A 45-year-old asymptomatic woman has a routine complete blood count (CBC) which shows a platelet count of 80,000/\u00b5L. Peripheral blood smear shows large platelet clumps. Given the likely diagnosis, Which of the following is the most appropriate next step in the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Repeat the CBC in a sodium citrate tube",
          "correct": true
        },
        {
          "label": "B",
          "text": "Start corticosteroids for ITP",
          "correct": false
        },
        {
          "label": "C",
          "text": "Order a bone marrow biopsy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Begin heparin therapy for HIT",
          "correct": false
        }
      ],
      "correct_answer": "A. Repeat the CBC in a sodium citrate tube",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Repeat the CBC in a sodium citrate tube</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Start corticosteroids for ITP : Corticosteroids are used to treat ITP, but this is not appropriate until pseudothrombocytopenia is ruled out.</li><li>\u2022 Option B. Start corticosteroids for ITP</li><li>\u2022 Option C. Order a bone marrow biopsy : A bone marrow biopsy is not necessary for the diagnosis of pseudothrombocytopenia.</li><li>\u2022 Option C. Order a bone marrow biopsy</li><li>\u2022 Option D. Begin heparin therapy for HIT : Heparin therapy is contraindicated in HIT and should not be started until this diagnosis is ruled out.</li><li>\u2022 Option D. Begin heparin therapy for HIT</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective :</li><li>\u2022 Repeating the CBC in a citrate tube is a simple and effective way to confirm pseudothrombocytopenia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "60fcaaff",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman presents with a 2-week history of fatigue, petechiae, and mucosal bleeding. Blood tests reveal isolated thrombocytopenia with a platelet count of 15,000/\u00b5L. Which of the following is the MOST APPROPRIATE initial treatment?",
      "options": [
        {
          "label": "A",
          "text": "Rituximab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Corticosteroids",
          "correct": true
        },
        {
          "label": "C",
          "text": "Eltrombopag",
          "correct": false
        },
        {
          "label": "D",
          "text": "Splenectomy",
          "correct": false
        }
      ],
      "correct_answer": "B. Corticosteroids",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Corticosteroids</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Rituximab : Second-line treatment for persistent/chronic ITP.</li><li>\u2022 Option A.</li><li>\u2022 Rituximab</li><li>\u2022 Option C. Eltrombopag : Second-line treatment for persistent/chronic ITP.</li><li>\u2022 Option C.</li><li>\u2022 Eltrombopag</li><li>\u2022 Option D. Splenectomy : Second-line treatment for persistent/chronic ITP.</li><li>\u2022 Option D. Splenectomy</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Corticosteroids are the mainstay of initial therapy for acute ITP due to their rapid effect on platelet counts.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e69379af",
      "audio": ""
    },
    {
      "text": "A 42-year-old woman with a 5-year history of chronic ITP has persistent thrombocytopenia (25,000/\u00b5L) despite prior treatments with corticosteroids, IVIg, and TPO-RAs. She experiences frequent bleeding and seeks further management options. Which of the following is the next step in her management?",
      "options": [
        {
          "label": "A",
          "text": "Rituximab infusion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Splenectomy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Danazol therapy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fostamatinib therapy",
          "correct": false
        }
      ],
      "correct_answer": "B. Splenectomy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Splenectomy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Rituximab infusion: While rituximab can be effective in some patients, its response rate is lower than splenectomy and the onset of action is delayed. It also carries potential for serious side effects like infections and infusion reactions.</li><li>\u2022 Option</li><li>\u2022 A. Rituximab infusion:</li><li>\u2022 Option C. Danazol therapy: Danazol is an older medication with limited evidence of efficacy in ITP and potential for masculinizing side effects in women, making it a less preferred option.</li><li>\u2022 Option</li><li>\u2022 C. Danazol therapy:</li><li>\u2022 Option D. Fostamatinib therapy: This is a newer option with promising results, but it has less long-term data than splenectomy and may have adverse effects like hypertension, diarrhea, and hepatotoxicity.</li><li>\u2022 Option</li><li>\u2022 D. Fostamatinib therapy:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 In patients with chronic ITP refractory to initial therapies, splenectomy offers the highest chance of long-term remission, but it should be considered after weighing the risks and benefits of surgery. Other options like rituximab and fostamatinib may be considered in select cases, while danazol is less commonly used due to its limited efficacy and side effect profile.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ed3ef11c",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman with ITP has a platelet count of 35,000/\u00b5L. She is asymptomatic and has no history of bleeding. Which of the following is the most appropriate management strategy?",
      "options": [
        {
          "label": "A",
          "text": "Observation",
          "correct": true
        },
        {
          "label": "B",
          "text": "Corticosteroids",
          "correct": false
        },
        {
          "label": "C",
          "text": "IVIG",
          "correct": false
        },
        {
          "label": "D",
          "text": "Splenectomy",
          "correct": false
        }
      ],
      "correct_answer": "A. Observation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Observation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Corticosteroids : Corticosteroids are not indicated for asymptomatic patients with mild thrombocytopenia.</li><li>\u2022 Option B. Corticosteroids</li><li>\u2022 Option C. IVIG : IVIG is reserved for more severe cases or when there is active bleeding.</li><li>\u2022 Option C.</li><li>\u2022 IVIG</li><li>\u2022 Option D. Splenectomy : Splenectomy is a last resort for refractory ITP and is not indicated at this stage.</li><li>\u2022 Option D.</li><li>\u2022 Splenectomy</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Observation is appropriate for asymptomatic patients with mild thrombocytopenia (platelet count >20-30K).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5aae8440",
      "audio": ""
    },
    {
      "text": "A 52-year-old woman develops new-onset thrombocytopenia and thrombosis 6 days after initiating unfractionated heparin (UFH) for DVT prophylaxis following knee replacement surgery. Her medical history is significant for hypertension and osteoarthritis. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Immune Thrombocytopenic Purpura (ITP)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Type I Heparin-Induced Thrombocytopenia (HIT)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Type II Heparin-Induced Thrombocytopenia (HIT)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Thrombotic Thrombocytopenic Purpura (TTP)",
          "correct": false
        }
      ],
      "correct_answer": "C. Type II Heparin-Induced Thrombocytopenia (HIT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Type II Heparin-Induced Thrombocytopenia (HIT)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Immune Thrombocytopenic Purpura (ITP) : ITP is an autoimmune disorder that can cause thrombocytopenia but is not typically associated with thrombosis.</li><li>\u2022 Option A. Immune Thrombocytopenic Purpura (ITP)</li><li>\u2022 Option B. Type I Heparin-Induced Thrombocytopenia (HIT): This is a non-immune mediated form of HIT that usually occurs within the first 2 days of heparin exposure and is not associated with thrombosis.</li><li>\u2022 Option B. Type I Heparin-Induced Thrombocytopenia (HIT):</li><li>\u2022 Option D. Thrombotic Thrombocytopenic Purpura (TTP): TTP is a rare disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and neurologic symptoms. It is not typically associated with heparin use.</li><li>\u2022 Option D. Thrombotic Thrombocytopenic Purpura (TTP):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 New-onset thrombocytopenia and thrombosis in a patient recently started on heparin should raise suspicion for Type II HIT, which warrants immediate discontinuation of heparin and initiation of alternative anticoagulation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9608ddbc",
      "audio": ""
    },
    {
      "text": "A 40-year-old female on prophylactic enoxaparin (LMWH) for 3 weeks after surgery develops a new DVT. Her platelet count has decreased by 40% from baseline. What is her 4Ts score for HIT?",
      "options": [
        {
          "label": "A",
          "text": "2",
          "correct": false
        },
        {
          "label": "B",
          "text": "3",
          "correct": false
        },
        {
          "label": "C",
          "text": "4",
          "correct": true
        },
        {
          "label": "D",
          "text": "5",
          "correct": false
        }
      ],
      "correct_answer": "C. 4",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 4</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c53d868f",
      "audio": ""
    },
    {
      "text": "A patient with HIT and no evidence of thrombosis requires anticoagulation. Which of the following is the recommended duration of anticoagulation therapy?",
      "options": [
        {
          "label": "A",
          "text": "1 week",
          "correct": false
        },
        {
          "label": "B",
          "text": "1 month",
          "correct": true
        },
        {
          "label": "C",
          "text": "3 months",
          "correct": false
        },
        {
          "label": "D",
          "text": "6 months",
          "correct": false
        }
      ],
      "correct_answer": "B. 1 month",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 1 month</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. 1 week: This is too short a duration. HIT antibodies can persist for weeks to months, and the risk of delayed thrombosis remains high during this period.</li><li>\u2022 Option</li><li>\u2022 A. 1 week:</li><li>\u2022 Option C. 3 months: This duration is typically recommended for patients with HIT who have experienced thrombotic events. While there is some debate about extending anticoagulation beyond one month in patients without thrombosis, the current consensus leans towards 1 month as sufficient in most cases.</li><li>\u2022 Option</li><li>\u2022 C. 3 months:</li><li>\u2022 have</li><li>\u2022 Option D. 6 months: This duration is unnecessarily long for patients with HIT without thrombosis. Prolonged anticoagulation carries its own risks, such as bleeding</li><li>\u2022 Option</li><li>\u2022 D. 6 months:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Even in the absence of thrombosis, HIT requires extended anticoagulation due to the persistent risk of thrombotic events.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fe997385",
      "audio": ""
    },
    {
      "text": "Which of the following statements about re-exposure to heparin in patients with a history of HIT is TRUE?",
      "options": [
        {
          "label": "A",
          "text": "Re-exposure is safe after 6 months.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Re-exposure is safe if the platelet count is normal.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Re-exposure should be avoided due to the high risk of recurrence.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Re-exposure is safe if a different type of heparin is used (e.g., LMWH instead of UFH).",
          "correct": false
        }
      ],
      "correct_answer": "C. Re-exposure should be avoided due to the high risk of recurrence.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Re-exposure should be avoided due to the high risk of recurrence.</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f93b4c38",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a typical clinical feature of Thrombotic Microangiopathy (TMA)?",
      "options": [
        {
          "label": "A",
          "text": "Thrombocytopenia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Microangiopathic hemolytic anemia (MAHA)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Prolonged PT and PTT",
          "correct": true
        },
        {
          "label": "D",
          "text": "Renal dysfunction",
          "correct": false
        }
      ],
      "correct_answer": "C. Prolonged PT and PTT",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Prolonged PT and PTT</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Thrombocytopenia : A key feature of TMA due to platelet consumption in microthrombi.</li><li>\u2022 Option A.</li><li>\u2022 Thrombocytopenia</li><li>\u2022 Option B. Microangiopathic hemolytic anemia (MAHA) : Also a key feature of TMA due to mechanical damage to red blood cells.</li><li>\u2022 Option B. Microangiopathic hemolytic anemia (MAHA)</li><li>\u2022 Option D. Renal dysfunction : Can occur due to microthrombi formation in the kidneys.</li><li>\u2022 Option D. Renal</li><li>\u2022 dysfunction</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Normal PT and PTT help differentiate TMA from other conditions like DIC, which typically present with abnormal coagulation tests.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cd58e84e",
      "audio": ""
    },
    {
      "text": "A 32-year-old woman presents with fever, altered mental status, thrombocytopenia, and evidence of hemolysis seen. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Immune Thrombocytopenia (ITP)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hemolytic Uremic Syndrome (HUS)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thrombotic Thrombocytopenic Purpura (TTP)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Disseminated Intravascular Coagulation (DIC)",
          "correct": false
        }
      ],
      "correct_answer": "C. Thrombotic Thrombocytopenic Purpura (TTP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Thrombotic Thrombocytopenic Purpura (TTP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Immune Thrombocytopenia ( ITP): ITP is characterized by isolated thrombocytopenia without MAHA or other systemic symptoms.</li><li>\u2022 Option A. Immune Thrombocytopenia</li><li>\u2022 ITP):</li><li>\u2022 Option B. Hemolytic Uremic Syndrome (HUS): HUS typically presents with renal failure and is more common in children following a gastrointestinal infection.</li><li>\u2022 Option B. Hemolytic Uremic Syndrome (HUS):</li><li>\u2022 Option D. Disseminated Intravascular Coagulation (DIC): DIC is a consumptive coagulopathy with prolonged clotting times and often bleeding complications.</li><li>\u2022 Option D. Disseminated Intravascular Coagulation</li><li>\u2022 (DIC):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The clinical pentad of TTP includes thrombocytopenia, MAHA, altered mental status, fever, and (less commonly) renal failure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fce922a0",
      "audio": ""
    },
    {
      "text": "A 4-month-old infant presents with lethargy, hypotonia, and developmental delay. Laboratory investigations reveal megaloblastic anemia, elevated homocysteine and methylmalonic acid (MMA) levels. Which of the following conditions is MOST LIKELY to predispose this infant to thrombotic microangiopathy (TMA)?",
      "options": [
        {
          "label": "A",
          "text": "Methylmalonic acidemia due to MMACHC mutation",
          "correct": true
        },
        {
          "label": "B",
          "text": "Dihydrofolate reductase (DHFR) deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Maple syrup urine disease (MSUD)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tyrosinemia type I",
          "correct": false
        }
      ],
      "correct_answer": "A. Methylmalonic acidemia due to MMACHC mutation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Methylmalonic acidemia due to MMACHC mutation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Dihydrofolate reductase (DHFR) deficiency : DHFR deficiency primarily affects folate metabolism and does not directly predispose to TMA.</li><li>\u2022 Option B. Dihydrofolate reductase (DHFR) deficiency</li><li>\u2022 Option C. Maple syrup urine disease (MSUD) : MSUD is an amino acid disorder and is not associated with increased risk of TMA.</li><li>\u2022 Option C. Maple syrup urine disease (MSUD)</li><li>\u2022 Option D. Tyrosinemia type I : Tyrosinemia type I is a metabolic disorder affecting tyrosine metabolism and does not typically predispose to TMA.</li><li>\u2022 Option D. Tyrosinemia type I</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 MMACHC mutations can lead to elevated homocysteine levels, which increases the risk of developing thrombotic microangiopathy (TMA) in affected individuals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9d9b5342",
      "audio": ""
    },
    {
      "text": "Which of the following is the PRIMARY agonist responsible for platelet aggregation?",
      "options": [
        {
          "label": "A",
          "text": "Thromboxane A2 (TxA2)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Adenosine Diphosphate (ADP)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thrombin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fibrinogen",
          "correct": true
        }
      ],
      "correct_answer": "D. Fibrinogen",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Fibrinogen</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Thromboxane A2 (TxA2) : TxA2 is a potent platelet activator and vasoconstrictor, but it does not directly mediate platelet aggregation.</li><li>\u2022 Option A. Thromboxane A2 (TxA2)</li><li>\u2022 Option B. Adenosine Diphosphate (ADP) : ADP is a weak platelet activator that promotes platelet aggregation by binding to P2Y12 and P2Y1 receptors.</li><li>\u2022 Option B. Adenosine Diphosphate (ADP)</li><li>\u2022 Option C. Thrombin : Thrombin is a powerful platelet activator and promotes aggregation through protease-activated receptors (PARs).</li><li>\u2022 Option C. Thrombin</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Fibrinogen is the primary agonist responsible for platelet aggregation by cross-linking activated platelets through GP IIb/IIIa receptors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "83b4585b",
      "audio": ""
    },
    {
      "text": "Which of the following drugs inhibits platelet aggregation by irreversibly blocking the P2Y12 receptor?",
      "options": [
        {
          "label": "A",
          "text": "Aspirin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Clopidogrel",
          "correct": true
        },
        {
          "label": "C",
          "text": "Abciximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Eptifibatide",
          "correct": false
        }
      ],
      "correct_answer": "B. Clopidogrel",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Clopidogrel</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Aspirin : Aspirin irreversibly inhibits cyclooxygenase (COX)-1, preventing TxA2 production.</li><li>\u2022 Option A. Aspirin</li><li>\u2022 Option C. Abciximab : Abciximab is a monoclonal antibody that blocks GP IIb/IIIa receptors.</li><li>\u2022 Option C.</li><li>\u2022 Abciximab</li><li>\u2022 Option D. Eptifibatide : Eptifibatide is a cyclic heptapeptide that reversibly blocks GP IIb/IIIa receptors.</li><li>\u2022 Option D. Eptifibatide</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Clopidogrel inhibits platelet aggregation by irreversibly blocking the P2Y12 receptor.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "198f0fae",
      "audio": ""
    },
    {
      "text": "A 5-year-old boy presents with a history of easy bruising, frequent nosebleeds, and prolonged bleeding after minor injuries. His parents report that he had significant bleeding during circumcision as a newborn. Platelet count and coagulation studies are normal. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Von Willebrand Disease (VWD)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hemophilia A",
          "correct": false
        },
        {
          "label": "C",
          "text": "Glanzmann thrombasthenia",
          "correct": true
        },
        {
          "label": "D",
          "text": "Immune Thrombocytopenia Purpura (ITP)",
          "correct": false
        }
      ],
      "correct_answer": "C. Glanzmann thrombasthenia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Glanzmann thrombasthenia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Von Willebrand Disease (VWD): VWD is the most common inherited bleeding disorder caused by a deficiency or defect in von Willebrand factor (vWF). While it can present with mucocutaneous bleeding, it is usually associated with prolonged bleeding time and abnormal platelet function tests (e.g., ristocetin cofactor activity).</li><li>\u2022 Option A. Von Willebrand Disease (VWD):</li><li>\u2022 Option B. Hemophilia A: Hemophilia A is an X-linked recessive disorder caused by a deficiency of factor VIII. It typically presents with deep tissue bleeding (e.g., hemarthrosis) rather than mucocutaneous bleeding.</li><li>\u2022 Option B. Hemophilia A:</li><li>\u2022 Option D. Immune Thrombocytopenia Purpura (ITP): ITP is an autoimmune disorder characterized by isolated thrombocytopenia due to increased platelet destruction. It is not typically associated with a history of significant bleeding in the neonatal period.</li><li>\u2022 Option D. Immune Thrombocytopenia Purpura (ITP):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Glanzmann thrombasthenia is a rare but important differential diagnosis in patients presenting with a history of mucocutaneous bleeding and normal platelet count and coagulation studies. A platelet aggregation test can confirm the diagnosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1bc8901c",
      "audio": ""
    },
    {
      "text": "A 30-year-old female presents with a history of heavy menstrual bleeding since menarche. She also reports easy bruising and prolonged bleeding after minor cuts. Physical examination reveals scattered petechiae. Which of the following tests is most likely to be diagnostic?",
      "options": [
        {
          "label": "A",
          "text": "Ristocetin cofactor activity",
          "correct": false
        },
        {
          "label": "B",
          "text": "Platelet aggregation studies",
          "correct": true
        },
        {
          "label": "C",
          "text": "Factor VIII assay",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bone marrow biopsy",
          "correct": false
        }
      ],
      "correct_answer": "B. Platelet aggregation studies",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Platelet aggregation studies</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Ristocetin cofactor activity : This test measures the function of von Willebrand factor (vWF) and is used in the diagnosis of von Willebrand disease.</li><li>\u2022 Option A. Ristocetin cofactor activity</li><li>\u2022 Option C. Factor VIII assay : This test is used to diagnose hemophilia A.</li><li>\u2022 Option C. Factor VIII assay</li><li>\u2022 Option D. Bone marrow biopsy : This test is not indicated in the initial workup of suspected Glanzmann thrombasthenia.</li><li>\u2022 Option D. Bone marrow biopsy</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Platelet aggregation studies are the definitive test for diagnosing Glanzmann thrombasthenia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "658cb1fd",
      "audio": ""
    },
    {
      "text": "A 4-year-old child presents with a history of easy bruising, frequent epistaxis, and heavy menstrual bleeding (in females). Peripheral blood smear shows giant platelets. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Von Willebrand Disease (VWD)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hemophilia A",
          "correct": false
        },
        {
          "label": "C",
          "text": "Glanzmann thrombasthenia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bernard-Soulier syndrome (BSS)",
          "correct": true
        }
      ],
      "correct_answer": "D. Bernard-Soulier syndrome (BSS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Bernard-Soulier syndrome (BSS)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Von Willebrand Disease (VWD) : VWD presents with mucocutaneous bleeding and prolonged bleeding time, but not giant platelets.</li><li>\u2022 Option A. Von Willebrand Disease (VWD)</li><li>\u2022 Option B. Hemophilia A : Hemophilia A is characterized by a deficiency of factor VIII and typically presents with deep tissue bleeding.</li><li>\u2022 Option B. Hemophilia A</li><li>\u2022 Option C. Glanzmann thrombasthenia : Glanzmann thrombasthenia is a platelet aggregation disorder and does not cause giant platelets.</li><li>\u2022 Option C. Glanzmann thrombasthenia</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Giant platelets on peripheral blood smear are a hallmark of Bernard-Soulier syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ee6fa290",
      "audio": ""
    },
    {
      "text": "Which of the following laboratory findings is NOT characteristic of Bernard-Soulier syndrome (BSS)?",
      "options": [
        {
          "label": "A",
          "text": "Thrombocytopenia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Giant platelets on peripheral smear",
          "correct": false
        },
        {
          "label": "C",
          "text": "Prolonged bleeding time",
          "correct": false
        },
        {
          "label": "D",
          "text": "Normal ristocetin cofactor activity",
          "correct": true
        }
      ],
      "correct_answer": "D. Normal ristocetin cofactor activity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Normal ristocetin cofactor activity</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8b29455a",
      "audio": ""
    },
    {
      "text": "A 3-year-old child presents with a history of easy bruising, frequent nosebleeds, and prolonged bleeding after minor injuries. The platelet count is normal, but the peripheral blood smear reveals large platelets, Ultrasound imaging showed Mild spleenomegaly. Given the likely diagnosis, Which of the following is the most characteristic electron microscopy finding in Gray platelet syndrome?",
      "options": [
        {
          "label": "A",
          "text": "Giant platelets",
          "correct": false
        },
        {
          "label": "B",
          "text": "Absence of dense granules",
          "correct": false
        },
        {
          "label": "C",
          "text": "Absence of alpha granules",
          "correct": true
        },
        {
          "label": "D",
          "text": "Abnormal platelet aggregation",
          "correct": false
        }
      ],
      "correct_answer": "C. Absence of alpha granules",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Absence of alpha granules</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Giant platelets : While platelets may be large on peripheral smear, giant platelets are more characteristic of Bernard-Soulier syndrome.</li><li>\u2022 Option A. Giant platelets</li><li>\u2022 Option B. Absence of dense granules : This is a feature of other platelet disorders, not Gray platelet syndrome.</li><li>\u2022 Option B. Absence of dense granules</li><li>\u2022 Option D. Abnormal platelet aggregation : Platelet aggregation is variable in Gray platelet syndrome but is not the most specific finding.</li><li>\u2022 Option D. Abnormal platelet aggregation</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The absence of alpha granules on electron microscopy is the hallmark of Gray platelet syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9886056c",
      "audio": ""
    },
    {
      "text": "A 5-year-old child presents with oculocutaneous albinism, recurrent bacterial infections, and easy bruising. Peripheral smear shows normal platelet count but abnormal granulation. On further evaluation, Platelet EM studies show \u03b4 granule deficiency. The treating physician is suspecting a platelet disorder, Which of the following genetic mutations is NOT associated with the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "HPS1",
          "correct": false
        },
        {
          "label": "B",
          "text": "HPS3",
          "correct": false
        },
        {
          "label": "C",
          "text": "HPS5",
          "correct": false
        },
        {
          "label": "D",
          "text": "NBEAL2",
          "correct": true
        }
      ],
      "correct_answer": "D. NBEAL2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) NBEAL2</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8b79a534",
      "audio": ""
    },
    {
      "text": "A 4-year-old child presents with recurrent pyogenic skin and respiratory infections, silver-grey hair, and nystagmus. Peripheral blood smear reveals giant granules in neutrophils. Given the likely diagnosis, Which of the following infections is MOST frequently associated with this condition?",
      "options": [
        {
          "label": "A",
          "text": "Staphylococcus aureus",
          "correct": true
        },
        {
          "label": "B",
          "text": "Streptococcus pneumoniae",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pseudomonas aeruginosa",
          "correct": false
        },
        {
          "label": "D",
          "text": "Candida albicans",
          "correct": false
        }
      ],
      "correct_answer": "A. Staphylococcus aureus",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Staphylococcus aureus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Streptococcus pneumoniae: While patients with Chediak-Higashi syndrome may be more susceptible to infections in general, there isn't a specific predisposition towards Streptococcus pneumoniae compared to Staphylococcus aureus.</li><li>\u2022 Option B. Streptococcus pneumoniae:</li><li>\u2022 Option C. Pseudomonas aeruginosa: Pseudomonas is more commonly associated with patients with cystic fibrosis or other immunocompromised states. It's not a hallmark infection for Chediak-Higashi.</li><li>\u2022 Option C. Pseudomonas aeruginosa:</li><li>\u2022 Option D. Candida albicans: This is a fungal infection, and while Chediak-Higashi syndrome patients may be more susceptible to infections overall, bacterial infections (especially those caused by Staphylococcus aureus) are of greater concern.</li><li>\u2022 Option D. Candida albicans:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Recurrent Staphylococcus aureus infections are a hallmark of Chediak-Higashi syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ae1af64d",
      "audio": ""
    },
    {
      "text": "Which of the following gene mutations is responsible for Chediak-Higashi syndrome?",
      "options": [
        {
          "label": "A",
          "text": "LYST",
          "correct": false
        },
        {
          "label": "B",
          "text": "CHS1",
          "correct": true
        },
        {
          "label": "C",
          "text": "NBEAL2",
          "correct": false
        },
        {
          "label": "D",
          "text": "HPS1",
          "correct": false
        }
      ],
      "correct_answer": "B. CHS1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. LYST: While historically known as LYST, the official gene symbol is now CHS1. Both refer to the same gene, so this is not technically incorrect, but B) is the preferred answer due to the updated nomenclature.</li><li>\u2022 Option A. LYST:</li><li>\u2022 Option C. NBEAL2: Mutations in the NBEAL2 gene cause Gray Platelet Syndrome (GPS), a distinct disorder with large platelets and bleeding tendency.</li><li>\u2022 Option C. NBEAL2:</li><li>\u2022 Option D. HPS1: Mutations in the HPS1 gene cause a subtype of Hermansky-Pudlak Syndrome (HPS), another disorder with albinism, but with a different pattern of organ involvement than Chediak-Higashi syndrome.</li><li>\u2022 Option D. HPS1:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Mutations in the CHS1 gene lead to defective lysosomal trafficking, resulting in the characteristic giant granules and impaired immune function in Chediak-Higashi syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c64569cd",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman presents with easy bruising, heavy menstrual bleeding, and prolonged bleeding after minor cuts. Her family history reveals similar bleeding tendencies in her mother and sister. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Hemophilia A",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hemophilia B",
          "correct": false
        },
        {
          "label": "C",
          "text": "Von Willebrand Disease (VWD) Type 1",
          "correct": true
        },
        {
          "label": "D",
          "text": "Von Willebrand Disease (VWD) Type 3",
          "correct": false
        }
      ],
      "correct_answer": "C. Von Willebrand Disease (VWD) Type 1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Von Willebrand Disease (VWD) Type 1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Hemophilia A and Option B. Hemophilia B: These are X-linked recessive disorders primarily affecting males and are characterized by factor VIII and IX deficiencies, respectively.</li><li>\u2022 Option</li><li>\u2022 A. Hemophilia A</li><li>\u2022 Option B. Hemophilia B:</li><li>\u2022 Option D. Von Willebrand Disease (VWD) Type 3 : This is a rare, severe form of VWD with almost complete absence of vWF, usually presenting with more severe bleeding symptoms.</li><li>\u2022 Option D. Von Willebrand Disease (VWD) Type 3</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 VWD Type 1 is the most common inherited bleeding disorder and often presents with mucocutaneous bleeding and a positive family history.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "95a5acc3",
      "audio": ""
    },
    {
      "text": "A 35-year-old man with a history of easy bruising and prolonged bleeding after minor procedures undergoes laboratory testing. The results reveal a normal von Willebrand factor (vWF) antigen level, but a decreased vWF ristocetin cofactor activity (RCoF). Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Von Willebrand disease (VWD) type 1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Von Willebrand disease (VWD) type 2",
          "correct": true
        },
        {
          "label": "C",
          "text": "Von Willebrand disease (VWD) type 3",
          "correct": false
        },
        {
          "label": "D",
          "text": "Acquired von Willebrand syndrome",
          "correct": false
        }
      ],
      "correct_answer": "B. Von Willebrand disease (VWD) type 2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Von Willebrand disease (VWD) type 2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Von Willebrand disease (VWD) type 1: In VWD type 1, both vWF antigen and RCoF levels are decreased proportionally, not just the RCoF.</li><li>\u2022 Option A. Von Willebrand disease (VWD) type 1:</li><li>\u2022 Option C. Von Willebrand disease (VWD) type 3: This is the most severe form of VWD with a near-complete absence of vWF, so both antigen and RCoF would be very low.</li><li>\u2022 Option C. Von Willebrand disease (VWD) type 3:</li><li>\u2022 Option D. Acquired von Willebrand syndrome: While this can mimic VWD, it is usually associated with underlying conditions like lymphoproliferative disorders, autoimmune diseases, or certain medications.</li><li>\u2022 Option D. Acquired von Willebrand syndrome:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 A normal vWF antigen level with a decreased RCoF strongly suggests a qualitative defect in vWF, which is characteristic of VWD type 2. Further testing can determine the specific subtype (2A, 2B, 2M, or 2N).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bf1aedbf",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with a lifelong history of heavy menstrual bleeding and easy bruising. She reports that her father also had similar bleeding issues. Her laboratory results show a normal platelet count, prolonged bleeding time, and reduced von Willebrand factor (vWF) antigen and ristocetin cofactor activity (R:Co). Which type of von Willebrand disease (VWD) is most likely?",
      "options": [
        {
          "label": "A",
          "text": "Type 1 VWD",
          "correct": true
        },
        {
          "label": "B",
          "text": "Type 2A VWD",
          "correct": false
        },
        {
          "label": "C",
          "text": "Type 2B VWD",
          "correct": false
        },
        {
          "label": "D",
          "text": "Type 3 VWD",
          "correct": false
        }
      ],
      "correct_answer": "A. Type 1 VWD",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Type 1 VWD</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Type 2A VWD : Presents with normal vWF antigen but decreased R:Co activity due to a qualitative defect in vWF multimers.</li><li>\u2022 Option B. Type 2A VWD</li><li>\u2022 Option C. Type 2B VWD : Presents with thrombocytopenia due to increased vWF-platelet binding, unlike the normal platelet count in this case.</li><li>\u2022 Option C. Type 2B VWD</li><li>\u2022 Option D. Type 3 VWD : Presents with severe deficiency of vWF, leading to more severe bleeding than described in this case.</li><li>\u2022 Option D. Type 3 VWD</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Type 1 VWD is the most common type and presents with a quantitative deficiency of vWF, causing mild to moderate bleeding.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f2b7ea9e",
      "audio": ""
    },
    {
      "text": "A 10-year-old boy presents with recurrent nosebleeds and prolonged bleeding after dental procedures. His laboratory results show a normal platelet count, prolonged bleeding time, and normal vWF antigen levels, but markedly reduced FVIII levels. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Type 1 VWD",
          "correct": false
        },
        {
          "label": "B",
          "text": "Type 2A VWD",
          "correct": false
        },
        {
          "label": "C",
          "text": "Type 2M VWD",
          "correct": false
        },
        {
          "label": "D",
          "text": "Type 2N VWD",
          "correct": true
        }
      ],
      "correct_answer": "D. Type 2N VWD",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Type 2N VWD</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Type 1 VWD: This type has a quantitative deficiency of vWF, so both vWF antigen and activity would be reduced.</li><li>\u2022 Option A. Type 1 VWD:</li><li>\u2022 Option B. Type 2A VWD: This type has a qualitative defect leading to decreased high molecular weight multimers of vWF, but FVIII levels are typically normal.</li><li>\u2022 Option B. Type 2A VWD:</li><li>\u2022 Option C. Type 2M VWD: This type also has a qualitative defect, but it mainly affects platelet adhesion, not FVIII binding. FVIII levels are usually normal.</li><li>\u2022 Option C. Type 2M VWD:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 When a patient presents with bleeding symptoms and a prolonged bleeding time, it is important to measure both vWF and FVIII levels to distinguish between VWD and hemophilia. A normal vWF antigen with decreased FVIII is highly suggestive of Type 2N VWD</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7d4f43ba",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman with a history of heavy menstrual bleeding and easy bruising is diagnosed with von Willebrand disease (VWD) type 1. Which of the following is the most appropriate initial treatment for a minor bleeding episode?",
      "options": [
        {
          "label": "A",
          "text": "Factor VIII concentrate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Recombinant von Willebrand factor (rVWF) concentrate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Desmopressin (DDAVP)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Cryoprecipitate",
          "correct": false
        }
      ],
      "correct_answer": "C. Desmopressin (DDAVP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Desmopressin (DDAVP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Factor VIII concentrate : Primarily used for hemophilia A, not VWD.</li><li>\u2022 Option A. Factor VIII concentrate</li><li>\u2022 Option B. rVWF concentrate : Reserved for more severe bleeding or VWD types 2 and 3.</li><li>\u2022 Option B. rVWF concentrate</li><li>\u2022 Option D. Cryoprecipitate : An older treatment option, less preferred due to risk of viral transmission.</li><li>\u2022 Option D. Cryoprecipitate</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 DDAVP is a safe and effective initial treatment for mild bleeding in VWD type 1.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "213409de",
      "audio": ""
    },
    {
      "text": "A 22-year-old man with a history of frequent nosebleeds and prolonged bleeding after a tooth extraction presents with recurrent, painless bloody urine. Examination reveals multiple hematomas and decreased range of motion with crepitus in both ankles. Laboratory studies show a normal platelet count, prolonged partial thromboplastin time (PTT), and hematuria without RBC casts. An x-ray of the pelvis shows no abnormalities. Further evaluation of this patient is most likely to show which of the following findings?",
      "options": [
        {
          "label": "A",
          "text": "Evasive behavior when asked about the hematomas",
          "correct": false
        },
        {
          "label": "B",
          "text": "History of spontaneous hematomas in paternal grandmother",
          "correct": false
        },
        {
          "label": "C",
          "text": "Petechiae in the oropharynx",
          "correct": false
        },
        {
          "label": "D",
          "text": "Intraarticular iron deposition",
          "correct": true
        }
      ],
      "correct_answer": "D. Intraarticular iron deposition",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Intraarticular iron deposition</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Evasive behavior when asked about the hematomas: While this might be present in some cases, it's not specific to hemophilia and doesn't help confirm the diagnosis.</li><li>\u2022 Option A. Evasive behavior when asked about the hematomas:</li><li>\u2022 Option B. History of spontaneous hematomas in paternal grandmother: While hemophilia is often inherited, a family history alone is not enough to diagnose the condition. Direct testing for factor deficiencies is needed.</li><li>\u2022 Option B. History of spontaneous hematomas in paternal grandmother:</li><li>\u2022 Option C. Petechiae in the oropharynx: Petechiae are typically associated with thrombocytopenia (low platelet count), not hemophilia. This patient's platelet count is normal.</li><li>\u2022 Option C. Petechiae in the oropharynx:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 In a patient with suspected hemophilia, further evaluation with imaging studies like MRI or ultrasound is essential to assess joint damage and confirm the diagnosis of hemophilic arthropathy. A positive family history can raise suspicion, but definitive diagnosis requires factor assays.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4b84f441",
      "audio": ""
    },
    {
      "text": "A 2-year-old boy presents with a swollen and painful right knee after falling from a chair. He has a history of easy bruising and prolonged bleeding after minor injuries. Family history reveals a maternal uncle with a bleeding disorder. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Von Willebrand Disease (VWD)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin K deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hemophilia A",
          "correct": true
        },
        {
          "label": "D",
          "text": "Disseminated Intravascular Coagulation (DIC)",
          "correct": false
        }
      ],
      "correct_answer": "C. Hemophilia A",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Hemophilia A</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Von Willebrand Disease (VWD): While it can cause bleeding, hemarthrosis is less common and the family history points more towards hemophilia .</li><li>\u2022 Option A. Von Willebrand Disease (VWD):</li><li>\u2022 .</li><li>\u2022 Option B. Vitamin K deficiency: This would cause bleeding due to impaired clotting factor synthesis, but it's less common in young children with no dietary restrictions.</li><li>\u2022 Option B. Vitamin K deficiency:</li><li>\u2022 Option D. Disseminated Intravascular Coagulation (DIC): This is a life-threatening condition with widespread clotting and bleeding, not just isolated hemarthrosis .</li><li>\u2022 Option D. Disseminated Intravascular Coagulation (DIC):</li><li>\u2022 .</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Hemarthrosis in young boys with a family history of bleeding disorders should raise suspicion for hemophilia A.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6777d082",
      "audio": ""
    },
    {
      "text": "A 10-year-old boy with severe hemophilia A has been receiving regular factor VIII replacement therapy. He presents with a hemarthrosis despite receiving his usual prophylactic dose. Which of the following is the most likely explanation?",
      "options": [
        {
          "label": "A",
          "text": "Non-compliance with therapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Development of an inhibitor against factor VIII",
          "correct": true
        },
        {
          "label": "C",
          "text": "Inadequate dose of factor VIII",
          "correct": false
        },
        {
          "label": "D",
          "text": "Factor VIII product contamination",
          "correct": false
        }
      ],
      "correct_answer": "B. Development of an inhibitor against factor VIII",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Development of an inhibitor against factor VIII</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Non-compliance with therapy : Non-compliance is less likely in a patient receiving regular prophylaxis.</li><li>\u2022 Option A. Non-compliance with therapy</li><li>\u2022 Option C. Inadequate dose of factor VIII : Inadequate dose would not explain the failure of the usual dose.</li><li>\u2022 Option C. Inadequate dose of factor VIII</li><li>\u2022 Option D. Factor VIII product contamination : Contamination is a rare occurrence.</li><li>\u2022 Option D. Factor VIII product contamination</li><li>\u2022 Educational objectives :</li><li>\u2022 Educational objectives</li><li>\u2022 :</li><li>\u2022 Suspect inhibitor development in hemophilia patients who fail to respond to their usual factor replacement dose.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7c1106f6",
      "audio": ""
    },
    {
      "text": "A 15-year-old boy with severe hemophilia A presents with sudden onset of abdominal pain and hematemesis. Which of the following is the most appropriate initial management?",
      "options": [
        {
          "label": "A",
          "text": "Immediate administration of factor VIII concentrate",
          "correct": true
        },
        {
          "label": "B",
          "text": "Emergency endoscopy to identify the bleeding source",
          "correct": false
        },
        {
          "label": "C",
          "text": "Urgent CT scan of the abdomen",
          "correct": false
        },
        {
          "label": "D",
          "text": "Admission to the ICU for monitoring",
          "correct": false
        }
      ],
      "correct_answer": "A. Immediate administration of factor VIII concentrate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Immediate administration of factor VIII concentrate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Emergency endoscopy to identify the bleeding source : Endoscopy can be helpful, but immediate factor replacement is a priority.</li><li>\u2022 Option B. Emergency endoscopy to identify the bleeding source</li><li>\u2022 Option C. Urgent CT scan of the abdomen : CT scan might be needed later, but not the most urgent step.</li><li>\u2022 Option C. Urgent CT scan of the abdomen</li><li>\u2022 Option D. Admission to the ICU for monitoring : ICU admission might be necessary depending on the severity, but factor replacement comes first.</li><li>\u2022 Option D. Admission to the ICU for monitoring</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Prioritize immediate factor replacement in hemophilia patients with severe bleeding episodes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0a8b1251",
      "audio": ""
    },
    {
      "text": "Which of the following coagulation factors are increased by the administration of DDAVP?",
      "options": [
        {
          "label": "A",
          "text": "Factor VIII only",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor IX only",
          "correct": false
        },
        {
          "label": "C",
          "text": "Both Factor VIII and von Willebrand Factor (vWF)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Factor VIII, vWF, and Factor IX",
          "correct": false
        }
      ],
      "correct_answer": "C. Both Factor VIII and von Willebrand Factor (vWF)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Both Factor VIII and von Willebrand Factor (vWF)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Factor VIII only : While DDAVP does increase Factor VIII, it also increases vWF.</li><li>\u2022 Option A. Factor VIII only</li><li>\u2022 Option B. Factor IX only : DDAVP does not affect Factor IX levels.</li><li>\u2022 Option B. Factor IX only</li><li>\u2022 Option D. Factor VIII, vWF, and Factor IX : This is incorrect because, as mentioned above, DDAVP does not affect Factor IX levels.</li><li>\u2022 Option D. Factor VIII, vWF, and Factor IX</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective :</li><li>\u2022 DDAVP is a useful therapeutic agent in certain bleeding disorders, particularly mild hemophilia A and some types of von Willebrand disease (VWD), due to its ability to increase the levels of both Factor VIII and vWF. Understanding its mechanism of action is crucial for selecting appropriate patients for treatment and anticipating its effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b43f29df",
      "audio": ""
    },
    {
      "text": "A 45-year-old male presents with a high fever, hypotension, and altered mental status. He has been experiencing abdominal pain and diarrhea for the past 24 hours. Laboratory investigations reveal prolonged prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombocytopenia. Which of the following is the most likely cause of his condition?",
      "options": [
        {
          "label": "A",
          "text": "Acute pancreatitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bacterial sepsis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Malignant hypertension",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thrombotic thrombocytopenic purpura (TTP)",
          "correct": false
        }
      ],
      "correct_answer": "B. Bacterial sepsis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Bacterial sepsis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient's clinical presentation of fever, hypotension, altered mental status, and laboratory findings (prolonged PT/aPTT, thrombocytopenia) are consistent with disseminated intravascular coagulation (DIC). The most common cause of DIC is sepsis, and given the patient's history of abdominal pain and diarrhea, bacterial sepsis is the most likely etiology.</li><li>\u2022 Explanation:</li><li>\u2022 Explanation:</li><li>\u2022 Option A. Acute pancreatitis : While pancreatitis can trigger DIC, it is less common than sepsis.</li><li>\u2022 Option A. Acute pancreatitis</li><li>\u2022 Option C. Malignant hypertension : Malignant hypertension can cause thrombotic microangiopathy but not typically DIC.</li><li>\u2022 Option C. Malignant hypertension</li><li>\u2022 Option D. Thrombotic thrombocytopenic purpura (TTP): TTP is a distinct disorder characterized by ADAMTS13 deficiency and does not typically present with prolonged PT/aPTT.</li><li>\u2022 Option D. Thrombotic thrombocytopenic purpura (TTP):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Sepsis is the most common cause of disseminated intravascular coagulation (DIC), and the clinical presentation often includes signs of systemic infection and abnormal coagulation parameters.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eb5f903e",
      "audio": ""
    },
    {
      "text": "A 28-year-old male presents with a history of mild bleeding tendencies since childhood, primarily after trauma or surgery. He is found to have prolonged PT and aPTT, both of which correct with mixing studies. Which of the following genetic mutations is most likely associated with his condition?",
      "options": [
        {
          "label": "A",
          "text": "Factor VIII gene mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor V gene mutation",
          "correct": false
        },
        {
          "label": "C",
          "text": "LMAN1 gene mutation",
          "correct": true
        },
        {
          "label": "D",
          "text": "Prothrombin gene mutation",
          "correct": false
        }
      ],
      "correct_answer": "C. LMAN1 gene mutation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) LMAN1 gene mutation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Factor VIII gene mutation : Causes hemophilia A, with isolated prolongation of aPTT.</li><li>\u2022 Option A. Factor VIII gene mutation</li><li>\u2022 Option B. Factor V gene mutation : Causes factor V deficiency, with isolated prolongation of PT.</li><li>\u2022 Option B. Factor V gene mutation</li><li>\u2022 Option D. Prothrombin gene mutation : Causes prothrombin deficiency, with isolated prolongation of PT.</li><li>\u2022 Option D. Prothrombin gene mutation</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Combined factor V and factor VIII deficiency is associated with mutations in the LMAN1 gene, leading to mild bleeding tendencies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8ad0ae74",
      "audio": ""
    },
    {
      "text": "A 35-year-old female presents with fatigue and pallor. Her reticulocyte count is 5%, hemoglobin is 9 g/dL, and hematocrit is 28%. What is her corrected reticulocyte count?",
      "options": [
        {
          "label": "A",
          "text": "2.5%",
          "correct": false
        },
        {
          "label": "B",
          "text": "3.0%",
          "correct": true
        },
        {
          "label": "C",
          "text": "5.0%",
          "correct": false
        },
        {
          "label": "D",
          "text": "10.0%",
          "correct": false
        }
      ],
      "correct_answer": "B. 3.0%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 3.0%.</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6cfd33f3",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with a history of heavy alcohol use presents with macrocytic anemia on a routine blood test. His MCV is 105 fL and his RPI is 3.5. What is the next best step in her management?",
      "options": [
        {
          "label": "A",
          "text": "Hemoglobin electrophoresis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Serum B12 and folate levels",
          "correct": true
        },
        {
          "label": "C",
          "text": "Direct antiglobulin test (DAT)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bone marrow biopsy",
          "correct": false
        }
      ],
      "correct_answer": "B. Serum B12 and folate levels",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Serum B12 and folate levels</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Hemoglobin electrophoresis: This test is used to identify abnormal types of hemoglobin, as seen in conditions like sickle cell disease or thalassemia. It is not helpful in diagnosing vitamin B12 or folate deficiency.</li><li>\u2022 Option A. Hemoglobin electrophoresis:</li><li>\u2022 Option C. Direct antiglobulin test (DAT): This test is used to diagnose autoimmune hemolytic anemias, where the body's immune system attacks its own red blood cells. This is not the primary concern in this patient.</li><li>\u2022 Option C.</li><li>\u2022 Direct antiglobulin test (DAT):</li><li>\u2022 Option D. Bone marrow biopsy : While a bone marrow biopsy can reveal megaloblastic changes (characteristic of B12/folate deficiency), it is an invasive procedure and usually reserved for cases where the diagnosis is unclear or there is suspicion of other marrow disorders.</li><li>\u2022 Option D. Bone</li><li>\u2022 marrow biopsy</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 In a patient with macrocytic anemia and a history suggestive of vitamin B12 or folate deficiency, the most helpful initial test is measuring serum B12 and folate levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "36440aa1",
      "audio": ""
    },
    {
      "text": "A 45-year-old male with a history of chronic kidney disease presents with fatigue and shortness of breath. His laboratory findings show a MCV 88 fL with a low reticulocyte production index (RPI < 2). Which of the following is the MOST likely cause of his anemia?",
      "options": [
        {
          "label": "A",
          "text": "Folate deficiency",
          "correct": false
        },
        {
          "label": "B",
          "text": "Iron deficiency anemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hemolytic anemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anemia of chronic disease",
          "correct": true
        }
      ],
      "correct_answer": "D. Anemia of chronic disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Anemia of chronic disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Folate deficiency: Macrocytic anemia with high RPI.</li><li>\u2022 Option A. Folate deficiency:</li><li>\u2022 Option B. Iron deficiency anemia: Microcytic anemia with low RPI.</li><li>\u2022 Option B. Iron deficiency anemia:</li><li>\u2022 Option C. Hemolytic anemia: Normocytic/macrocytic anemia with high RPI.</li><li>\u2022 Option C. Hemolytic anemia:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Normocytic anemia with low RPI in the setting of chronic disease should prompt consideration of anemia of chronic disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f3256155",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with a history of rheumatoid arthritis presents with fatigue and a normocytic anemia (MCV 90 fL). His iron studies show the following: Serum iron: 30 mcg/dL (normal: 60-170 mcg/dL) TIBC: 200 mcg/dL (normal: 240-450 mcg/dL) Ferritin: 350 ng/mL (normal: 20-500 ng/mL) Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Anemia of chronic disease (ACD)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Iron deficiency anemia (IDA)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thalassemia trait",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sideroblastic anemia (SA)",
          "correct": false
        }
      ],
      "correct_answer": "A. Anemia of chronic disease (ACD)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Anemia of chronic disease (ACD)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Iron deficiency anemia (IDA): IDA would typically present with low serum iron, high TIBC, and low ferritin.</li><li>\u2022 Option B. Iron deficiency anemia (IDA):</li><li>\u2022 Option C. Thalassemia trait: This is a genetic condition causing microcytic anemia, not normocytic.</li><li>\u2022 Option C. Thalassemia trait:</li><li>\u2022 Option D. Sideroblastic anemia (SA): SA is less likely in this scenario as it often presents with elevated serum iron and ferritin.</li><li>\u2022 Option D. Sideroblastic anemia (SA):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Recognizing the distinct pattern of iron studies in anemia of chronic disease (low serum iron, low TIBC, and normal to elevated ferritin) is crucial for differentiating it from iron deficiency anemia. In the setting of a chronic inflammatory condition like rheumatoid arthritis, anemia of chronic disease is a common consideration.</li><li>\u2022 Recognizing the distinct pattern of iron studies in anemia of chronic disease (low serum iron, low TIBC, and normal to elevated ferritin) is crucial for differentiating it from iron deficiency anemia.</li><li>\u2022 In the setting of a chronic inflammatory condition like rheumatoid arthritis, anemia of chronic disease is a common consideration.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9ed46f3a",
      "audio": ""
    },
    {
      "text": "A 45-year-old male with a history of chronic alcoholism presents with fatigue, pallor, and a microcytic anemia. His iron studies reveal elevated iron, TIBC, and ferritin. Blood smear shows basophilic stippling. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Iron deficiency anemia (IDA)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sideroblastic anemia (SA)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Thalassemia trait",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anemia of chronic disease (ACD)",
          "correct": false
        }
      ],
      "correct_answer": "B. Sideroblastic anemia (SA)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Sideroblastic anemia (SA)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Iron deficiency anemia (IDA): IDA would typically present with microcytic anemia but with low serum iron, high TIBC, and low ferritin.</li><li>\u2022 Option A. Iron deficiency anemia (IDA):</li><li>\u2022 Option C. Thalassemia trait: While thalassemia can also cause microcytic anemia, it would not typically cause elevated iron indices and basophilic stippling. Hemoglobin electrophoresis would be needed for definitive diagnosis.</li><li>\u2022 Option C. Thalassemia trait:</li><li>\u2022 Option D. Anemia of chronic disease (ACD): ACD usually presents as a normocytic anemia, though it can occasionally be microcytic. However, the iron indices in ACD would show low serum iron, low TIBC, and normal or elevated ferritin.</li><li>\u2022 Option D. Anemia of chronic disease (ACD):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 the classic presentation and laboratory findings of sideroblastic anemia, particularly in the setting of chronic alcoholism:</li><li>\u2022 Microcytic anemia: Small red blood cells (MCV < 80 fL) Elevated iron indices: High serum iron, high total iron binding capacity (TIBC), and high ferritin Basophilic stippling: Characteristic finding on peripheral blood smear History of alcohol abuse: A risk factor for sideroblastic anemia.</li><li>\u2022 Microcytic anemia: Small red blood cells (MCV < 80 fL)</li><li>\u2022 Elevated iron indices: High serum iron, high total iron binding capacity (TIBC), and high ferritin</li><li>\u2022 Basophilic stippling: Characteristic finding on peripheral blood smear</li><li>\u2022 History of alcohol abuse: A risk factor for sideroblastic anemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cbbb9cd6",
      "audio": ""
    },
    {
      "text": "A patient with microcytic anemia fails to respond to oral iron supplementation. Which of the following should be considered in the differential diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Thalassemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sideroblastic anemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anemia of chronic disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All of the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All of the above</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3040b3bc",
      "audio": ""
    },
    {
      "text": "A 32-year-old woman with heavy menstrual bleeding presents with fatigue and pallor. Her lab results show a microcytic anemia with an elevated red cell distribution width and a low reticulocyte count. Which of the following laboratory findings would MOST likely be seen in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Normal serum iron, normal TIBC, and normal ferritin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Low serum iron, high TIBC, and low ferritin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Low serum iron, low TIBC, and high ferritin",
          "correct": false
        },
        {
          "label": "D",
          "text": "High serum iron, normal TIBC, and high ferritin",
          "correct": false
        }
      ],
      "correct_answer": "B. Low serum iron, high TIBC, and low ferritin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Low serum iron, high TIBC, and low ferritin</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ea582abf",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman of Mediterranean descent is found to have mild microcytic anemia on routine blood work. Her iron studies are normal, and hemoglobin electrophoresis reveals an elevated HbA2 level. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Iron deficiency anemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anemia of chronic disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Beta-thalassemia trait",
          "correct": true
        },
        {
          "label": "D",
          "text": "Alpha-thalassemia trait",
          "correct": false
        }
      ],
      "correct_answer": "C. Beta-thalassemia trait",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Beta-thalassemia trait</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Iron deficiency anemia (IDA): While IDA is the most common cause of microcytic anemia, it would typically present with abnormal iron studies (low serum iron, low ferritin, and high total iron-binding capacity).</li><li>\u2022 Option A. Iron deficiency anemia (IDA):</li><li>\u2022 Option B. Anemia of chronic disease (ACD): ACD is typically normocytic, but can occasionally be microcytic. However, it would not typically cause elevated HbA2 levels on electrophoresis.</li><li>\u2022 Option B. Anemia of chronic disease (ACD):</li><li>\u2022 Option D. Alpha-thalassemia trait: Alpha thalassemia is another inherited disorder that can cause microcytic anemia, but it would not typically cause elevated HbA2 levels. Instead, it may be associated with an elevated HbH level or a normal hemoglobin electrophoresis.</li><li>\u2022 Option D. Alpha-thalassemia trait:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Beta-thalassemia is a common cause of microcytic anemia in individuals of Mediterranean descent. Hemoglobin electrophoresis is essential for diagnosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dc4f97a2",
      "audio": ""
    },
    {
      "text": "A 40-year-old female with a history of systemic lupus erythematosus (SLE) presents with fatigue, pallor, and jaundice. Her laboratory evaluation reveals a normocytic anemia with a positive direct antiglobulin test (DAT). Which of the following is the most likely mechanism of her anemia?",
      "options": [
        {
          "label": "A",
          "text": "Iron deficiency",
          "correct": false
        },
        {
          "label": "B",
          "text": "Folate deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Immune-mediated hemolysis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Impaired erythropoiesis",
          "correct": false
        }
      ],
      "correct_answer": "C. Immune-mediated hemolysis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Immune-mediated hemolysis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Iron deficiency: While iron deficiency can cause anemia, it typically results in a microcytic anemia (smaller red blood cells), not normocytic. Additionally, it would not explain the positive DAT or jaundice.</li><li>\u2022 Option A. Iron deficiency:</li><li>\u2022 Option B. Folate deficiency: Folate deficiency can lead to megaloblastic anemia, which is a type of macrocytic anemia (larger red blood cells), not normocytic. It would also not explain the positive DAT or jaundice.</li><li>\u2022 Option B. Folate deficiency:</li><li>\u2022 Option D. Impaired erythropoiesis: While SLE can sometimes affect the bone marrow and lead to impaired red blood cell production, it's less common than immune-mediated hemolysis and wouldn't explain the positive DAT.</li><li>\u2022 Option D. Impaired erythropoiesis:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The combination of normocytic anemia, positive DAT, and jaundice in a patient with SLE strongly points toward immune-mediated hemolysis as the underlying cause.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8ce3eaca",
      "audio": ""
    },
    {
      "text": "In a healthy adult male, the average daily iron absorption from dietary sources is approximately:",
      "options": [
        {
          "label": "A",
          "text": "0.5 mg",
          "correct": false
        },
        {
          "label": "B",
          "text": "1 mg",
          "correct": true
        },
        {
          "label": "C",
          "text": "1.4 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "2 mg",
          "correct": false
        }
      ],
      "correct_answer": "B. 1 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 1 mg</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5bdc818d",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman with heavy menstrual periods complains of fatigue and brittle nails. Her lab results show a serum ferritin of 18 ng/mL and her TIBC was 370. Peripheral smear turns out to be normal. What is the MOST likely stage of iron deficiency in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Negative iron balance",
          "correct": true
        },
        {
          "label": "B",
          "text": "Iron-deficient erythropoiesis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Iron deficiency anemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Iron overload",
          "correct": false
        }
      ],
      "correct_answer": "A. Negative iron balance",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Negative iron balance</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Iron-deficient erythropoiesis: In this stage, hemoglobin and hematocrit would likely start to decline.</li><li>\u2022 Option B. Iron-deficient erythropoiesis:</li><li>\u2022 Option C. Iron deficiency anemia: This stage is characterized by a clear drop in hemoglobin and hematocrit, along with microcytic and hypochromic red blood cells on peripheral smear.</li><li>\u2022 Option C. Iron deficiency anemia:</li><li>\u2022 Option D. Iron overload: This is the opposite of iron deficiency and is associated with elevated ferritin, normal to low TIBC, and other systemic complications.</li><li>\u2022 Option D. Iron overload:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Early detection of iron deficiency through low serum ferritin is crucial for timely intervention and prevention of progression to iron deficiency anemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b70c406f",
      "audio": ""
    },
    {
      "text": "Which of the following substances can IMPAIR the absorption of iron supplements?",
      "options": [
        {
          "label": "A",
          "text": "Ascorbic acid",
          "correct": false
        },
        {
          "label": "B",
          "text": "Orange juice",
          "correct": false
        },
        {
          "label": "C",
          "text": "Meat",
          "correct": false
        },
        {
          "label": "D",
          "text": "Antacids",
          "correct": true
        }
      ],
      "correct_answer": "D. Antacids",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Antacids</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option (A, B, C): Vitamin C (in ascorbic acid and orange juice) and meat can all improve iron absorption.</li><li>\u2022 Option (A, B, C):</li><li>\u2022 ascorbic acid</li><li>\u2022 orange juice)</li><li>\u2022 meat</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Patients taking iron supplements should avoid taking antacids concurrently, as this can reduce absorption.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ebc9e692",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman with iron deficiency anemia is prescribed ferrous sulfate. Which of the following statements about ferrous sulphate is INCORRECT?",
      "options": [
        {
          "label": "A",
          "text": "It is a common and effective oral iron supplement.",
          "correct": false
        },
        {
          "label": "B",
          "text": "It should be taken on an empty stomach for optimal absorption.",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is often combined with ascorbic acid to enhance absorption.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It is the iron preparation with the highest elemental iron content.",
          "correct": true
        }
      ],
      "correct_answer": "D. It is the iron preparation with the highest elemental iron content.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) It is the iron preparation with the highest elemental iron content</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. It is a common and effective oral iron supplement: This is correct. Ferrous sulfate is widely used and effective for treating iron deficiency anemia.</li><li>\u2022 Option A. It is a common and effective oral iron supplement:</li><li>\u2022 Option B. It should be taken on an empty stomach for optimal absorption: This is also correct. Iron is best absorbed in an acidic environment, so taking it on an empty stomach or with vitamin C (which enhances acidity) improves absorption.</li><li>\u2022 Option B. It should be taken on an empty stomach for optimal absorption:</li><li>\u2022 Option C. It is often combined with ascorbic acid to enhance absorption: This is true. Ascorbic acid (vitamin C) helps convert ferric iron to ferrous iron, the form more readily absorbed by the body.</li><li>\u2022 Option C. It is often combined with ascorbic acid to enhance absorption:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Different iron preparations vary in their elemental iron content, but most are well absorbed and effective in treating iron deficiency anemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c7f90a73",
      "audio": ""
    },
    {
      "text": "A patient has experienced anaphylaxis to iron dextran in the past. Which of the following statements is MOST accurate regarding their future management of iron deficiency anemia?",
      "options": [
        {
          "label": "A",
          "text": "They can safely receive any other parenteral iron formulation.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Oral iron therapy is the only safe option for them.",
          "correct": false
        },
        {
          "label": "C",
          "text": "They should be referred for blood transfusion as needed.",
          "correct": false
        },
        {
          "label": "D",
          "text": "They may be able to receive alternative parenteral iron formulations under close supervision.",
          "correct": true
        }
      ],
      "correct_answer": "D. They may be able to receive alternative parenteral iron formulations under close supervision.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) They may be able to receive alternative parenteral iron formulations under close supervision.</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b0ae89d4",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with severe iron deficiency anemia requires rapid replenishment of her iron stores. Which of the following parenteral iron preparations would provide the highest amount of iron in a single infusion?",
      "options": [
        {
          "label": "A",
          "text": "Ferric gluconate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Iron sucrose",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ferric carboxymaltose",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ferric derisomaltose",
          "correct": true
        }
      ],
      "correct_answer": "D. Ferric derisomaltose",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Ferric derisomaltose</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Ferric gluconate: Delivers a much lower dose of iron per infusion (125 mg).</li><li>\u2022 Option A. Ferric gluconate:</li><li>\u2022 Option B. Iron sucrose: Delivers a lower dose of iron per infusion (200 mg).</li><li>\u2022 Option B. Iron sucrose:</li><li>\u2022 Option C. Ferric carboxymaltose: Delivers a lower dose of iron per infusion (750 mg).</li><li>\u2022 Option C. Ferric carboxymaltose:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Ferric derisomaltose is a valuable option for patients with severe iron deficiency anemia who require rapid correction of iron stores, as it allows for the administration of a large dose of iron in a single infusion. However, it's important to consider potential side effects and contraindications before choosing this preparation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7edaf1d4",
      "audio": ""
    },
    {
      "text": "A patient with iron deficiency anemia is started on oral iron supplementation. When would you expect to see the PEAK reticulocyte response, indicating that the bone marrow is actively producing new red blood cells?",
      "options": [
        {
          "label": "A",
          "text": "Within 24-48 hours of starting therapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "3-4 days after starting therapy",
          "correct": false
        },
        {
          "label": "C",
          "text": "7-10 days after starting therapy",
          "correct": true
        },
        {
          "label": "D",
          "text": "14-21 days after starting therapy",
          "correct": false
        }
      ],
      "correct_answer": "C. 7-10 days after starting therapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 7-10 days after starting therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Within 24-48 hours of starting therapy: This is too soon to expect a peak response. It takes several days for the bone marrow to ramp up red blood cell production.</li><li>\u2022 Option A.</li><li>\u2022 Within 24-48 hours of starting therapy:</li><li>\u2022 Option B. 3-4 days after starting therapy: While the reticulocyte count may start to rise within 3-4 days, the peak response is typically later.</li><li>\u2022 Option B. 3-4 days after starting therapy:</li><li>\u2022 Option D. 14-21 days after starting therapy: This is too late for the peak response. If there's no significant increase by this time, it could suggest a lack of response to therapy or an alternative diagnosis.</li><li>\u2022 Option D. 14-21 days after starting therapy:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The reticulocyte count is a valuable tool for monitoring the response to iron therapy in iron deficiency anemia. An increase in reticulocytes within 4-7 days and a peak response at 7-10 days are expected findings, indicating that the treatment is effective.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a80dca6",
      "audio": ""
    },
    {
      "text": "A 30-year-old woman with microcytic anemia is given an iron tolerance test. Two hours after ingesting two iron tablets on an empty stomach, her serum iron level increases by 80 mcg/dL. What is the most likely interpretation of this result?",
      "options": [
        {
          "label": "A",
          "text": "Normal iron absorption",
          "correct": false
        },
        {
          "label": "B",
          "text": "Iron malabsorption",
          "correct": true
        },
        {
          "label": "C",
          "text": "Iron overload",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vitamin B12 deficiency",
          "correct": false
        }
      ],
      "correct_answer": "B. Iron malabsorption",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Iron malabsorption</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2fa2916c",
      "audio": ""
    },
    {
      "text": "In infants who survive Hb Bart's hydrops fetalis, the approximate percentage that experiences neurodevelopmental delay is:",
      "options": [
        {
          "label": "A",
          "text": "10%",
          "correct": false
        },
        {
          "label": "B",
          "text": "20%",
          "correct": true
        },
        {
          "label": "C",
          "text": "30%",
          "correct": false
        },
        {
          "label": "D",
          "text": "40%",
          "correct": false
        }
      ],
      "correct_answer": "B. 20%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 20%</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. 10%: This underestimates the risk of neurodevelopmental delay in this population.</li><li>\u2022 Option A. 10%:</li><li>\u2022 Option C. 30%: This overestimates the risk of neurodevelopmental delay in this population.</li><li>\u2022 Option C. 30%:</li><li>\u2022 Option D. 40%: This is the percentage of survivors who experience growth retardation, not neurodevelopmental delay.</li><li>\u2022 Option D. 40%:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Hb Bart\u2019s hydrops fetalis is best prevented by screening couples at risk and antenatal diagnosis. Intrauterine therapy and perinatal intensive care have permitted survival of some infants with Hb Bart hydrops fetalis. As growth retardation affects ~40% and neurodevelopmental delay is present in 20% of survivors, prevention is the best approach.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "69d00d55",
      "audio": ""
    },
    {
      "text": "Which of the following alpha-globin gene arrangements is MOST likely to be associated with Hemoglobin H (HbH) disease?",
      "options": [
        {
          "label": "A",
          "text": "\u03b1\u03b1/\u03b1\u03b1",
          "correct": false
        },
        {
          "label": "B",
          "text": "-\u03b1/\u03b1\u03b1",
          "correct": false
        },
        {
          "label": "C",
          "text": "--/\u03b1\u03b1",
          "correct": false
        },
        {
          "label": "D",
          "text": "--/-\u03b1",
          "correct": true
        }
      ],
      "correct_answer": "D. --/-\u03b1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) --/-\u03b1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. \u03b1\u03b1/\u03b1\u03b1: \u03b1-thal. With Myelodysplasia - Mutations in ATRX ; striking male predominance. Hematologic findings of HbH disease.</li><li>\u2022 Option A. \u03b1\u03b1/\u03b1\u03b1:</li><li>\u2022 Option B. -\u03b1/\u03b1\u03b1: Represents the silent carrier state of alpha-thalassemia, with only one alpha-globin gene deleted. It typically doesn't cause significant clinical symptoms.</li><li>\u2022 Option B.</li><li>\u2022 -\u03b1/\u03b1\u03b1:</li><li>\u2022 Option C. --/\u03b1\u03b1: Represents alpha-thalassemia trait, where two alpha-globin genes are deleted. This condition can lead to mild anemia but is not associated with HbH disease.</li><li>\u2022 Option C.</li><li>\u2022 --/\u03b1\u03b1:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The specific arrangement and number of alpha-globin gene deletions determine the severity of alpha-thalassemia. HbH disease, a moderate form of the condition, is caused by the deletion or inactivation of three out of four alpha-globin genes, represented by the genotype --/-\u03b1 (other gene arrangement: \u03b1 T \u03b1/- -, \u03b1 T \u03b1/\u03b1 T \u03b1)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c051cf5a",
      "audio": ""
    },
    {
      "text": "A 30-year-old man with microcytic anemia is found to have a mutation in the 3' end-processing sequence of the beta-globin gene. Which of the following is the MOST likely consequence of this mutation?",
      "options": [
        {
          "label": "A",
          "text": "Prevention of RNA polyadenylation and reduced beta-globin production",
          "correct": true
        },
        {
          "label": "B",
          "text": "Introduction of a stop codon and premature termination of translation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Creation of an alternative splice site in an intron",
          "correct": false
        },
        {
          "label": "D",
          "text": "Total absence of beta-globin production",
          "correct": false
        }
      ],
      "correct_answer": "A. Prevention of RNA polyadenylation and reduced beta-globin production",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Prevention of RNA polyadenylation and reduced beta-globin production</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2e7208eb",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman of Mediterranean descent presents with mild anemia and microcytosis. Her iron studies are normal, and genetic testing reveals a change in the promoter region of the beta-globin gene. Which type of beta-thalassemia is she most likely to have?",
      "options": [
        {
          "label": "A",
          "text": "Beta-zero ( \u03b2 0) thalassemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Beta-plus ( \u03b2 +) thalassemia",
          "correct": true
        },
        {
          "label": "C",
          "text": "Delta-beta ( \u03b4\u03b2 ) thalassemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hemoglobin Lepore thalassemia",
          "correct": false
        }
      ],
      "correct_answer": "B. Beta-plus ( \u03b2 +) thalassemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Beta-plus (\u03b2+) thalassemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Beta-zero (\u03b20) thalassemia: Caused by severe mutations, not promoter changes, leading to complete absence of beta-globin production.</li><li>\u2022 Option A.</li><li>\u2022 Beta-zero (\u03b20) thalassemia:</li><li>\u2022 Option C. Delta-beta (\u03b4\u03b2) thalassemia: Deletion of both delta and beta globin genes causes a different clinical picture.</li><li>\u2022 Option C.</li><li>\u2022 Delta-beta (\u03b4\u03b2) thalassemia:</li><li>\u2022 Option D. Hemoglobin Lepore thalassemia : Rare condition caused by delta-beta globin gene fusion, not promoter mutations.</li><li>\u2022 Option D. Hemoglobin Lepore thalassemia</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Promoter mutations are a common cause of milder beta-thalassemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "885f2192",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman with a history of mild anemia on routine blood work presents for a follow-up appointment. She reports good energy levels and denies any recent illnesses or blood loss. Her physical examination is unremarkable. A peripheral blood smear is shown in the image. Which of the following hematological conditions is MOST likely represented in this blood smear?",
      "options": [
        {
          "label": "A",
          "text": "Iron deficiency anemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin B12 deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sickle cell anemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Beta-thalassemia intermedia",
          "correct": true
        }
      ],
      "correct_answer": "D. Beta-thalassemia intermedia",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/31/screenshot-2024-07-31-124914.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Beta-thalassemia intermedia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Iron deficiency anemia: While also microcytic and hypochromic, it usually does not exhibit target cells or the degree of poikilocytosis seen here.</li><li>\u2022 Option A. Iron deficiency anemia:</li><li>\u2022 Option B. Vitamin B12 deficiency: Causes macrocytic (large red blood cell) anemia, not microcytic.</li><li>\u2022 Option B. Vitamin B12 deficiency:</li><li>\u2022 Option C. Sickle cell anemia: Characterized by sickle-shaped red blood cells, which are not present in this image.</li><li>\u2022 Option C. Sickle cell anemia:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The presence of target cells, anisocytosis, poikilocytosis, hypochromia and microcytosis in a blood smear strongly suggests beta-thalassemia intermedia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "715e4fef",
      "audio": ""
    },
    {
      "text": "A 30-years-old male with a history of beta-thalassemia major has been receiving regular blood transfusions every 3 weeks to maintain a pre-transfusion hemoglobin level of 9.5 g/dL. Despite adherence to his transfusion schedule, he has recently developed fatigue, skin hyperpigmentation and hepatomegaly. Which of the following is the most likely cause of his new symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Insufficient blood transfusions",
          "correct": false
        },
        {
          "label": "B",
          "text": "Iron overload",
          "correct": true
        },
        {
          "label": "C",
          "text": "Folate deficiency",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vitamin B12 deficiency",
          "correct": false
        }
      ],
      "correct_answer": "B. Iron overload",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Iron overload</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Insufficient blood transfusions: The patient is adhering to the transfusion schedule, and his hemoglobin level is within the target range for thalassemia major. Thus, insufficient transfusions are unlikely to be the cause of his symptoms.</li><li>\u2022 Option A. Insufficient blood transfusions:</li><li>\u2022 Option C. Folate deficiency: Folate deficiency typically causes megaloblastic anemia with macrocytic red blood cells. This is not consistent with the patient's history of thalassemia major or the presentation with microcytic anemia.</li><li>\u2022 Option C. Folate deficiency:</li><li>\u2022 Option D. Vitamin B12 deficiency: Similar to folate deficiency, vitamin B12 deficiency causes megaloblastic anemia, which is inconsistent with the patient's presentation.</li><li>\u2022 Option D. Vitamin B12 deficiency:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Iron chelation therapy is crucial in patients with thalassemia major receiving regular transfusions to prevent iron overload and its associated complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b2601889",
      "audio": ""
    },
    {
      "text": "Which of the following chelating agents is administered orally for the treatment of iron overload in patients with thalassemia major?",
      "options": [
        {
          "label": "A",
          "text": "Deferoxamine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Deferiprone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Deferasirox",
          "correct": false
        },
        {
          "label": "D",
          "text": "Both B and C",
          "correct": true
        }
      ],
      "correct_answer": "D. Both B and C",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Both B and C</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Deferoxamine: Deferoxamine is an intravenous iron chelator and requires subcutaneous infusion over several hours, making it less convenient for long-term use.</li><li>\u2022 Option A. Deferoxamine:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Oral iron chelators like deferiprone and deferasirox have revolutionized the management of iron overload in thalassemia major by offering a more convenient and less invasive alternative to deferoxamine. Early and consistent chelation therapy is crucial for preventing iron-related complications and improving the quality of life for patients with thalassemia major.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c39060e4",
      "audio": ""
    },
    {
      "text": "A patient presents with anemia and acrocyanosis that worsens in cold weather. Which of the following laboratory findings is most consistent with cold agglutinin syndrome (CAS)?",
      "options": [
        {
          "label": "A",
          "text": "Positive direct antiglobulin test (DAT) with anti-IgG specificity",
          "correct": false
        },
        {
          "label": "B",
          "text": "Positive DAT with anti-C3d specificity",
          "correct": false
        },
        {
          "label": "C",
          "text": "Positive DAT with anti-IgM specificity",
          "correct": true
        },
        {
          "label": "D",
          "text": "Negative DAT",
          "correct": false
        }
      ],
      "correct_answer": "C. Positive DAT with anti-IgM specificity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Positive DAT with anti-IgM specificity</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Positive direct antiglobulin test (DAT) with anti-IgG specificity and Option B. Positive DAT with anti-C3d specificity are more commonly associated with WAIHA.</li><li>\u2022 Option A. Positive direct antiglobulin test (DAT) with anti-IgG specificity</li><li>\u2022 Option</li><li>\u2022 B. Positive DAT with anti-C3d specificity</li><li>\u2022 Option D. Negative DAT : A negative DAT would not be expected in a patient with autoimmune hemolytic anemia.</li><li>\u2022 Option D.</li><li>\u2022 Negative DAT</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 A positive DAT with anti-IgM specificity is a key laboratory finding in the diagnosis of CAS.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fadf61ec",
      "audio": ""
    },
    {
      "text": "A 68-year-old man with a history of lymphoma presents with fatigue, jaundice, and splenomegaly. Peripheral blood smear shows spherocytes. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Cold agglutinin disease (CAD)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Paroxysmal cold hemoglobinuria (PCH)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Warm autoimmune hemolytic anemia (WAIHA)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Microangiopathic hemolytic anemia (MAHA)",
          "correct": false
        }
      ],
      "correct_answer": "C. Warm autoimmune hemolytic anemia (WAIHA)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Warm autoimmune hemolytic anemia (WAIHA)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Cold agglutinin disease (CAD): Primarily presents with acrocyanosis and anemia, and blood smear often reveals agglutination.</li><li>\u2022 Option A. Cold agglutinin disease (CAD):</li><li>\u2022 Option B. Paroxysmal cold hemoglobinuria (PCH): Paroxysmal cold hemoglobinuria (PCH) is rare and typically presents with biphasic hemolysis and hemoglobinuria after cold exposure.</li><li>\u2022 Option B. Paroxysmal cold hemoglobinuria (PCH):</li><li>\u2022 Option D. Microangiopathic hemolytic anemia (MAHA): Presents with schistocytes on peripheral smear and is associated with underlying conditions like thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS).</li><li>\u2022 Option D. Microangiopathic hemolytic anemia (MAHA):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 WAIHA is the most common type of autoimmune hemolytic anemia and can be associated with underlying lymphoproliferative disorders like lymphoma</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "556a756e",
      "audio": ""
    },
    {
      "text": "Which of the following is the most common cause of death in adult patients with sickle cell disease?",
      "options": [
        {
          "label": "A",
          "text": "Acute chest syndrome",
          "correct": true
        },
        {
          "label": "B",
          "text": "Stroke",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sepsis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pulmonary hypertension",
          "correct": false
        }
      ],
      "correct_answer": "A. Acute chest syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Acute chest syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Stroke: While stroke is a significant cause of morbidity and mortality in children with sickle cell disease (SCD), it is less common in adults.</li><li>\u2022 Option B. Stroke:</li><li>\u2022 Option C. Sepsis: Sepsis is a major concern in SCD patients of all ages due to functional asplenia (decreased spleen function). However, acute chest syndrome remains the leading cause of death in adults.</li><li>\u2022 Option C. Sepsis:</li><li>\u2022 Option D. Pulmonary hypertension: Pulmonary hypertension is a serious complication of SCD, contributing to morbidity and mortality. However, it is not as frequent a cause of death as acute chest syndrome in adults.</li><li>\u2022 Option D. Pulmonary hypertension:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Early recognition and aggressive management of acute chest syndrome are crucial in preventing mortality in sickle cell disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9ae1f76a",
      "audio": ""
    },
    {
      "text": "The genetic mutation in sickle cell disease results in the substitution of which amino acid in the beta-globin chain?",
      "options": [
        {
          "label": "A",
          "text": "Glutamic acid to lysine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glutamic acid to valine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Valine to glutamic acid",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lysine to glutamic acid",
          "correct": false
        }
      ],
      "correct_answer": "B. Glutamic acid to valine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Glutamic acid to valine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Glutamic acid to lysine: This substitution does occur in some hemoglobin variants (e.g., HbC), but not in sickle cell disease (HbS). HbC causes a milder form of anemia compared to HbS.</li><li>\u2022 Option A. Glutamic acid to lysine:</li><li>\u2022 Option C. Valine to glutamic acid: This would be the reverse of the actual mutation in sickle cell disease and would result in a different hemoglobin variant.</li><li>\u2022 Option C. Valine to glutamic acid:</li><li>\u2022 Option D. Lysine to glutamic acid: This substitution is not associated with any known hemoglobinopathy.</li><li>\u2022 Option D. Lysine to glutamic acid:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The specific amino acid substitution (glutamic acid to valine) in sickle cell disease is responsible for the structural and functional abnormalities of hemoglobin S (HbS) that lead to sickling and the associated clinical manifestations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6e82e9d3",
      "audio": ""
    },
    {
      "text": "A 28-year-old African American woman presents with mild anemia and complains of intermittent abdominal pain. On peripheral blood smear, target cells and rhomboid crystals are noted within red blood cells. Given the likely diagnosis, Which of the following amino acid changes is responsible for this condition?",
      "options": [
        {
          "label": "A",
          "text": "Glutamic acid to lysine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Valine to glutamic acid",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lysine to glutamic acid",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glutamic acid to valine",
          "correct": false
        }
      ],
      "correct_answer": "A. Glutamic acid to lysine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Glutamic acid to lysine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Valine to glutamic acid: This substitution is the characteristic change for sickle cell anemia (HbS).</li><li>\u2022 Option B. Valine to glutamic acid:</li><li>\u2022 Option C. Lysine to glutamic acid: Swapping these two positively charged amino acids would likely have a minimal effect on hemoglobin function.</li><li>\u2022 Option C. Lysine to glutamic acid:</li><li>\u2022 Option D. Glutamic acid to valine: This substitution is also seen in HbS and leads to the polymerization of red blood cells.</li><li>\u2022 Option D. Glutamic acid to valine:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 HbC disease is a milder form of hemoglobinopathy compared to sickle cell disease, but it is important to distinguish it based on the specific amino acid substitution.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e786964f",
      "audio": ""
    },
    {
      "text": "A 10-year-old child presents with severe anemia, jaundice, and splenomegaly. Their hemoglobin level is 5 g/dL. The peripheral blood smear shows numerous target cells and sickled red blood cells. Which of the following hemoglobinopathies is most likely?",
      "options": [
        {
          "label": "A",
          "text": "HbC disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "HbSC disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "HbD disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "HbDC disease",
          "correct": true
        }
      ],
      "correct_answer": "D. HbDC disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) HbDC disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. HbC disease: Usually mild anemia without severe complications.</li><li>\u2022 Option A. HbC disease:</li><li>\u2022 Option B. HbSC disease: Typically less severe than HbSS, with a hemoglobin level usually >10 g/dL.</li><li>\u2022 Option B. HbSC disease:</li><li>\u2022 Option C. HbD disease: Typically asymptomatic or mild anemia.</li><li>\u2022 Option C. HbD disease:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 HbDC disease is a severe hemoglobinopathy that can present similarly to sickle cell disease (HbSS).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "31be3d6a",
      "audio": ""
    },
    {
      "text": "Which of the following is the MOST common inheritance pattern of G6PD deficiency?",
      "options": [
        {
          "label": "A",
          "text": "Autosomal dominant",
          "correct": false
        },
        {
          "label": "B",
          "text": "Autosomal recessive",
          "correct": false
        },
        {
          "label": "C",
          "text": "X-linked dominant",
          "correct": false
        },
        {
          "label": "D",
          "text": "X-linked recessive",
          "correct": true
        }
      ],
      "correct_answer": "D. X-linked recessive",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) X-linked recessive</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a5a46862",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with PNH treated with eculizumab develops recurrent abdominal pain and difficulty swallowing. Which of the following complications is MOST likely?",
      "options": [
        {
          "label": "A",
          "text": "Budd-Chiari syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Esophageal stricture",
          "correct": false
        },
        {
          "label": "C",
          "text": "Portal vein thrombosis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Gastric ulcer",
          "correct": false
        }
      ],
      "correct_answer": "C. Portal vein thrombosis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Portal vein thrombosis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Budd-Chiari syndrome: This is a rare condition involving obstruction of hepatic veins, typically presenting with liver enlargement, abdominal pain, and ascites. While possible in PNH, it's less likely than portal vein thrombosis given the dysphagia (difficulty swallowing).</li><li>\u2022 Option A. Budd-Chiari syndrome:</li><li>\u2022 Option B. Esophageal stricture: Strictures usually cause progressive dysphagia and are not typically associated with acute abdominal pain. While PNH can cause esophageal dysmotility, strictures are less common.</li><li>\u2022 Option B. Esophageal stricture:</li><li>\u2022 Option D. Gastric ulcer: While abdominal pain is a possible symptom of gastric ulcers, they are not a common complication specifically associated with PNH.</li><li>\u2022 Option D. Gastric ulcer:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Paroxysmal nocturnal hemoglobinuria (PNH) predisposes individuals to a hypercoagulable state. This means they are at higher risk for blood clots forming in unusual locations. Portal vein thrombosis is one such complication, and its presentation can include abdominal pain and difficulty swallowing. It's important for clinicians to maintain a high index of suspicion for thrombosis in PNH patients, even while on eculizumab therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "26c3e260",
      "audio": ""
    },
    {
      "text": "A 65-year-old vegan presents with fatigue, pallor, and numbness and tingling in their hands and feet. Which of the following laboratory findings would be MOST consistent with the suspected diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Microcytic anemia and normal methylmalonic acid (MMA) level",
          "correct": false
        },
        {
          "label": "B",
          "text": "Macrocytic anemia and elevated MMA level",
          "correct": true
        },
        {
          "label": "C",
          "text": "Macrocytic anemia and normal MMA level",
          "correct": false
        },
        {
          "label": "D",
          "text": "Normocytic anemia and elevated homocysteine level",
          "correct": false
        }
      ],
      "correct_answer": "B. Macrocytic anemia and elevated MMA level",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Macrocytic anemia and elevated MMA level</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Microcytic anemia and normal methylmalonic acid (MMA) level: Microcytic anemia is associated with iron deficiency, not B12 deficiency.</li><li>\u2022 Option A. Microcytic anemia and normal methylmalonic acid (MMA) level:</li><li>\u2022 Option C. Macrocytic anemia and normal MMA level: While macrocytic anemia is consistent with B12 deficiency, normal MMA levels would not be expected.</li><li>\u2022 Option C. Macrocytic anemia and normal MMA level:</li><li>\u2022 Option D. Normocytic anemia and elevated homocysteine level: Normocytic anemia is not typical of B12 deficiency, and while homocysteine can be elevated in both B12 and folate deficiencies, it's not specific for B12.</li><li>\u2022 Option D. Normocytic anemia and elevated homocysteine level:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Vitamin B12 deficiency should be suspected in vegans presenting with neurological symptoms and macrocytic anemia. Elevated MMA levels are a specific marker for B12 deficiency.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "703d3190",
      "audio": ""
    },
    {
      "text": "A patient with vitamin B12 deficiency is found to have pancytopenia (low counts of all blood cell types). Which of the following is the most likely mechanism for this finding?",
      "options": [
        {
          "label": "A",
          "text": "Autoimmune destruction of blood cells",
          "correct": false
        },
        {
          "label": "B",
          "text": "Impaired DNA synthesis in hematopoietic stem cells",
          "correct": true
        },
        {
          "label": "C",
          "text": "Bone marrow infiltration with malignant cells",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypersplenism",
          "correct": false
        }
      ],
      "correct_answer": "B. Impaired DNA synthesis in hematopoietic stem cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Impaired DNA synthesis in hematopoietic stem cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Autoimmune destruction of blood cells: While some autoimmune conditions can cause pancytopenia, it's not the primary mechanism in vitamin B12 deficiency.</li><li>\u2022 Option A. Autoimmune destruction of blood cells:</li><li>\u2022 Option C. Bone marrow infiltration with malignant cells: This would be more typical of leukemias or other malignancies, not vitamin B12 deficiency.</li><li>\u2022 Option C. Bone marrow infiltration with malignant cells:</li><li>\u2022 Option D. Hypersplenism: Hypersplenism can cause some degree of cytopenia, but it usually doesn't affect all cell lines equally, and it's not the primary cause in B12 deficiency.</li><li>\u2022 Option D. Hypersplenism:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Vitamin B12 deficiency can cause pancytopenia due to impaired DNA synthesis in hematopoietic stem cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e6fabe21",
      "audio": ""
    },
    {
      "text": "A 65-year-old woman with pernicious anemia (PA) presents with severe anemia (hemoglobin 7 g/dL) and neurologic symptoms. Which of the following is the MOST appropriate initial treatment?",
      "options": [
        {
          "label": "A",
          "text": "Oral cyanocobalamin 1000 mcg daily",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intramuscular (IM) hydroxocobalamin 1000 mcg every 3 months",
          "correct": false
        },
        {
          "label": "C",
          "text": "Intramuscular (IM) hydroxocobalamin 1000 mcg every 3-7 days for 6 doses, then every 3 months",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sublingual cyanocobalamin 1000 mcg daily",
          "correct": false
        }
      ],
      "correct_answer": "C. Intramuscular (IM) hydroxocobalamin 1000 mcg every 3-7 days for 6 doses, then every 3 months",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Intramuscular (IM) hydroxocobalamin 1000 mcg every 3-7 days for 6 doses, then every 3 months</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Oral cyanocobalamin 1000 mcg daily: While high-dose oral cyanocobalamin can be used in some cases, it is less efficient than IM injections, especially when rapid repletion is needed due to severe anemia or neurological symptoms.</li><li>\u2022 Option A. Oral cyanocobalamin 1000 mcg daily:</li><li>\u2022 Option B. Intramuscular (IM) hydroxocobalamin 1000 mcg every 3 months: This is a typical maintenance dose, but the initial treatment for severe deficiency requires more frequent dosing to rapidly correct the deficit.</li><li>\u2022 Option B. Intramuscular (IM) hydroxocobalamin 1000 mcg every 3 months:</li><li>\u2022 Option D. Sublingual cyanocobalamin 1000 mcg daily: Sublingual absorption of B12 is less reliable and may not be sufficient for a patient with severe anemia and neurological symptoms.</li><li>\u2022 Option D. Sublingual cyanocobalamin 1000 mcg daily:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The preferred initial treatment for severe B12 deficiency with neurological symptoms is intramuscular hydroxocobalamin given every 3-7 days for 6 doses, followed by maintenance therapy every 3 months.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1ff480de",
      "audio": ""
    },
    {
      "text": "Which of the following medications is MOST likely to interfere with folate metabolism and potentially lead to folate deficiency?",
      "options": [
        {
          "label": "A",
          "text": "Aspirin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Methotrexate",
          "correct": true
        },
        {
          "label": "D",
          "text": "Atorvastatin",
          "correct": false
        }
      ],
      "correct_answer": "C. Methotrexate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Methotrexate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Aspirin: While aspirin can cause some minor interference with folate absorption at very high doses, it's not a major contributor to folate deficiency at typical doses.</li><li>\u2022 Option A. Aspirin:</li><li>\u2022 Option B. Metformin: Metformin primarily affects glucose metabolism and doesn't have a direct impact on folate metabolism. However, long-term metformin use has been associated with mild decreases in vitamin B12 levels, which can sometimes be confused with folate deficiency.</li><li>\u2022 Option B. Metformin:</li><li>\u2022 Option D. Atorvastatin: Atorvastatin is a cholesterol-lowering medication (statin) and does not interfere with folate metabolism.</li><li>\u2022 Option D. Atorvastatin:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 While all medications should be reviewed when a patient presents with folate deficiency, methotrexate stands out as the most likely culprit due to its direct inhibitory effect on dihydrofolate reductase, a key enzyme in folate metabolism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4b51e77e",
      "audio": ""
    },
    {
      "text": "A 40-year-old man presents with fatigue, abdominal pain, and dark urine, especially in the morning. Laboratory tests reveal hemoglobinuria and decreased levels of CD55 and CD59 on red blood cells. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Autoimmune hemolytic anemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Paroxysmal nocturnal hemoglobinuria (PNH)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sickle cell disease",
          "correct": false
        }
      ],
      "correct_answer": "C. Paroxysmal nocturnal hemoglobinuria (PNH)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Paroxysmal nocturnal hemoglobinuria (PNH)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Autoimmune hemolytic anemia: While it can present with anemia and hemolysis, it typically does not cause hemoglobinuria or have decreased CD55/CD59 levels.</li><li>\u2022 Option A. Autoimmune hemolytic anemia:</li><li>\u2022 Option B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: This usually presents with episodic hemolysis triggered by oxidative stress, not specifically at night.</li><li>\u2022 Option B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency:</li><li>\u2022 Option D. Sickle cell disease: This is a genetic hemoglobinopathy with distinct clinical and laboratory findings.</li><li>\u2022 Option D. Sickle cell disease:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 PNH is a rare acquired hemolytic anemia characterized by intravascular hemolysis, often more pronounced at night, and decreased CD55 and CD59 levels on blood cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b88a03ef",
      "audio": ""
    },
    {
      "text": "Which of the following hemoglobin electrophoresis patterns is consistent with sickle cell trait?",
      "options": [
        {
          "label": "A",
          "text": "Predominant HbA peak with a small HbS peak",
          "correct": true
        },
        {
          "label": "B",
          "text": "Predominant HbS peak with a small HbA peak",
          "correct": false
        },
        {
          "label": "C",
          "text": "Absence of HbA peak, predominant HbF peak",
          "correct": false
        },
        {
          "label": "D",
          "text": "Predominant HbA peak with elevated HbA2 peak",
          "correct": false
        }
      ],
      "correct_answer": "A. Predominant HbA peak with a small HbS peak",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Predominant HbA peak with a small HbS peak</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Predominant HbS peak with a small HbA peak: This pattern is characteristic of sickle cell disease (SCD), not sickle cell trait. In SCD, both beta-globin genes are mutated, resulting in primarily HbS production.</li><li>\u2022 Option B. Predominant HbS peak with a small HbA peak:</li><li>\u2022 Option C. Absence of HbA peak, predominant HbF peak: This pattern can be seen in certain conditions like beta-thalassemia major or hereditary persistence of fetal hemoglobin (HPFH). It is not consistent with sickle cell trait.</li><li>\u2022 Option C. Absence of HbA peak, predominant HbF peak:</li><li>\u2022 Option D. Predominant HbA peak with elevated HbA2 peak: This pattern is suggestive of beta-thalassemia trait. While both beta-thalassemia trait and sickle cell trait can cause mild anemia, their Hb electrophoresis patterns differ.</li><li>\u2022 Option D. Predominant HbA peak with elevated HbA2 peak:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The Hb electrophoresis pattern in sickle cell trait differs from that of sickle cell disease, which shows a predominant HbS peak.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "050544f1",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a potential benefit of hydroxyurea therapy in sickle cell disease?",
      "options": [
        {
          "label": "A",
          "text": "Reduced frequency of vaso-occlusive crises",
          "correct": false
        },
        {
          "label": "B",
          "text": "Increased fetal hemoglobin (HbF) levels",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decreased risk of acute chest syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Increased risk of infection",
          "correct": true
        }
      ],
      "correct_answer": "D. Increased risk of infection",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Increased risk of infection</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "613353fe",
      "audio": ""
    },
    {
      "text": "A 35-year-old patient with sickle cell disease (SCD) and a history of frequent vaso-occlusive crises is being considered for treatment with crizanlizumab, a monoclonal antibody that targets P-selectin. What is the PRIMARY mechanism of action of crizanlizumab in preventing vaso-occlusive crises in SCD?",
      "options": [
        {
          "label": "A",
          "text": "Increasing fetal hemoglobin (HbF) levels",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreasing red blood cell sickling",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibiting platelet aggregation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Blocking adhesive interactions between sickle cells and endothelial cells",
          "correct": true
        }
      ],
      "correct_answer": "D. Blocking adhesive interactions between sickle cells and endothelial cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Blocking adhesive interactions between sickle cells and endothelial cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increasing fetal hemoglobin (HbF) levels: Hydroxyurea, not crizanlizumab, is the primary medication used to increase HbF levels in sickle cell disease.</li><li>\u2022 Option A. Increasing fetal hemoglobin (HbF) levels:</li><li>\u2022 Option B. Decreasing red blood cell sickling: While reducing adhesion can indirectly help prevent sickling, crizanlizumab's primary mechanism is not directly targeting the sickling process itself.</li><li>\u2022 Option B. Decreasing red blood cell sickling:</li><li>\u2022 Option C. Inhibiting platelet aggregation: While platelets play a role in vaso-occlusion, crizanlizumab's primary target is P-selectin on endothelial cells, not platelets.</li><li>\u2022 Option C. Inhibiting platelet aggregation:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 P-selectin blockade is a novel therapeutic approach in SCD that targets the adhesive interactions involved in vaso-occlusion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0994f1ce",
      "audio": ""
    },
    {
      "text": "An 11-year-old boy is brought to the physician by his mother because of worsening fatigue. His mother reports that he seems to have trouble keeping up with his older brothers when playing outside. Physical examination shows conjunctival pallor. A hemoglobin electrophoresis is performed. This patient's results are shown in comparison to those of a patient with known sickle cell anemia and a child with normal hemoglobin. Based on this electrophoresis, which of the following types of hemoglobin are dominant in this patient's blood?",
      "options": [
        {
          "label": "A",
          "text": "HbC only",
          "correct": false
        },
        {
          "label": "B",
          "text": "HbA and HbC",
          "correct": false
        },
        {
          "label": "C",
          "text": "HbA and HbS",
          "correct": false
        },
        {
          "label": "D",
          "text": "HbS and HbC",
          "correct": true
        }
      ],
      "correct_answer": "D. HbS and HbC",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/31/whatsapp-image-2024-07-31-at-50300-pm.jpeg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) HbS and HbC</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. HbC only: Individuals homozygous for HbC have hemoglobin C disease, which typically manifests with mild anemia. The electrophoresis pattern of a patient with HbC disease would show a single thicker band that migrates even less than HbS.</li><li>\u2022 Option A. HbC only:</li><li>\u2022 Option B. HbA and HbC: Individuals with the hemoglobin C trait would have both HbA and HbC in their blood. Hemoglobin electrophoresis of this patient shows HbC but not HbA. Moreover, hemoglobin C trait is usually an asymptomatic carrier state, unlike this patient with fatigue.</li><li>\u2022 Option B. HbA and HbC:</li><li>\u2022 Option C. HbA and HbS: Individuals heterozygous for the sickle cell trait would have both HbA and HbS in their blood. Hemoglobin electrophoresis of this patient shows HbS but not HbA. Moreover, individuals heterozygous for the sickle cell trait are usually asymptomatic, unlike this patient with fatigue.</li><li>\u2022 Option C. HbA and HbS:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "530c8818",
      "audio": ""
    },
    {
      "text": "A 30-year-old woman with G6PD deficiency presents with jaundice and fatigue. Her laboratory results show hemoglobin of 8 g/dL and elevated indirect bilirubin. Which of the following medications would be MOST likely to trigger this hemolytic episode?",
      "options": [
        {
          "label": "A",
          "text": "Acetaminophen",
          "correct": false
        },
        {
          "label": "B",
          "text": "Penicillin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ciprofloxacin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nitrofurantoin",
          "correct": true
        }
      ],
      "correct_answer": "D. Nitrofurantoin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Nitrofurantoin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Acetaminophen : Acetaminophen is not a common trigger of G6PD deficiency-related hemolysis.</li><li>\u2022 Option A.</li><li>\u2022 Acetaminophen</li><li>\u2022 Option B. Penicillin : Penicillin is generally safe in G6PD deficiency.</li><li>\u2022 Option B.</li><li>\u2022 Penicillin</li><li>\u2022 Option C. Ciprofloxacin : Ciprofloxacin is not a common trigger of G6PD deficiency-related hemolysis.</li><li>\u2022 Option C.</li><li>\u2022 Ciprofloxacin</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 It is crucial to avoid medications that can trigger hemolysis in patients with G6PD deficiency.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dfe11c2f",
      "audio": ""
    },
    {
      "text": "A 30-year-old woman with a history of hereditary spherocytosis presents with fatigue and pallor. Her laboratory tests reveal anemia with an increased mean corpuscular hemoglobin concentration (MCHC) and an increased red cell distribution width (RDW). Which of the following tests would be MOST helpful in confirming the diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Bone marrow biopsy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hemoglobin electrophoresis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Osmotic fragility test (OFT)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Direct antiglobulin test (DAT)",
          "correct": false
        }
      ],
      "correct_answer": "C. Osmotic fragility test (OFT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Osmotic fragility test (OFT)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Bone marrow biopsy is not typically needed for the diagnosis of HS.</li><li>\u2022 Option A. Bone marrow biopsy</li><li>\u2022 Option B.  Hemoglobin electrophoresis is used to diagnose hemoglobinopathies, not HS.</li><li>\u2022 Option B.  Hemoglobin electrophoresis</li><li>\u2022 Option D. Direct antiglobulin test (DAT) is used to diagnose autoimmune hemolytic anemia, not HS.</li><li>\u2022 Option D. Direct antiglobulin test (DAT)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The osmotic fragility test is a useful tool for diagnosing hereditary spherocytosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6cbe1791",
      "audio": ""
    },
    {
      "text": "Which of the following is the most definitive treatment for hereditary spherocytosis?",
      "options": [
        {
          "label": "A",
          "text": "Folate supplementation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Blood transfusions",
          "correct": false
        },
        {
          "label": "C",
          "text": "Splenectomy",
          "correct": true
        },
        {
          "label": "D",
          "text": "Iron chelation therapy",
          "correct": false
        }
      ],
      "correct_answer": "C. Splenectomy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Splenectomy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Folate supplementation and Option B. Blood transfusions are supportive measures but do not cure the disease.</li><li>\u2022 Option A. Folate supplementation</li><li>\u2022 Option B. Blood transfusions</li><li>\u2022 Option D. Iron chelation therapy is used to treat iron overload, not hereditary spherocytosis.</li><li>\u2022 Option D. Iron chelation therapy</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Splenectomy is the definitive treatment for hereditary spherocytosis but is typically reserved for patients with moderate to severe disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f476818b",
      "audio": ""
    },
    {
      "text": "A 15-year-old girl with hereditary spherocytosis presents with right upper quadrant pain. Ultrasound reveals gallstones. Which of the following is the most likely mechanism of gallstone formation in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Increased cholesterol secretion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreased bile acid synthesis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Increased pigment excretion",
          "correct": true
        },
        {
          "label": "D",
          "text": "Decreased gallbladder motility",
          "correct": false
        }
      ],
      "correct_answer": "C. Increased pigment excretion",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Increased pigment excretion</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increased cholesterol secretion: While cholesterol is a major component of gallstones, increased secretion is not the primary culprit in HS.</li><li>\u2022 Option A. Increased cholesterol secretion:</li><li>\u2022 Option B. Decreased bile acid synthesis: Decreased bile acid synthesis can promote cholesterol gallstones, but it is not a major factor in pigment gallstone formation seen in HS.</li><li>\u2022 Option B. Decreased bile acid synthesis:</li><li>\u2022 Option D. Decreased gallbladder motility: Decreased gallbladder motility can contribute to gallstone formation, but it is not the most specific or common finding in HS.</li><li>\u2022 Option D. Decreased gallbladder motility:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Gallstones are a common complication of hereditary spherocytosis due to increased pigment excretion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "04366519",
      "audio": ""
    },
    {
      "text": "Which of the following tests is considered the GOLD STANDARD for diagnosing paroxysmal nocturnal hemoglobinuria (PNH)?",
      "options": [
        {
          "label": "A",
          "text": "Peripheral blood smear",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ham's test",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sucrose hemolysis test",
          "correct": false
        },
        {
          "label": "D",
          "text": "High-sensitivity flow cytometry",
          "correct": true
        }
      ],
      "correct_answer": "D. High-sensitivity flow cytometry",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) High-sensitivity flow cytometry</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Peripheral blood smear: While it may show signs of hemolysis (like fragmented red blood cells or spherocytes), it cannot definitively diagnose PNH.</li><li>\u2022 Option A. Peripheral blood smear:</li><li>\u2022 Option B. Ham's test: This is an older, less specific test for PNH that is rarely used today due to its lower sensitivity and potential for false positives.</li><li>\u2022 Option B. Ham's test:</li><li>\u2022 Option C. Sucrose hemolysis test: This test is also less sensitive and specific than flow cytometry.</li><li>\u2022 Option C. Sucrose hemolysis test:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 High-sensitivity flow cytometry is the gold standard for diagnosing PNH due to its ability to directly detect the absence of GPI-anchored proteins on red and white blood cells. Older tests like the Ham's test and sucrose hemolysis test are less reliable and have been largely replaced by flow cytometry.</li><li>\u2022 High-sensitivity flow cytometry is the gold standard for diagnosing PNH due to its ability to directly detect the absence of GPI-anchored proteins on red and white blood cells.</li><li>\u2022 Older tests like the Ham's test and sucrose hemolysis test are less reliable and have been largely replaced by flow cytometry.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d71e8181",
      "audio": ""
    },
    {
      "text": "Which of the following is the first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH)?",
      "options": [
        {
          "label": "A",
          "text": "Prednisone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ravulizumab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Rituximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cyclosporine",
          "correct": false
        }
      ],
      "correct_answer": "B. Ravulizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Ravulizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Prednisone: While corticosteroids like prednisone may be used in some cases of autoimmune hemolytic anemia, they are not the first-line treatment for PNH. They are less effective than eculizumab or ravulizumab at controlling hemolysis and thrombosis.</li><li>\u2022 Option A. Prednisone:</li><li>\u2022 Option C. Rituximab: Rituximab is a monoclonal antibody that targets B cells. While it can be used in some autoimmune disorders, it is not indicated for PNH.</li><li>\u2022 Option C. Rituximab:</li><li>\u2022 Option D. Cyclosporine: Cyclosporine is an immunosuppressant used in various conditions, including organ transplantation and some autoimmune disorders. It has no direct effect on the complement system, which is the primary driver of PNH, and thus is not used in its treatment.</li><li>\u2022 Option D. Cyclosporine:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Eculizumab and ravulizumab have revolutionized the treatment of PNH by significantly reducing hemolysis, thrombosis risk, and improving quality of life.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "72e07db8",
      "audio": ""
    },
    {
      "text": "A 16-year-old male presents with fatigue, recurrent infections, and easy bruising. Laboratory findings reveal pancytopenia, and a bone marrow biopsy shows hypocellular marrow replaced with fat. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute myeloid leukemia (AML)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Myelodysplastic syndrome (MDS)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Aplastic anemia (AA)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Vitamin B12 deficiency",
          "correct": false
        }
      ],
      "correct_answer": "C. Aplastic anemia (AA)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Aplastic anemia (AA)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Acute myeloid leukemia (AML): AML would typically present with blasts (immature white blood cells) in the peripheral blood and a hypercellular bone marrow.</li><li>\u2022 Option A. Acute myeloid leukemia (AML):</li><li>\u2022 Option B. Myelodysplastic syndrome (MDS): MDS is characterized by dysplastic changes in the bone marrow and peripheral blood cells, which are not present in this scenario.</li><li>\u2022 Option B. Myelodysplastic syndrome (MDS):</li><li>\u2022 Option D. Vitamin B12 deficiency: While vitamin B12 deficiency can cause pancytopenia, it usually manifests with a macrocytic anemia (large red blood cells) and megaloblastic changes in the bone marrow.</li><li>\u2022 Option D. Vitamin B12 deficiency:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Aplastic anemia is a diagnosis of exclusion, characterized by pancytopenia and hypocellular bone marrow.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6ffbb9f0",
      "audio": ""
    },
    {
      "text": "Flow cytometry in a patient with suspected aplastic anemia is most likely to reveal:",
      "options": [
        {
          "label": "A",
          "text": "Increased CD34+ cells",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreased or absent CD34+ cells",
          "correct": true
        },
        {
          "label": "C",
          "text": "Increased blasts",
          "correct": false
        },
        {
          "label": "D",
          "text": "Monoclonal B-cell population",
          "correct": false
        }
      ],
      "correct_answer": "B. Decreased or absent CD34+ cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Decreased or absent CD34+ cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increased CD34+ cells: This would be seen in conditions with increased hematopoietic activity, such as recovery from chemotherapy or certain leukemias. It's not expected in aplastic anemia where the bone marrow is failing.</li><li>\u2022 Option A. Increased CD34+ cells:</li><li>\u2022 Option C. Increased blasts: Increased blasts (immature blood cells) would suggest acute leukemia or myelodysplastic syndrome (MDS), not aplastic anemia.</li><li>\u2022 Option C. Increased blasts:</li><li>\u2022 Option D. Monoclonal B-cell population: This finding would be more indicative of a lymphoproliferative disorder, such as chronic lymphocytic leukemia (CLL) or lymphoma, rather than aplastic anemia.</li><li>\u2022 Option D. Monoclonal B-cell population:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Flow cytometry can help confirm the diagnosis of aplastic anemia by demonstrating a lack of CD34+ cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "57cf5375",
      "audio": ""
    },
    {
      "text": "An 18-year-old male presents with severe fatigue, recurrent infections, and easy bruising. Laboratory investigations reveal pancytopenia, and a bone marrow biopsy shows markedly hypocellular marrow. He has an HLA-matched sibling. Which of the following is the MOST appropriate first-line treatment for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Immunosuppressive therapy (IST)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Allogeneic hematopoietic stem cell transplant (HSCT)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Supportive care with blood transfusions and antibiotics",
          "correct": false
        },
        {
          "label": "D",
          "text": "Androgens",
          "correct": false
        }
      ],
      "correct_answer": "B. Allogeneic hematopoietic stem cell transplant (HSCT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Allogeneic hematopoietic stem cell transplant (HSCT)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Immunosuppressive therapy (IST): While IST is an effective treatment for aplastic anemia, it's typically the first-line choice for patients who don't have a matched sibling donor or are older. It aims to suppress the immune system, which is often attacking the bone marrow in acquired aplastic anemia.</li><li>\u2022 Option A. Immunosuppressive therapy (IST):</li><li>\u2022 Option C. Supportive care with blood transfusions and antibiotics: This is crucial for managing the symptoms and complications of aplastic anemia (e.g., anemia, infection). However, it is not a curative treatment.</li><li>\u2022 Option C. Supportive care with blood transfusions and antibiotics:</li><li>\u2022 Option D. Androgens: Androgens (male sex hormones) can sometimes stimulate the bone marrow, but their efficacy is limited and not usually the first-line choice in severe aplastic anemia.</li><li>\u2022 Option D. Androgens:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The best treatment approach for aplastic anemia depends on the patient's age, severity of the disease, and availability of a matched sibling donor. For young patients with severe aplastic anemia and a matched sibling donor, allogeneic HSCT offers the best chance for a cure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d3340d6f",
      "audio": ""
    },
    {
      "text": "A 68-year-old woman presents with pancytopenia and a bone marrow biopsy revealing trilineage dysplasia. Cytogenetic analysis shows a normal karyotype. Which of the following would be the most appropriate next step in the workup?",
      "options": [
        {
          "label": "A",
          "text": "Repeat bone marrow biopsy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Molecular testing for gene mutations",
          "correct": true
        },
        {
          "label": "C",
          "text": "Start treatment with erythropoietin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Transfuse packed red blood cells and platelets",
          "correct": false
        }
      ],
      "correct_answer": "B. Molecular testing for gene mutations",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Molecular testing for gene mutations</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Repeat bone marrow biopsy: Repeat bone marrow biopsy is not necessary if the initial biopsy is diagnostic.</li><li>\u2022 Option A. Repeat bone marrow biopsy:</li><li>\u2022 Option C. Start treatment with erythropoietin: Erythropoietin is used to treat anemia in MDS, but it is not a diagnostic test.</li><li>\u2022 Option C. Start treatment with erythropoietin:</li><li>\u2022 Option D. Transfuse packed red blood cells and platelets: Transfusion support may be needed, but it is not the next step in the diagnostic workup.</li><li>\u2022 Option D. Transfuse packed red blood cells and platelets:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Molecular testing for gene mutations is essential for the accurate diagnosis and management of MDS, especially in cases with a normal karyotype.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "030b9579",
      "audio": ""
    },
    {
      "text": "Which of the following statements about myelodysplastic syndromes (MDS) is FALSE?",
      "options": [
        {
          "label": "A",
          "text": "MDS is a clonal hematopoietic stem cell disorder.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Most patients with MDS will eventually progress to acute myeloid leukemia (AML).",
          "correct": true
        },
        {
          "label": "C",
          "text": "The risk of transformation to AML is higher in patients with complex karyotype abnormalities.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allogeneic stem cell transplantation is the only curative option for MDS.",
          "correct": false
        }
      ],
      "correct_answer": "B. Most patients with MDS will eventually progress to acute myeloid leukemia (AML).",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Most patients with MDS will eventually progress to acute myeloid leukemia (AML).</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "967c7b58",
      "audio": ""
    },
    {
      "text": "Which of the following morphological features on a peripheral blood smear is LEAST likely to be seen in myelodysplastic syndrome (MDS)?",
      "options": [
        {
          "label": "A",
          "text": "Pseudo-Pelger-Huet anomaly (hypolobulated neutrophils)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ring sideroblasts",
          "correct": false
        },
        {
          "label": "C",
          "text": "Howell-Jolly bodies",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypersegmented neutrophils",
          "correct": true
        }
      ],
      "correct_answer": "D. Hypersegmented neutrophils",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Hypersegmented neutrophils</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Pseudo-Pelger-Huet anomaly (hypolobulated neutrophils): This is a classic finding in MDS, reflecting the dysplasia (abnormal maturation) of the myeloid lineage. Neutrophils may have bilobed or unsegmented nuclei.</li><li>\u2022 Option A. Pseudo-Pelger-Huet anomaly (hypolobulated neutrophils):</li><li>\u2022 Option B. Ring sideroblasts: These are red blood cells with iron deposits arranged in a ring around the nucleus, often seen in MDS, especially in cases with sideroblastic anemia.</li><li>\u2022 Option B. Ring sideroblasts:</li><li>\u2022 Option C. Howell-Jolly bodies: These are nuclear remnants in red blood cells, indicating impaired splenic function or dyserythropoiesis, both of which can be seen in MDS.</li><li>\u2022 Option C. Howell-Jolly bodies:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 MDS is characterized by dysplastic changes in various blood cell lines, but hypersegmented neutrophils are not typically seen.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ce27ca6c",
      "audio": ""
    },
    {
      "text": "A 65-year-old male presents with fatigue, weakness, and easy bruising. Peripheral blood smear shows macrocytic anemia and dysplastic neutrophils. Cytogenetic analysis reveals a deletion in the long arm of chromosome 5 (del(5q)). According to the IPSS-R, what is the patient's prognostic risk category?",
      "options": [
        {
          "label": "A",
          "text": "Very low",
          "correct": false
        },
        {
          "label": "B",
          "text": "Low",
          "correct": true
        },
        {
          "label": "C",
          "text": "Intermediate",
          "correct": false
        },
        {
          "label": "D",
          "text": "High",
          "correct": false
        }
      ],
      "correct_answer": "B. Low",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Low</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Very Low: While del(5q) MDS is a lower-risk subtype, it doesn't fall into the \"very low\" category, which is usually reserved for patients with very few cytopenias and no cytogenetic abnormalities.</li><li>\u2022 Option A. Very Low:</li><li>\u2022 Option C. Intermediate: This category typically includes patients with more cytopenias or less favorable cytogenetic findings than those with isolated del(5q).</li><li>\u2022 Option C. Intermediate:</li><li>\u2022 Option D. High: These categories are reserved for MDS with a high risk of progression to acute myeloid leukemia (AML), which is not typical of isolated del(5q). These patients usually have excess blasts in the bone marrow, complex karyotypes, or specific genetic mutations associated with worse outcomes.</li><li>\u2022 Option D. High:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Del(5q) is a favorable cytogenetic abnormality in MDS associated with a better prognosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bc69ed78",
      "audio": ""
    },
    {
      "text": "A 58-year-old man is diagnosed with myelodysplastic syndrome (MDS) with an isolated deletion in chromosome 7 (del(7q)). Which of the following is the most appropriate treatment option for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Lenalidomide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Azacitidine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decitabine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Supportive care",
          "correct": true
        }
      ],
      "correct_answer": "D. Supportive care",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Supportive care</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Lenalidomide: Lenalidomide is a targeted therapy specifically approved for MDS with isolated del(5q), not del(7q). It is not effective in patients with del(7q) MDS.</li><li>\u2022 Option A. Lenalidomide:</li><li>\u2022 Option B. Azacitidine: Azacitidine is a hypomethylating agent used for higher-risk MDS, but it has not shown significant benefit in patients with isolated del(7q).</li><li>\u2022 Option B. Azacitidine:</li><li>\u2022 Option C. Decitabine: Similar to azacitidine, decitabine is another hypomethylating agent used in higher-risk MDS and is not a specific treatment for del(7q).</li><li>\u2022 Option C. Decitabine:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Supportive care is the primary treatment for MDS with isolated del(7q).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "895a8a98",
      "audio": ""
    },
    {
      "text": "A 62-year-old woman presents with complaints of headache, dizziness, and erythromelalgia (burning pain in the hands and feet). Her complete blood count (CBC) shows a platelet count of 950,000/\u00b5L. Given likely diagnosis, which of the following genetic mutations is most commonly associated with essential thrombocythemia (ET)?",
      "options": [
        {
          "label": "A",
          "text": "JAK2 V617F",
          "correct": true
        },
        {
          "label": "B",
          "text": "BCR-ABL1",
          "correct": false
        },
        {
          "label": "C",
          "text": "CALR",
          "correct": false
        },
        {
          "label": "D",
          "text": "MPL",
          "correct": false
        }
      ],
      "correct_answer": "A. JAK2 V617F",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) JAK2 V617F</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4a6a6603",
      "audio": ""
    },
    {
      "text": "A patient with Essential thrombocythemia (ET) is at increased risk for which of the following complications?",
      "options": [
        {
          "label": "A",
          "text": "Thrombosis (arterial or venous)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bleeding",
          "correct": false
        },
        {
          "label": "C",
          "text": "Transformation to acute myeloid leukemia (AML)",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All of the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All of the above</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "01183758",
      "audio": ""
    },
    {
      "text": "Which of the following genetic mutations is most commonly associated with primary myelofibrosis (PMF)?",
      "options": [
        {
          "label": "A",
          "text": "JAK2 V617F",
          "correct": true
        },
        {
          "label": "B",
          "text": "BCR-ABL1",
          "correct": false
        },
        {
          "label": "C",
          "text": "CALR",
          "correct": false
        },
        {
          "label": "D",
          "text": "MPL",
          "correct": false
        }
      ],
      "correct_answer": "A. JAK2 V617F",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) JAK2 V617F</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. BCR-ABL1 : This mutation is associated with chronic myeloid leukemia (CML).</li><li>\u2022 Option B. BCR-ABL1</li><li>\u2022 Option C. CALR and Option D. MPL : These mutations are also found in PMF but are less common than JAK2 V617F.</li><li>\u2022 Option C. CALR</li><li>\u2022 Option D. MPL</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 JAK2 V617F is the most common mutation in PMF and can have prognostic implications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "555707f5",
      "audio": ""
    },
    {
      "text": "A 68-year-old man presents with fatigue, early satiety, and abdominal discomfort. Physical examination reveals massive splenomegaly. Peripheral blood smear shows teardrop cells, nucleated red blood cells, and giant platelets. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Chronic myeloid leukemia (CML)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Polycythemia vera (PV)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Essential thrombocythemia (ET)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Primary myelofibrosis (PMF)",
          "correct": true
        }
      ],
      "correct_answer": "D. Primary myelofibrosis (PMF)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Primary myelofibrosis (PMF)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Chronic myeloid leukemia (CML) : CML presents with leukocytosis and a left shift but not typically with teardrop cells or marked splenomegaly.</li><li>\u2022 Option A. Chronic myeloid leukemia (CML)</li><li>\u2022 Option B. Polycythemia vera (PV) : PV is characterized by elevated red blood cell mass, not fibrosis or teardrop cells.</li><li>\u2022 Option B. Polycythemia vera (PV)</li><li>\u2022 Option C. Essential thrombocythemia (ET) : ET presents with isolated thrombocytosis, not the constellation of findings seen in this patient.</li><li>\u2022 Option C. Essential thrombocythemia (ET)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Teardrop cells, nucleated red blood cells, giant platelets, and massive splenomegaly are key features of PMF.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "99773602",
      "audio": ""
    },
    {
      "text": "Which of the following stains is used to differentiate between ALL and AML?",
      "options": [
        {
          "label": "A",
          "text": "Periodic acid-Schiff (PAS)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Myeloperoxidase (MPO)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Sudan Black B (SBB)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nonspecific esterase (NSE)",
          "correct": false
        }
      ],
      "correct_answer": "B. Myeloperoxidase (MPO)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Myeloperoxidase (MPO)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Optio n A. Periodic acid-Schiff (PAS) : PAS stains glycogen and mucopolysaccharides and is used to identify lymphoid blasts in ALL.</li><li>\u2022 Optio</li><li>\u2022 n A. Periodic acid-Schiff (PAS)</li><li>\u2022 Option C. Sudan Black B (SBB) : SBB stains lipids and is positive in AML blasts.</li><li>\u2022 Option C. Sudan Black B (SBB)</li><li>\u2022 Option D. Nonspecific esterase (NSE) : NSE stains esterases and is used to identify monocytic cells.</li><li>\u2022 Option D. Nonspecific esterase (NSE)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 MPO staining is a valuable tool for differentiating between AML and ALL based on the presence or absence of myeloperoxidase in blast cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "045e631c",
      "audio": ""
    },
    {
      "text": "A 7-year-old child presents with fatigue, pallor, fever, and bone pain. Peripheral blood smear shows blasts. Which of the following laboratory findings is more suggestive of acute lymphoblastic leukemia (ALL) than acute myeloid leukemia (AML)?",
      "options": [
        {
          "label": "A",
          "text": "Auer rods on peripheral smear",
          "correct": false
        },
        {
          "label": "B",
          "text": "Terminal deoxynucleotidyl transferase (TdT) positivity",
          "correct": true
        },
        {
          "label": "C",
          "text": "Myeloperoxidase (MPO) positivity",
          "correct": false
        },
        {
          "label": "D",
          "text": "Elevated lactate dehydrogenase (LDH) levels",
          "correct": false
        }
      ],
      "correct_answer": "B. Terminal deoxynucleotidyl transferase (TdT) positivity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Terminal deoxynucleotidyl transferase (TdT) positivity</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "559b7cbc",
      "audio": ""
    },
    {
      "text": "A patient newly diagnosed with APL is started on all-trans retinoic acid (ATRA). Within two weeks, they develop fever, dyspnea, and pulmonary infiltrates. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Differentiation syndrome (APL differentiation syndrome)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tumor lysis syndrome",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pulmonary embolism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pneumonia",
          "correct": false
        }
      ],
      "correct_answer": "A. Differentiation syndrome (APL differentiation syndrome)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Differentiation syndrome (APL differentiation syndrome)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Tumor lysis syndrome: This is a metabolic complication that can occur in rapidly proliferating malignancies after chemotherapy. It is characterized by electrolyte abnormalities like hyperkalemia, hyperphosphatemia, and hypocalcemia, along with acute kidney injury. These features are not typically seen in differentiation syndrome.</li><li>\u2022 Option B. Tumor lysis syndrome:</li><li>\u2022 Option C. Pulmonary embolism: While pulmonary infiltrates are seen in both differentiation syndrome and pulmonary embolism, the patient's recent initiation of ATRA therapy makes differentiation syndrome more likely. Pulmonary embolism would typically present with sudden-onset pleuritic chest pain and hypoxia.</li><li>\u2022 Option C. Pulmonary embolism:</li><li>\u2022 Option D. Pneumonia: Pneumonia is a possible differential diagnosis, but the temporal association with ATRA initiation and the absence of typical infectious symptoms (cough, sputum production) makes differentiation syndrome more likely.</li><li>\u2022 Option D. Pneumonia:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Differentiation syndrome is a serious but manageable complication of ATRA in APL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a74e3231",
      "audio": ""
    },
    {
      "text": "A 35-year-old patient presents with fatigue, bruising, and bleeding gums. Bone marrow biopsy reveals hypergranular promyelocytes with Auer rods. Which combination therapy is MOST appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "ATRA + Hydroxyurea",
          "correct": false
        },
        {
          "label": "B",
          "text": "ATO + Cytarabine",
          "correct": false
        },
        {
          "label": "C",
          "text": "ATRA + ATO",
          "correct": false
        },
        {
          "label": "D",
          "text": "ATRA + ATO + Chemotherapy",
          "correct": true
        }
      ],
      "correct_answer": "D. ATRA + ATO + Chemotherapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) ATRA + ATO + Chemotherapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. ATRA + Hydroxyurea: Hydroxyurea is a cytoreductive agent used in other types of leukemia, but it is not effective for APL. The combination of ATRA and hydroxyurea is not the standard of care.</li><li>\u2022 Option A. ATRA + Hydroxyurea:</li><li>\u2022 Option B. ATO + Cytarabine: While both ATO and cytarabine are used in the treatment of APL, they are not typically used together without ATRA. ATRA is crucial for inducing differentiation of leukemic cells and preventing differentiation syndrome.</li><li>\u2022 Option B. ATO + Cytarabine:</li><li>\u2022 Option C. ATRA + ATO: This combination is highly effective in APL, but the addition of chemotherapy (usually an anthracycline like daunorubicin or idarubicin) further improves outcomes by targeting the leukemic cells directly.</li><li>\u2022 Option C. ATRA + ATO:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Combination therapy with ATRA, ATO, and chemotherapy is the standard of care for APL due to its high cure rates and low relapse rates.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "af627652",
      "audio": ""
    },
    {
      "text": "A 78-year-old patient is diagnosed with newly diagnosed AML but has significant comorbidities and is considered unfit for intensive induction chemotherapy (\"7+3\"). Which of the following is the most appropriate treatment option?",
      "options": [
        {
          "label": "A",
          "text": "Standard \"7+3\" induction chemotherapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Midostaurin + Gemtuzumab ozogamicin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hypomethylating agent (HMA) + Venetoclax",
          "correct": true
        },
        {
          "label": "D",
          "text": "Allogeneic stem cell transplant",
          "correct": false
        }
      ],
      "correct_answer": "C. Hypomethylating agent (HMA) + Venetoclax",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Hypomethylating agent (HMA) + Venetoclax</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Standard \"7+3\" induction chemotherapy : Standard \"7+3\" is too intensive for unfit patients.</li><li>\u2022 Option A.</li><li>\u2022 Standard \"7+3\" induction chemotherapy</li><li>\u2022 Option B. Midostaurin + Gemtuzumab ozogamicin : Midostaurin and Gemtuzumab are often added to standard induction, not used in isolation for unfit patients.</li><li>\u2022 Option B. Midostaurin + Gemtuzumab ozogamicin</li><li>\u2022 Option D. Allogeneic stem cell transplant : Allogeneic stem cell transplant is a potential curative option but is generally not feasible for older patients with comorbidities.</li><li>\u2022 Option D. Allogeneic stem cell transplant</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 HMA + Venetoclax offers a less intensive, yet effective, treatment option for older or unfit AML patients.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c6688e67",
      "audio": ""
    },
    {
      "text": "A 45-year-old man presents with fatigue, weight loss, and abdominal fullness. Physical examination reveals splenomegaly. Peripheral blood smear shows a leukocytosis with left shift. Which of the following genetic abnormalities is most likely to be found in this patient?",
      "options": [
        {
          "label": "A",
          "text": "JAK2 V617F",
          "correct": false
        },
        {
          "label": "B",
          "text": "BCR-ABL1",
          "correct": true
        },
        {
          "label": "C",
          "text": "FLT3-ITD",
          "correct": false
        },
        {
          "label": "D",
          "text": "t(15;17)",
          "correct": false
        }
      ],
      "correct_answer": "B. BCR-ABL1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) BCR-ABL1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. JAK2 V617F : Associated with myeloproliferative neoplasms (MPNs) like polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).</li><li>\u2022 Option A. JAK2 V617F</li><li>\u2022 Option C. FLT3-ITD : More commonly associated with acute myeloid leukemia (AML).</li><li>\u2022 Option C. FLT3-ITD</li><li>\u2022 Option D. t(15;17) : Associated with acute promyelocytic leukemia (APL), a subtype of AML.</li><li>\u2022 Option D. t(15;17)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 BCR-ABL1 fusion gene is the diagnostic hallmark of CML.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "408c6fc9",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a common feature of blast crisis in CML?",
      "options": [
        {
          "label": "A",
          "text": "Increasing splenomegaly",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bone pain",
          "correct": false
        },
        {
          "label": "C",
          "text": "Constitutional symptoms (fever, night sweats, weight loss)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Normalization of the white blood cell count",
          "correct": true
        }
      ],
      "correct_answer": "D. Normalization of the white blood cell count",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Normalization of the white blood cell count</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increasing splenomegaly: Blast cells can infiltrate the spleen, causing it to enlarge further.</li><li>\u2022 Option A. Increasing splenomegaly:</li><li>\u2022 Option B. Bone pain: Blast cells can also infiltrate the bone marrow, leading to bone pain.</li><li>\u2022 Option B. Bone pain:</li><li>\u2022 Option C. Constitutional symptoms (fever, night sweats, weight loss): These are common symptoms of advanced CML and blast crisis due to the underlying malignancy.</li><li>\u2022 Option C. Constitutional symptoms (fever, night sweats, weight loss):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Blast crisis is a serious complication of CML, and it is important to recognize its clinical features.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "754164dc",
      "audio": ""
    },
    {
      "text": "A 55-year-old male presents with fatigue, weight loss, and abdominal fullness. Physical examination reveals splenomegaly. Which of the following tests is the MOST appropriate initial diagnostic step?",
      "options": [
        {
          "label": "A",
          "text": "Bone marrow biopsy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Flow cytometry",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cytogenetic analysis (karyotype)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Complete blood count (CBC) with differential",
          "correct": true
        }
      ],
      "correct_answer": "D. Complete blood count (CBC) with differential",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Complete blood count (CBC) with differential</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Bone marrow biopsy : While a bone marrow biopsy is eventually needed to confirm the diagnosis and assess response to therapy, it's not the initial step.</li><li>\u2022 Option A. Bone marrow biopsy</li><li>\u2022 Option B. Flow cytometry : Flow cytometry is helpful for further characterization of the leukemia cells, but not the initial diagnostic test.</li><li>\u2022 Option B. Flow cytometry</li><li>\u2022 Option C. Cytogenetic analysis (karyotype) : This is important to confirm the Philadelphia chromosome translocation, but CBC is done first.</li><li>\u2022 Option C. Cytogenetic analysis (karyotype)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 CBC with differential is the first-line test in suspected CML due to its ability to detect characteristic hematologic abnormalities.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "49a6fd02",
      "audio": ""
    },
    {
      "text": "What is the diagnostic hallmark of chronic myeloid leukemia (CML)?",
      "options": [
        {
          "label": "A",
          "text": "JAK2 V617F mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(15;17) translocation",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(9;22) translocation (Philadelphia chromosome)",
          "correct": true
        },
        {
          "label": "D",
          "text": "t(8;21) translocation",
          "correct": false
        }
      ],
      "correct_answer": "C. t(9;22) translocation (Philadelphia chromosome)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) t(9;22) translocation (Philadelphia chromosome)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. JAK2 V617F mutation : This mutation is associated with myeloproliferative neoplasms (MPNs), not CML.</li><li>\u2022 Option A. JAK2 V617F mutation</li><li>\u2022 Option B. t(15;17) translocation : This translocation is the hallmark of acute promyelocytic leukemia (APL).</li><li>\u2022 Option B. t(15;17) translocation</li><li>\u2022 Option D. t(8;21) translocation : This translocation is associated with acute myeloid leukemia (AML).</li><li>\u2022 Option D. t(8;21) translocation</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The Philadelphia chromosome is the defining genetic feature of CML.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7b17debe",
      "audio": ""
    },
    {
      "text": "A 48-year-old patient with CML in chronic phase has been on imatinib for 3 years and now has rising BCR-ABL1 transcripts. Genetic testing reveals a T315I mutation. What is the most appropriate next step in management?",
      "options": [
        {
          "label": "A",
          "text": "Increase the dose of imatinib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Switch to dasatinib",
          "correct": false
        },
        {
          "label": "C",
          "text": "Switch to nilotinib",
          "correct": false
        },
        {
          "label": "D",
          "text": "Initiate ponatinib",
          "correct": true
        }
      ],
      "correct_answer": "D. Initiate ponatinib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Initiate ponatinib</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increase the dose of imatinib: Increasing the dose of imatinib will not be effective because the T315I mutation confers resistance to this drug and other first and second-generation TKIs.</li><li>\u2022 Option A. Increase the dose of imatinib:</li><li>\u2022 Option B. Switch to dasatinib: Dasatinib is a second-generation TKI, but it is not effective against the T315I mutation.</li><li>\u2022 Option B. Switch to dasatinib:</li><li>\u2022 Option C. Switch to nilotinib: Nilotinib is another second-generation TKI that is not effective against the T315I mutation.</li><li>\u2022 Option C. Switch to nilotinib:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Ponatinib is a third-generation TKI specifically designed to overcome TKI resistance, especially due to the T315I mutation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1acf5c42",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a correct statement regarding nilotinib in CML?",
      "options": [
        {
          "label": "A",
          "text": "It is a first-line therapy for chronic phase CML.",
          "correct": true
        },
        {
          "label": "B",
          "text": "It is used in the treatment of accelerated phase CML.",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is contraindicated in patients with blastic phase CML.",
          "correct": false
        },
        {
          "label": "D",
          "text": "It is used at a higher dose in patients who are resistant or intolerant to prior TKI therapy.",
          "correct": false
        }
      ],
      "correct_answer": "A. It is a first-line therapy for chronic phase CML.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) It is a first-line therapy for chronic phase CML.</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "680b2021",
      "audio": ""
    },
    {
      "text": "Which of the following is more commonly associated with acute lymphoblastic leukemia (ALL) than acute myeloid leukemia (AML)?",
      "options": [
        {
          "label": "A",
          "text": "Hepatosplenomegaly",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lymphadenopathy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Gingival hyperplasia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Skin infiltration",
          "correct": false
        }
      ],
      "correct_answer": "B. Lymphadenopathy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Lymphadenopathy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Hepatosplenomegaly: While hepatosplenomegaly (enlargement of the liver and spleen) can be seen in both ALL and AML, it is not a distinguishing feature between the two. Both conditions can cause infiltration of these organs by leukemic cells.</li><li>\u2022 Option A. Hepatosplenomegaly:</li><li>\u2022 Option C. Gingival hyperplasia: This is a rare finding in both ALL and AML, but it is more commonly associated with acute monocytic leukemia (a subtype of AML).</li><li>\u2022 Option C. Gingival hyperplasia:</li><li>\u2022 Option D. Skin infiltration: Skin infiltration (leukemia cutis) can occur in both ALL and AML, but it is relatively uncommon in both.</li><li>\u2022 Option D. Skin infiltration:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 While both ALL and AML can involve extramedullary sites, lymphadenopathy is more characteristic of ALL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a9ca6583",
      "audio": ""
    },
    {
      "text": "A 60-year-old man presents with fatigue, weight loss, and gingival bleeding. Peripheral blood smear shows myeloblasts with Auer rods. Which of the following cytogenetic abnormalities is most likely to be found in this patient?",
      "options": [
        {
          "label": "A",
          "text": "t(9;22)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(15;17)",
          "correct": true
        },
        {
          "label": "C",
          "text": "inv(16)",
          "correct": false
        },
        {
          "label": "D",
          "text": "t(8;21)",
          "correct": false
        }
      ],
      "correct_answer": "B. t(15;17)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) t(15;17)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. t(9;22): This translocation is the hallmark of chronic myeloid leukemia (CML), not acute promyelocytic leukemia (APL).</li><li>\u2022 Option A. t(9;22):</li><li>\u2022 Option C. inv(16): This inversion is associated with acute myeloid leukemia (AML) with eosinophilia, not APL.</li><li>\u2022 Option C. inv(16):</li><li>\u2022 Option D. t(8;21): This translocation is associated with a favorable-risk subtype of AML, but not APL.</li><li>\u2022 Option D. t(8;21):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Auer rods are highly specific for APL, and the presence of this cytogenetic abnormality (t(15;17)) is diagnostic for APL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1f4c240f",
      "audio": ""
    },
    {
      "text": "Which of the following cytogenetic abnormalities is associated with a high risk of relapse in AML?",
      "options": [
        {
          "label": "A",
          "text": "inv(16)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(15;17)",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(8;21)",
          "correct": false
        },
        {
          "label": "D",
          "text": "-5/del(5q)",
          "correct": true
        }
      ],
      "correct_answer": "D. -5/del(5q)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) -5/del(5q)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. inv(16): This inversion is associated with acute myeloid leukemia with abnormal eosinophils (AML M4Eo) and generally has a favorable prognosis.</li><li>\u2022 Option A. inv(16):</li><li>\u2022 Option B. t(15;17): This translocation is the hallmark of acute promyelocytic leukemia (APL), a subtype of AML. APL has a good prognosis when treated promptly with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).</li><li>\u2022 Option B. t(15;17):</li><li>\u2022 Option C. t(8;21): This translocation is associated with acute myeloid leukemia with maturation (AML M2) and also has a relatively favorable prognosis.</li><li>\u2022 Option C. t(8;21):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Cytogenetic abnormalities can significantly impact prognosis and treatment choices in AML.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "17ee4246",
      "audio": ""
    },
    {
      "text": "Which of the following genetic mutations would make an IDH inhibitor a potential treatment option for an AML patient who is ineligible for HMA therapy?",
      "options": [
        {
          "label": "A",
          "text": "FLT3-ITD",
          "correct": false
        },
        {
          "label": "B",
          "text": "NPM1",
          "correct": false
        },
        {
          "label": "C",
          "text": "IDH1/IDH2",
          "correct": true
        },
        {
          "label": "D",
          "text": "TP53",
          "correct": false
        }
      ],
      "correct_answer": "C. IDH1/IDH2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) IDH1/IDH2</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b124326f",
      "audio": ""
    },
    {
      "text": "A 3-year-old child with Down syndrome presents with pallor, fatigue, and bruising. Bone marrow biopsy shows megakaryoblastic proliferation and fibrosis. Which of the following leukemia subtypes is most likely?",
      "options": [
        {
          "label": "A",
          "text": "Acute lymphoblastic leukemia (ALL)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acute myeloid leukemia (AML)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Acute megakaryoblastic leukemia (AMKL)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Juvenile myelomonocytic leukemia (JMML)",
          "correct": false
        }
      ],
      "correct_answer": "C. Acute megakaryoblastic leukemia (AMKL)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Acute megakaryoblastic leukemia (AMKL)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Acute lymphoblastic leukemia (ALL): While ALL is the most common leukemia in children with Down syndrome, it doesn't usually present with the specific bone marrow findings described here (megakaryoblastic proliferation and fibrosis).</li><li>\u2022 Option A. Acute lymphoblastic leukemia (ALL):</li><li>\u2022 Option B. Acute myeloid leukemia (AML): This is too broad of a category. While AMKL is a subtype of AML, it has distinct features that differentiate it from other AML subtypes.</li><li>\u2022 Option B. Acute myeloid leukemia (AML):</li><li>\u2022 Option D. Juvenile myelomonocytic leukemia (JMML): JMML is another myeloid leukemia that can occur in young children, but it is not specifically associated with Down syndrome and usually presents with different bone marrow findings (monocytic proliferation).</li><li>\u2022 Option D. Juvenile myelomonocytic leukemia (JMML):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 AMKL is a specific type of AML associated with Down syndrome and GATA1 mutations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "59d9c967",
      "audio": ""
    },
    {
      "text": "A 60-year-old patient with newly diagnosed multiple myeloma and no significant comorbidities is being evaluated for treatment. Which of the following is the most appropriate initial therapy?",
      "options": [
        {
          "label": "A",
          "text": "Daratumumab monotherapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Corticosteroids (CS) + IMiD (e.g., lenalidomide)",
          "correct": false
        },
        {
          "label": "C",
          "text": "CS + proteasome inhibitor (e.g., bortezomib) + daratumumab",
          "correct": true
        },
        {
          "label": "D",
          "text": "Autologous hematopoietic stem cell transplant (HSCT)",
          "correct": false
        }
      ],
      "correct_answer": "C. CS + proteasome inhibitor (e.g., bortezomib) + daratumumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Daratumumab monotherapy: While daratumumab is a potent anti-CD38 monoclonal antibody with significant efficacy in multiple myeloma, it is not typically used as a single agent in the initial treatment of newly diagnosed patients. It is usually combined with other drugs to achieve a more robust response.</li><li>\u2022 Option A. Daratumumab monotherapy:</li><li>\u2022 Option B. Corticosteroids (CS) + IMiD (e.g., lenalidomide): This combination can be effective, but it is not the standard of care for transplant-eligible patients. Adding a proteasome inhibitor (PI) to this regimen has been shown to improve response rates and survival.</li><li>\u2022 Option</li><li>\u2022 B. Corticosteroids (CS) + IMiD (e.g., lenalidomide):</li><li>\u2022 Option D. Autologous hematopoietic stem cell transplant (HSCT): HSCT is a consolidation therapy option for multiple myeloma patients after initial induction therapy. It is not the first-line treatment, but it is often considered for transplant-eligible patients who achieve a good response to induction therapy.</li><li>\u2022 Option</li><li>\u2022 D. Autologous hematopoietic stem cell transplant (HSCT):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The standard initial therapy for multiple myeloma involves a combination of drugs targeting different pathways to maximize efficacy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d557c9b7",
      "audio": ""
    },
    {
      "text": "A 50-year-old male presents with stage IV CHL, an albumin of 3.5 g/dL, hemoglobin of 9 g/dL, and a WBC count of 16,000/\u00b5L with 500 lymphocytes/\u00b5L. According to the IPS, how many risk factors does he have?",
      "options": [
        {
          "label": "A",
          "text": "2",
          "correct": false
        },
        {
          "label": "B",
          "text": "3",
          "correct": false
        },
        {
          "label": "C",
          "text": "4",
          "correct": true
        },
        {
          "label": "D",
          "text": "5",
          "correct": false
        }
      ],
      "correct_answer": "C. 4",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 4</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "05f88bc7",
      "audio": ""
    },
    {
      "text": "A 15-year-old male presents with a rapidly enlarging jaw mass and systemic B symptoms. Biopsy reveals medium-sized lymphoid cells with a starry sky pattern. Which of the following cytogenetic abnormalities is most likely associated with this lymphoma?",
      "options": [
        {
          "label": "A",
          "text": "t(11;14)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(14;18)",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(8;14)",
          "correct": true
        },
        {
          "label": "D",
          "text": "t(11;18)",
          "correct": false
        }
      ],
      "correct_answer": "C. t(8;14)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) t(8;14)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. t(11;14): This translocation is characteristic of Mantle Cell Lymphoma. It involves the cyclin D1 gene and leads to increased cell cycle progression.</li><li>\u2022 Option</li><li>\u2022 A. t(11;14):</li><li>\u2022 Option B. t(14;18): This translocation is associated with Follicular Lymphoma. It involves the BCL2 gene, which inhibits apoptosis and promotes cell survival.</li><li>\u2022 Option</li><li>\u2022 B. t(14;18):</li><li>\u2022 Option D. t(11;18): This translocation is also associated with Mantle Cell Lymphoma, like option A.</li><li>\u2022 Option</li><li>\u2022 D. t(11;18):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Burkitt lymphoma is a highly aggressive B-cell lymphoma characterized by a specific translocation, t(8;14).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "18c2b32a",
      "audio": ""
    },
    {
      "text": "A 25-year-old female presents with abdominal pain and a palpable mass. Biopsy reveals Burkitt's lymphoma. Which of the following infectious agents is most likely associated with this case?",
      "options": [
        {
          "label": "A",
          "text": "Epstein-Barr virus (EBV)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Human Immunodeficiency Virus (HIV)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hepatitis C virus (HCV)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Helicobacter pylori (H. pylori)",
          "correct": false
        }
      ],
      "correct_answer": "A. Epstein-Barr virus (EBV)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Epstein-Barr virus (EBV)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Human Immunodeficiency Virus (HIV): While HIV infection increases the risk of various lymphomas, including Burkitt's lymphoma, it is not the most common infectious agent directly associated with Burkitt's lymphoma.</li><li>\u2022 Option</li><li>\u2022 B. Human Immunodeficiency Virus (HIV):</li><li>\u2022 Option C. Hepatitis C virus (HCV): HCV is primarily associated with liver disease and certain types of lymphoma, but not Burkitt's lymphoma.</li><li>\u2022 Option</li><li>\u2022 C. Hepatitis C virus (HCV):</li><li>\u2022 Option D. Helicobacter pylori (H. pylori): H. pylori is a bacterium that infects the stomach and is associated with gastric cancer and lymphoma of the stomach (MALT lymphoma), but not Burkitt's lymphoma.</li><li>\u2022 Option</li><li>\u2022 D. Helicobacter pylori (H. pylori):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 EBV plays a significant role in the pathogenesis of Burkitt's lymphoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8f588d40",
      "audio": ""
    },
    {
      "text": "Which genetic abnormality defines double-hit lymphoma (DHL)?",
      "options": [
        {
          "label": "A",
          "text": "t(14;18) with MYC overexpression",
          "correct": false
        },
        {
          "label": "B",
          "text": "MYC translocation with BCL2 or BCL6 rearrangement",
          "correct": true
        },
        {
          "label": "C",
          "text": "BCL2 translocation with BCL6 rearrangement",
          "correct": false
        },
        {
          "label": "D",
          "text": "Trisomy 12 with BCL6 rearrangement",
          "correct": false
        }
      ],
      "correct_answer": "B. MYC translocation with BCL2 or BCL6 rearrangement",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) MYC translocation with BCL2 or BCL6 rearrangement</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. t(14;18) with MYC overexpression: While t(14;18) is associated with BCL2 overexpression and is seen in follicular lymphoma, it alone does not define DHL. DHL requires the additional presence of a MYC translocation.</li><li>\u2022 Option</li><li>\u2022 A. t(14;18) with MYC overexpression:</li><li>\u2022 Option C. BCL2 translocation with BCL6 rearrangement: This combination of rearrangements is not characteristic of DHL. DHL specifically requires a MYC translocation.</li><li>\u2022 Option</li><li>\u2022 C. BCL2 translocation with BCL6 rearrangement:</li><li>\u2022 Option D. Trisomy 12 with BCL6 rearrangement: Trisomy 12 is associated with chronic lymphocytic leukemia (CLL), and while BCL6 rearrangement can occur in various lymphomas, this combination does not define DHL.</li><li>\u2022 Option</li><li>\u2022 D. Trisomy 12 with BCL6 rearrangement:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The combined dysregulation of MYC and BCL2/BCL6 is the defining feature of DHL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f90cd01f",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman presents with painless, slowly enlarging lymph nodes in her neck and axillae. Lymph node biopsy reveals small, cleaved lymphocytes with a follicular pattern. Which of the following genetic abnormalities is most commonly associated with this type of lymphoma?",
      "options": [
        {
          "label": "A",
          "text": "t(8;14)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(11;14)",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(14;18)",
          "correct": true
        },
        {
          "label": "D",
          "text": "t(15;17)",
          "correct": false
        }
      ],
      "correct_answer": "C. t(14;18)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) t(14;18)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. t(8;14): This translocation is characteristic of Burkitt lymphoma. It leads to overexpression of the MYC oncogene, promoting cell growth and proliferation.</li><li>\u2022 Option</li><li>\u2022 A. t(8;14):</li><li>\u2022 Option B. t(11;14): This translocation is associated with mantle cell lymphoma. It leads to overexpression of cyclin D1, which regulates the cell cycle.</li><li>\u2022 Option</li><li>\u2022 B. t(11;14):</li><li>\u2022 Option D. t(15;17): This translocation is associated with acute promyelocytic leukemia (APL). It leads to the fusion of the PML and RARA genes, disrupting normal cell differentiation.</li><li>\u2022 Option</li><li>\u2022 D. t(15;17):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 t(14;18) is a diagnostic feature of FL and contributes to its indolent nature.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7a6a3e35",
      "audio": ""
    },
    {
      "text": "Which of the following chemotherapy regimens is NOT typically used as a first-line treatment for symptomatic follicular lymphoma (FL)?",
      "options": [
        {
          "label": "A",
          "text": "R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)",
          "correct": false
        },
        {
          "label": "B",
          "text": "R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisone)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bendamustine-rituximab (BR)",
          "correct": false
        },
        {
          "label": "D",
          "text": "HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine)",
          "correct": true
        }
      ],
      "correct_answer": "D. HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): This is a widely used and effective first-line treatment for FL. It combines the monoclonal antibody rituximab with a standard chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone).</li><li>\u2022 Option</li><li>\u2022 A. R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone):</li><li>\u2022 Option B. R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisone): This is another commonly used first-line regimen for FL, particularly in older or less fit patients. It is similar to R-CHOP but uses vincristine instead of doxorubicin, which is associated with less cardiotoxicity.</li><li>\u2022 Option</li><li>\u2022 B. R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisone):</li><li>\u2022 Option C. Bendamustine-rituximab (BR): This is a well-tolerated and effective regimen that has gained popularity as a first-line treatment for FL, especially in patients who may not tolerate the anthracycline component of R-CHOP.</li><li>\u2022 Option</li><li>\u2022 C. Bendamustine-rituximab (BR):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 FL is typically treated with less intensive chemotherapy regimens compared to aggressive lymphomas.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "80c3138d",
      "audio": ""
    },
    {
      "text": "A 55-year-old male presents with fatigue, splenomegaly, and pancytopenia. Peripheral blood smear shows \"hairy cells\" with cytoplasmic projections. Which of the following markers is most specific for the diagnosis of hairy cell leukemia (HCL)?",
      "options": [
        {
          "label": "A",
          "text": "CD19",
          "correct": false
        },
        {
          "label": "B",
          "text": "CD20",
          "correct": false
        },
        {
          "label": "C",
          "text": "CD103",
          "correct": true
        },
        {
          "label": "D",
          "text": "CD30",
          "correct": false
        }
      ],
      "correct_answer": "C. CD103",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) CD103</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. CD19: This is a B-cell marker that is expressed in HCL, but it is not specific to HCL. It is also found on other B-cell malignancies.</li><li>\u2022 Option A. CD19:</li><li>\u2022 Option B. CD20: Similar to CD19, this is a B-cell marker present in HCL but not specific to it.</li><li>\u2022 Option B. CD20:</li><li>\u2022 Option D. CD30: This marker is primarily associated with classical Hodgkin lymphoma and anaplastic large cell lymphoma. It is not expressed in HCL.</li><li>\u2022 Option D. CD30:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 CD103 is a key diagnostic marker for hairy cell leukemia</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3097ec5d",
      "audio": ""
    },
    {
      "text": "A 70-year-old man presents with fatigue and mild lymphadenopathy. Blood tests reveal lymphocytosis with smudge cells on peripheral smear. Flow cytometry shows CD5 and CD23 positivity. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute myeloid leukemia (AML)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Mantle cell lymphoma (MCL)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hodgkin lymphoma (HL)",
          "correct": false
        }
      ],
      "correct_answer": "C. Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Acute myeloid leukemia (AML): AML is characterized by the proliferation of immature myeloid cells in the bone marrow and blood. It does not typically present with smudge cells or CD5/CD23 positivity.</li><li>\u2022 Option A. Acute myeloid leukemia (AML):</li><li>\u2022 Option B. Mantle cell lymphoma (MCL): MCL is a type of B-cell lymphoma with a characteristic t(11;14) translocation. While it can present with lymphocytosis, it typically lacks smudge cells and does not express CD23.</li><li>\u2022 Option</li><li>\u2022 B. Mantle cell lymphoma (MCL):</li><li>\u2022 Option D. Hodgkin lymphoma (HL): HL is characterized by the presence of Reed-Sternberg cells, which are large, atypical cells not seen in CLL/SLL. HL typically does not present with smudge cells or a predominantly lymphocytic infiltrate.</li><li>\u2022 Option D. Hodgkin lymphoma (HL):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 CLL/SLL is a B-cell neoplasm characterized by the accumulation of small, mature lymphocytes with specific immunophenotypic markers.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "475145a5",
      "audio": ""
    },
    {
      "text": "Which of the following is a potential adverse effect of venetoclax, a BCL2 inhibitor used in CLL/SLL treatment?",
      "options": [
        {
          "label": "A",
          "text": "Tumor lysis syndrome",
          "correct": true
        },
        {
          "label": "B",
          "text": "Atrial fibrillation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diarrhea",
          "correct": false
        },
        {
          "label": "D",
          "text": "Peripheral neuropathy",
          "correct": false
        }
      ],
      "correct_answer": "A. Tumor lysis syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Tumor lysis syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Atrial fibrillation: While cardiac arrhythmias can be a side effect of some cancer therapies, atrial fibrillation is not a common side effect specifically associated with venetoclax.</li><li>\u2022 Option</li><li>\u2022 B. Atrial fibrillation:</li><li>\u2022 Option C. Diarrhea: Diarrhea is a common side effect of many chemotherapies but is not a characteristic side effect of venetoclax.</li><li>\u2022 Option</li><li>\u2022 C. Diarrhea:</li><li>\u2022 Option D. Peripheral neuropathy: Peripheral neuropathy (damage to peripheral nerves causing numbness, tingling, or pain) can be a side effect of certain chemotherapy agents, but it is not typically associated with venetoclax.</li><li>\u2022 Option</li><li>\u2022 D. Peripheral neuropathy:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Monitoring for and preventing TLS is crucial when initiating venetoclax therapy in CLL/SLL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "37e690ae",
      "audio": ""
    },
    {
      "text": "Which of the following genetic abnormalities is associated with a poor prognosis in CLL/SLL?",
      "options": [
        {
          "label": "A",
          "text": "Del(13q)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Del(17p)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Mutated IgVH genes",
          "correct": false
        },
        {
          "label": "D",
          "text": "Trisomy 12",
          "correct": false
        }
      ],
      "correct_answer": "B. Del(17p)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Del(17p)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Del(13q): This is the most common genetic abnormality in CLL/SLL and is associated with a favorable prognosis. It typically involves deletion of the microRNA genes miR-15a and miR-16-1, which regulate B-cell survival.</li><li>\u2022 Option</li><li>\u2022 A. Del(13q):</li><li>\u2022 Option C. Mutated IgVH genes: CLL/SLL cases with mutated IgVH genes generally have a more indolent course and better prognosis compared to those with unmutated IgVH genes.</li><li>\u2022 Option</li><li>\u2022 C. Mutated IgVH genes:</li><li>\u2022 Option D. Trisomy 12: This is an intermediate-risk genetic abnormality in CLL/SLL, with a prognosis between that of del(13q) and del(17p). It can be associated with atypical morphology and increased proliferative activity.</li><li>\u2022 Option</li><li>\u2022 D. Trisomy 12:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 del(17p) is a high-risk genetic abnormality in CLL/SLL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "df2759cf",
      "audio": ""
    },
    {
      "text": "Which of the following is a potential advantage of targeted therapies like BTK inhibitors or BCL2 inhibitors over traditional chemotherapy in CLL/SLL treatment?",
      "options": [
        {
          "label": "A",
          "text": "Lower risk of infection",
          "correct": false
        },
        {
          "label": "B",
          "text": "Improved tolerability",
          "correct": false
        },
        {
          "label": "C",
          "text": "Higher response rates in certain patient subgroups",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All of the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All of the above</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "09a9886e",
      "audio": ""
    },
    {
      "text": "A 45-year-old man from Japan presents with hypercalcemia, lytic bone lesions, and skin rash. Peripheral blood smear reveals atypical lymphocytes with \"cloverleaf\" nuclei. Which of the following viruses is most likely associated with this clinical presentation?",
      "options": [
        {
          "label": "A",
          "text": "Epstein-Barr virus (EBV)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Human T-lymphotropic virus type 1 (HTLV-1)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Human immunodeficiency virus (HIV)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cytomegalovirus (CMV)",
          "correct": false
        }
      ],
      "correct_answer": "B. Human T-lymphotropic virus type 1 (HTLV-1)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Human T-lymphotropic virus type 1 (HTLV-1)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Epstein-Barr virus (EBV): EBV is associated with other lymphoid malignancies, such as Burkitt lymphoma and Hodgkin lymphoma, but not typically with ATLL.</li><li>\u2022 Option</li><li>\u2022 A. Epstein-Barr virus (EBV):</li><li>\u2022 Option C. Human immunodeficiency virus (HIV): While HIV increases the risk of various malignancies, including lymphomas, it is not the primary cause of ATLL.</li><li>\u2022 Option</li><li>\u2022 C. Human immunodeficiency virus (HIV):</li><li>\u2022 Option D. Cytomegalovirus (CMV): CMV is a common virus that usually causes mild or asymptomatic infections. It is not linked to the development of ATLL.</li><li>\u2022 Option</li><li>\u2022 D. Cytomegalovirus (CMV):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 HTLV-1 infection is a crucial risk factor for ATLL, particularly in endemic regions like Japan and the Caribbean.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e18cc40e",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman with a history of breast implants presents with a rapidly enlarging axillary lymph node. Excisional biopsy reveals large atypical cells with horseshoe-shaped nuclei and abundant cytoplasm. Immunohistochemical staining shows strong expression of CD30. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Hodgkin lymphoma (HL)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Diffuse large B-cell lymphoma (DLBCL)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anaplastic large cell lymphoma (ALCL)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)",
          "correct": false
        }
      ],
      "correct_answer": "C. Anaplastic large cell lymphoma (ALCL)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Anaplastic large cell lymphoma (ALCL)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Hodgkin lymphoma (HL): While HL can express CD30, it lacks the characteristic hallmark cells with horseshoe-shaped nuclei seen in ALCL. RS cells are usually larger and have a bilobed or multi-lobed nucleus.</li><li>\u2022 Option</li><li>\u2022 A. Hodgkin lymphoma (HL):</li><li>\u2022 Option B. Diffuse large B-cell lymphoma (DLBCL): DLBCL is a B-cell lymphoma and would not express CD30. The cells in DLBCL are also not typically described as having horseshoe-shaped nuclei.</li><li>\u2022 Option</li><li>\u2022 B. Diffuse large B-cell lymphoma (DLBCL):</li><li>\u2022 Option D. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS): PTCL-NOS is a heterogeneous group of T-cell lymphomas. While it can share some features with ALCL, it does not have the specific hallmark cells or the same association with breast implants.</li><li>\u2022 Option</li><li>\u2022 D. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 ALCL is a T-cell lymphoma characterized by large atypical cells, CD30 expression, and potential association with breast implants.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1415a12f",
      "audio": ""
    },
    {
      "text": "A 70-year-old man with a history of monoclonal gammopathy of undetermined significance (MGUS) presents with new-onset renal insufficiency. Which of the following is the most likely mechanism underlying his renal dysfunction?",
      "options": [
        {
          "label": "A",
          "text": "Glomerulonephritis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tubulointerstitial nephritis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Light chain cast nephropathy",
          "correct": true
        },
        {
          "label": "D",
          "text": "Obstructive uropathy",
          "correct": false
        }
      ],
      "correct_answer": "C. Light chain cast nephropathy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Light chain cast nephropathy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Glomerulonephritis: Glomerulonephritis is an inflammation of the glomeruli, the tiny filters in the kidneys. While it can cause renal insufficiency, it's not the most common mechanism in patients with MM or MGUS.</li><li>\u2022 Option</li><li>\u2022 A. Glomerulonephritis:</li><li>\u2022 Option B. Tubulointerstitial nephritis: This condition involves inflammation of the tubules and the surrounding tissue in the kidneys. It can be caused by medications or infections but is less likely in the context of MGUS progressing to MM.</li><li>\u2022 Option</li><li>\u2022 B. Tubulointerstitial nephritis:</li><li>\u2022 Option D. Obstructive uropathy: This refers to a blockage of the urinary tract, which can lead to kidney damage. While it's possible, it's less likely to be the primary cause of renal insufficiency in a patient with MM or MGUS.</li><li>\u2022 Option</li><li>\u2022 D. Obstructive uropathy:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The progression of MGUS to multiple myeloma often leads to the production of excess light chains, which can cause kidney damage through light chain cast nephropathy. It's a crucial consideration in the management of these patients.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9483349b",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a component of the SLIM criteria?",
      "options": [
        {
          "label": "A",
          "text": ">60% clonal bone marrow plasma cells",
          "correct": false
        },
        {
          "label": "B",
          "text": "Involved SFLC \u2265100 mg/L",
          "correct": false
        },
        {
          "label": "C",
          "text": "\u22652 focal lesions (>5mm) on whole-body MRI",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serum creatinine >2 mg/dL",
          "correct": true
        }
      ],
      "correct_answer": "D. Serum creatinine >2 mg/dL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Serum creatinine >2 mg/dL</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ed0763ad",
      "audio": ""
    },
    {
      "text": "Which of the following bone marrow plasma cell (BMPC) percentages would NOT meet the criteria for myeloma-defining events (MDE)?",
      "options": [
        {
          "label": "A",
          "text": "15%",
          "correct": true
        },
        {
          "label": "B",
          "text": "65%",
          "correct": false
        },
        {
          "label": "C",
          "text": "72%",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. 15%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 15%</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e3930bf1",
      "audio": ""
    },
    {
      "text": "A 62-year-old male presents with a 3-month history of worsening fatigue, back pain, and unintentional weight loss. On examination, he is pale and has point tenderness over the lumbar spine. Laboratory findings reveal anemia, hypercalcemia, and elevated creatinine. A skeletal survey shows multiple lytic lesions in the spine and pelvis. Serum electrophoresis was done and the image is shown below. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Monoclonal gammopathy of undetermined significance (MGUS)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Smoldering multiple myeloma (SMM)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Multiple myeloma (MM)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Waldenstr\u00f6m macroglobulinemia (WM)",
          "correct": false
        }
      ],
      "correct_answer": "C. Multiple myeloma (MM)",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/02/screenshot-2024-08-02-104412.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Multiple myeloma (MM)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Monoclonal gammopathy of undetermined significance (MGUS): MGUS is a benign condition where a small amount of monoclonal protein (M-protein) is present in the blood, but there are no symptoms or signs of end-organ damage (CRAB criteria). The patient in this scenario clearly has CRAB criteria, ruling out MGUS.</li><li>\u2022 Option</li><li>\u2022 A. Monoclonal gammopathy of undetermined significance (MGUS):</li><li>\u2022 Option B. Smoldering multiple myeloma (SMM): SMM is a precursor to multiple myeloma and is characterized by a higher level of M-protein or bone marrow plasma cells than MGUS, but still no CRAB criteria. This patient's presentation with anemia, hypercalcemia, and renal insufficiency indicates organ damage, making SMM less likely.</li><li>\u2022 Option</li><li>\u2022 B. Smoldering multiple myeloma (SMM):</li><li>\u2022 Option D. Waldenstr\u00f6m macroglobulinemia (WM): WM is a type of lymphoma where malignant B cells produce excessive IgM antibodies. While it can present with some similar features to multiple myeloma (like fatigue and anemia), it typically doesn't cause bone pain, hypercalcemia, or lytic bone lesions.</li><li>\u2022 Option</li><li>\u2022 D. Waldenstr\u00f6m macroglobulinemia (WM):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Multiple myeloma is a plasma cell malignancy that can present with various symptoms, including bone pain, anemia, renal insufficiency, and hypercalcemia. The presence of CRAB criteria, along with lytic bone lesions and monoclonal protein in the serum or urine, are key diagnostic features.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "001851e8",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman presents with painless cervical lymphadenopathy and pruritus. Excisional biopsy of a lymph node reveals Reed-Sternberg (RS) cells positive for CD15 and CD30. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Classical Hodgkin Lymphoma (CHL)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diffuse large B-cell lymphoma (DLBCL)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Follicular lymphoma (FL)",
          "correct": false
        }
      ],
      "correct_answer": "A. Classical Hodgkin Lymphoma (CHL)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Classical Hodgkin Lymphoma (CHL)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) : This subtype is characterized by \"popcorn\" cells, which are negative for CD15 and CD30.</li><li>\u2022 Option B. Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)</li><li>\u2022 Option C. Diffuse large B-cell lymphoma (DLBCL) and Option D. Follicular lymphoma (FL) : These are non-Hodgkin lymphomas with different histopathological features.</li><li>\u2022 Option C. Diffuse large B-cell lymphoma (DLBCL)</li><li>\u2022 Option D. Follicular lymphoma (FL)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 CHL is diagnosed based on the presence of classic RS cells positive for CD15 and CD30.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d0588df5",
      "audio": ""
    },
    {
      "text": "Which of the following markers is typically positive in NLPHL but negative in CHL?",
      "options": [
        {
          "label": "A",
          "text": "CD15",
          "correct": false
        },
        {
          "label": "B",
          "text": "CD20",
          "correct": true
        },
        {
          "label": "C",
          "text": "CD30",
          "correct": false
        },
        {
          "label": "D",
          "text": "CD45",
          "correct": false
        }
      ],
      "correct_answer": "B. CD20",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) CD20</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. CD15: This marker is often positive in CHL, particularly in the Reed-Sternberg cells. It may be positive in NLPHL but is not a defining characteristic.</li><li>\u2022 Option A.</li><li>\u2022 CD15:</li><li>\u2022 Option C. CD30: This marker is typically positive in CHL, especially in the Reed-Sternberg cells. It is usually negative in NLPHL.</li><li>\u2022 Option C.</li><li>\u2022 CD30:</li><li>\u2022 Option D. CD45: This marker is a general leukocyte marker and is expressed in both CHL and NLPHL, but it is not helpful in differentiating between the two.</li><li>\u2022 Option D.</li><li>\u2022 CD45:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 CD20 expression can help differentiate between CHL and NLPHL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d3042ecf",
      "audio": ""
    },
    {
      "text": "A 65-year-old male presents with a rapidly enlarging cervical lymph node and complains of fatigue, night sweats, and unintentional weight loss. A lymph node biopsy confirms the diagnosis of diffuse large B-cell lymphoma (DLBCL). Which of the following treatment regimens is the most appropriate initial therapy for this patient?",
      "options": [
        {
          "label": "A",
          "text": "R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)",
          "correct": true
        },
        {
          "label": "B",
          "text": "R-EPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin)",
          "correct": false
        },
        {
          "label": "C",
          "text": "HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Radiotherapy alone",
          "correct": false
        }
      ],
      "correct_answer": "A. R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. R-EPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin): This is a more intensive regimen typically reserved for younger patients with high-risk disease or certain subtypes of DLBCL. It may not be suitable Option for older patients due to increased toxicity.</li><li>\u2022 Option B.</li><li>\u2022 R-EPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin):</li><li>\u2022 Option</li><li>\u2022 Option C. HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine): This is another intensive regimen often used in specific subtypes of aggressive lymphoma or for relapsed/refractory disease. It is not the standard first-line treatment for DLBCL.</li><li>\u2022 Option C. HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine):</li><li>\u2022 Option D. Radiotherapy alone: While radiotherapy may be used in certain situations (e.g., localized disease), it is not sufficient as the sole treatment for most cases of DLBCL.</li><li>\u2022 Option D.</li><li>\u2022 Radiotherapy alone:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 R-CHOP is the standard first-line treatment for most newly diagnosed patients with DLBCL, including the elderly.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0d570b2c",
      "audio": ""
    },
    {
      "text": "A 60-year-old male presents with abdominal discomfort, fatigue, and weight loss. Endoscopy reveals multiple gastric ulcers. Biopsy shows small to medium-sized lymphoid cells with CD5 expression but lacking CD23. Which of the following cytogenetic abnormalities is most characteristic of this lymphoma?",
      "options": [
        {
          "label": "A",
          "text": "t(14;18)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(8;14)",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(11;14)",
          "correct": true
        },
        {
          "label": "D",
          "text": "t(15;17)",
          "correct": false
        }
      ],
      "correct_answer": "C. t(11;14)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) t(11;14)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. t(14;18): This translocation is characteristic of follicular lymphoma, not mantle cell lymphoma. It involves the BCL2 gene, which inhibits apoptosis.</li><li>\u2022 Option A. t(14;18):</li><li>\u2022 Option B. t(8;14): This translocation is the hallmark of Burkitt lymphoma. It leads to overexpression of the MYC oncogene, which promotes cell growth and proliferation.</li><li>\u2022 Option</li><li>\u2022 B. t(8;14):</li><li>\u2022 Option D. t(15;17): This translocation is associated with acute promyelocytic leukemia (APL), a type of acute myeloid leukemia. It involves the PML and RARA genes.</li><li>\u2022 Option</li><li>\u2022 D. t(15;17):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 t(11;14) is a diagnostic feature of MCL and is associated with cyclin D1 overexpression.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "31b907e3",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a standard treatment option for mantle cell lymphoma (MCL)?",
      "options": [
        {
          "label": "A",
          "text": "R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bendamustine-rituximab (BR)",
          "correct": false
        },
        {
          "label": "C",
          "text": "HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone alternating with Methotrexate and Cytarabine)",
          "correct": false
        },
        {
          "label": "D",
          "text": "ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)",
          "correct": true
        }
      ],
      "correct_answer": "D. ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "574e1247",
      "audio": ""
    },
    {
      "text": "Which of the following genetic abnormalities is most frequently associated with extranodal marginal zone lymphoma (ENMZL) of mucosa-associated lymphoid tissue (MALT)?",
      "options": [
        {
          "label": "A",
          "text": "t(8;14)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(11;18)",
          "correct": true
        },
        {
          "label": "C",
          "text": "t(14;18)",
          "correct": false
        },
        {
          "label": "D",
          "text": "t(11;14)",
          "correct": false
        }
      ],
      "correct_answer": "B. t(11;18)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) t(11;18)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. t(8;14): This translocation is the hallmark of Burkitt lymphoma, a highly aggressive B-cell lymphoma. It leads to the overexpression of the MYC oncogene.</li><li>\u2022 Option</li><li>\u2022 A. t(8;14):</li><li>\u2022 Option C. t(14;18): This translocation is characteristic of follicular lymphoma, another type of B-cell lymphoma. It involves the BCL2 gene, which inhibits apoptosis.</li><li>\u2022 Option C. t(14;18):</li><li>\u2022 Option D. t(11;14): This translocation is the hallmark of mantle cell lymphoma, a type of B-cell lymphoma. It leads to overexpression of cyclin D1, promoting cell cycle progression.</li><li>\u2022 Option D. t(11;14):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The t(11;18) translocation is a characteristic feature of MALT lymphoma and can guide treatment decisions, as cases with this translocation may not respond to H. pylori eradication alone.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3cbcdc6d",
      "audio": ""
    },
    {
      "text": "Which of the following infectious agents is most commonly associated with gastric MALT lymphoma?",
      "options": [
        {
          "label": "A",
          "text": "Epstein-Barr Virus (EBV)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Helicobacter pylori",
          "correct": true
        },
        {
          "label": "C",
          "text": "Chlamydia psittaci",
          "correct": false
        },
        {
          "label": "D",
          "text": "Borrelia burgdorferi",
          "correct": false
        }
      ],
      "correct_answer": "B. Helicobacter pylori",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Helicobacter pylori</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Epstein-Barr Virus (EBV): EBV is associated with several types of lymphomas, including Burkitt lymphoma and Hodgkin lymphoma, but not typically with gastric MALT lymphoma.</li><li>\u2022 Option</li><li>\u2022 A. Epstein-Barr Virus (EBV):</li><li>\u2022 Option C. Chlamydia psittaci: This bacterium is associated with psittacosis (parrot fever) and can sometimes cause conjunctivitis. It is not linked to the development of gastric MALT lymphoma.</li><li>\u2022 Option C. Chlamydia psittaci:</li><li>\u2022 Option D. Borrelia burgdorferi: This bacterium is the causative agent of Lyme disease and is sometimes associated with cutaneous (skin) MALT lymphoma, but not gastric MALT lymphoma.</li><li>\u2022 Option D. Borrelia burgdorferi:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 H. pylori infection is a significant risk factor for developing gastric MALT lymphoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "15cecc8b",
      "audio": ""
    },
    {
      "text": "Which of the following laboratory findings is characteristic of hairy cell leukemia (HCL)?",
      "options": [
        {
          "label": "A",
          "text": "Positive tartrate-resistant acid phosphatase (TRAP) stain",
          "correct": true
        },
        {
          "label": "B",
          "text": "Positive myeloperoxidase (MPO) stain",
          "correct": false
        },
        {
          "label": "C",
          "text": "Increased serum uric acid levels",
          "correct": false
        },
        {
          "label": "D",
          "text": "BCR-ABL1 fusion gene",
          "correct": false
        }
      ],
      "correct_answer": "A. Positive tartrate-resistant acid phosphatase (TRAP) stain",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Positive tartrate-resistant acid phosphatase (TRAP) stain</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Positive myeloperoxidase (MPO) stain: MPO is an enzyme found in myeloid cells (neutrophils, eosinophils, and monocytes) and is used to diagnose myeloid leukemias. It is not typically positive in HCL.</li><li>\u2022 Option</li><li>\u2022 B. Positive myeloperoxidase (MPO) stain:</li><li>\u2022 Option C. Increased serum uric acid levels: While elevated uric acid levels can be seen in various hematologic malignancies due to increased cell turnover, it is not a specific finding for HCL.</li><li>\u2022 Option</li><li>\u2022 C. Increased serum uric acid levels:</li><li>\u2022 Option D. BCR-ABL1 fusion gene: This genetic abnormality is the hallmark of chronic myeloid leukemia (CML) and is not associated with HCL.</li><li>\u2022 Option</li><li>\u2022 D. BCR-ABL1 fusion gene:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 A positive TRAP stain is a useful diagnostic clue for hairy cell leukemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f96f3ba5",
      "audio": ""
    },
    {
      "text": "A 55-year-old man presents with a persistent itchy, scaly rash on his trunk that has progressed over several months. Skin biopsy reveals epidermotropic lymphoid infiltrates with haloed lymphocytes. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Psoriasis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Atopic dermatitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mycosis fungoides (MF)",
          "correct": true
        },
        {
          "label": "D",
          "text": "S\u00e9zary syndrome",
          "correct": false
        }
      ],
      "correct_answer": "C. Mycosis fungoides (MF)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Mycosis fungoides (MF)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Psoriasis: Psoriasis can present with scaly plaques, but it usually has a well-demarcated border and lacks the characteristic epidermotropic lymphoid infiltrate with haloed lymphocytes seen in MF.</li><li>\u2022 Option A. Psoriasis:</li><li>\u2022 Option B. Atopic dermatitis: Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and scaly rashes. However, it does not typically present with epidermotropic lymphoid infiltrates or haloed lymphocytes.</li><li>\u2022 Option</li><li>\u2022 B. Atopic dermatitis:</li><li>\u2022 Option D. S\u00e9zary syndrome: S\u00e9zary syndrome is an advanced form of cutaneous T-cell lymphoma (CTCL) characterized by erythroderma (widespread redness of the skin), circulating atypical T cells (S\u00e9zary cells), and generalized lymphadenopathy. While it can present with similar skin findings to MF, the widespread involvement and presence of S\u00e9zary cells in the blood distinguish it from early-stage MF.</li><li>\u2022 Option</li><li>\u2022 D. S\u00e9zary syndrome:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 MF is the most common type of cutaneous T-cell lymphoma (CTCL) and presents with a variety of skin manifestations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "be7dc88c",
      "audio": ""
    },
    {
      "text": "A 60-year-old man presents with generalized erythroderma (redness of the skin), intense pruritus, and lymphadenopathy. Peripheral blood smear reveals atypical lymphocytes with cerebriform nuclei. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Atopic dermatitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Psoriasis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mycosis fungoides (MF)",
          "correct": false
        },
        {
          "label": "D",
          "text": "S\u00e9zary syndrome (SS)",
          "correct": true
        }
      ],
      "correct_answer": "D. S\u00e9zary syndrome (SS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) S\u00e9zary syndrome (SS)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Atopic dermatitis: While atopic dermatitis can cause itchy skin, it usually presents with localized patches of dry, scaly skin and does not typically cause erythroderma or lymphadenopathy. It also doesn't have the characteristic cerebriform nuclei seen in SS.</li><li>\u2022 Option</li><li>\u2022 A. Atopic dermatitis:</li><li>\u2022 Option B. Psoriasis: Psoriasis can also cause itchy, scaly skin, but the plaques are usually well-demarcated and silvery. It does not typically progress to erythroderma or involve lymph nodes. Again, the cerebriform nuclei are not a feature of psoriasis.</li><li>\u2022 Option</li><li>\u2022 B. Psoriasis:</li><li>\u2022 Option C. Mycosis fungoides (MF): MF is another type of CTCL and can share some skin features with SS. However, it usually progresses more slowly and doesn't always present with erythroderma. In the early stages of MF, the atypical lymphocytes are typically confined to the skin, not circulating in the blood.</li><li>\u2022 Option</li><li>\u2022 C. Mycosis fungoides (MF):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 SS is characterized by erythroderma, circulating S\u00e9zary cells, and lymphadenopathy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f65ba2f3",
      "audio": ""
    },
    {
      "text": "A 65-year-old asymptomatic man undergoes routine blood tests, which reveal a serum M-protein level of 2.5 g/dL. Urine protein electrophoresis is negative. Bone marrow biopsy shows <10% clonal plasma cells. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Multiple Myeloma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Waldenstr\u00f6m macroglobulinemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Monoclonal gammopathy of undetermined significance (MGUS)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Smoldering multiple myeloma",
          "correct": false
        }
      ],
      "correct_answer": "C. Monoclonal gammopathy of undetermined significance (MGUS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Monoclonal gammopathy of undetermined significance (MGUS)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Multiple Myeloma: Multiple myeloma would present with a higher M-protein level, a greater percentage of plasma cells in the bone marrow, and evidence of end-organ damage.</li><li>\u2022 Option</li><li>\u2022 A. Multiple Myeloma:</li><li>\u2022 Option B. Waldenstr\u00f6m macroglobulinemia: This is characterized by the overproduction of IgM antibodies, resulting in a high serum M-protein level. It also often presents with symptoms like hyperviscosity syndrome.</li><li>\u2022 Option</li><li>\u2022 B. Waldenstr\u00f6m macroglobulinemia:</li><li>\u2022 Option D. Smoldering multiple myeloma: This is a precursor to multiple myeloma with a higher M-protein level (>3 g/dL) and/or bone marrow plasma cells (10-60%) but no end-organ damage.</li><li>\u2022 Option</li><li>\u2022 D. Smoldering multiple myeloma:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 MGUS is a common, premalignant condition that requires monitoring for progression to multiple myeloma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b5fe9a48",
      "audio": ""
    },
    {
      "text": "What is the approximate annual risk of progression of SMM to multiple myeloma?",
      "options": [
        {
          "label": "A",
          "text": "1%",
          "correct": false
        },
        {
          "label": "B",
          "text": "10%",
          "correct": true
        },
        {
          "label": "C",
          "text": "25%",
          "correct": false
        },
        {
          "label": "D",
          "text": "50%",
          "correct": false
        }
      ],
      "correct_answer": "B. 10%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 10%</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2ed289a3",
      "audio": ""
    },
    {
      "text": "A 68-year-old man presents with fatigue, bone pain, and elevated serum creatinine. Serum protein electrophoresis reveals an M-spike, and bone marrow biopsy shows 30% plasma cells. Skeletal survey reveals multiple lytic lesions. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Monoclonal gammopathy of undetermined significance (MGUS)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Smoldering multiple myeloma (SMM)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Multiple myeloma (MM)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Waldenstr\u00f6m's macroglobulinemia (WM)",
          "correct": false
        }
      ],
      "correct_answer": "C. Multiple myeloma (MM)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Multiple myeloma (MM)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Monoclonal gammopathy of undetermined significance (MGUS): MGUS is a benign condition characterized by a small M-spike and low levels of plasma cells in the bone marrow (<10%). Crucially, MGUS patients do not have end-organ damage (CRAB criteria).</li><li>\u2022 Option</li><li>\u2022 A. Monoclonal gammopathy of undetermined significance (MGUS):</li><li>\u2022 Option B. Smoldering multiple myeloma (SMM): SMM is an intermediate stage between MGUS and multiple myeloma. While it has a higher risk of progression to myeloma, SMM patients typically lack the CRAB criteria that define multiple myeloma.</li><li>\u2022 Option</li><li>\u2022 B. Smoldering multiple myeloma (SMM):</li><li>\u2022 Option D. Waldenstr\u00f6m's macroglobulinemia (WM): WM is a type of lymphoma characterized by the overproduction of IgM antibodies. While it can share some features with multiple myeloma (like an M-spike), the clinical presentation and bone marrow findings are different. WM typically does not cause lytic bone lesions.</li><li>\u2022 Option</li><li>\u2022 D. Waldenstr\u00f6m's macroglobulinemia (WM):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Multiple myeloma is characterized by the presence of CRAB criteria, which distinguish it from MGUS and SMM.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b07436c0",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a type of chimeric antigen receptor (CAR) T-cell therapy approved for multiple myeloma?",
      "options": [
        {
          "label": "A",
          "text": "Cilta-cel",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ide-cel",
          "correct": false
        },
        {
          "label": "C",
          "text": "Abecma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Brexucabtagene autoleucel (Tecartus)",
          "correct": true
        }
      ],
      "correct_answer": "D. Brexucabtagene autoleucel (Tecartus)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Brexucabtagene autoleucel (Tecartus)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Cilta-cel (Carvykti): This CAR T-cell therapy targets the B-cell maturation antigen (BCMA) on myeloma cells. It is FDA-approved for adult patients with relapsed or refractory multiple myeloma after at least four prior lines of therapy.</li><li>\u2022 Option</li><li>\u2022 A. Cilta-cel (Carvykti):</li><li>\u2022 Option B. Ide-cel (Abecma): This is another BCMA-directed CAR T-cell therapy approved for adult patients with relapsed or refractory multiple myeloma after at least four prior lines of therapy. It was the first CAR T-cell therapy approved for myeloma.</li><li>\u2022 Option</li><li>\u2022 B. Ide-cel (Abecma):</li><li>\u2022 Option C. Abecma: This is the same therapy as Ide-cel.</li><li>\u2022 Option</li><li>\u2022 C. Abecma:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 CAR T-cell therapy is a promising new treatment option for relapsed/refractory multiple myeloma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fd7152fc",
      "audio": ""
    },
    {
      "text": "A 65-year-old patient with newly diagnosed multiple myeloma has a serum \u03b22-microglobulin (\u03b22m) level of 2.8 mg/L and serum albumin of 3.8 g/dL. Based on the ISS, what is this patient's stage?",
      "options": [
        {
          "label": "A",
          "text": "Stage I",
          "correct": true
        },
        {
          "label": "B",
          "text": "Stage II",
          "correct": false
        },
        {
          "label": "C",
          "text": "Stage III",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. Stage I",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Stage I</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1a97d731",
      "audio": ""
    },
    {
      "text": "A patient with newly diagnosed multiple myeloma has a bone marrow biopsy revealing a t(14;16) translocation. Which of the following statements is true regarding this patient's prognosis?",
      "options": [
        {
          "label": "A",
          "text": "The patient has standard-risk myeloma and a good prognosis.",
          "correct": false
        },
        {
          "label": "B",
          "text": "The patient has high-risk myeloma and a poor prognosis.",
          "correct": true
        },
        {
          "label": "C",
          "text": "The t(14;16) translocation is not a significant prognostic factor in multiple myeloma.",
          "correct": false
        },
        {
          "label": "D",
          "text": "The patient requires immediate allogeneic stem cell transplantation.",
          "correct": false
        }
      ],
      "correct_answer": "B. The patient has high-risk myeloma and a poor prognosis.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) The patient has high-risk myeloma and a poor prognosis.</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d5e06815",
      "audio": ""
    },
    {
      "text": "A 75-year-old male presents with fatigue, weight loss, and blurred vision. Laboratory findings show elevated IgM levels and anemia. Bone marrow biopsy reveals lymphoid cells with plasmacytic differentiation. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Multiple Myeloma (MM)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Waldenstr\u00f6m Macroglobulinemia (WM)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Monoclonal Gammopathy of Undetermined Significance (MGUS)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Smoldering Multiple Myeloma (SMM)",
          "correct": false
        }
      ],
      "correct_answer": "B. Waldenstr\u00f6m Macroglobulinemia (WM)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Waldenstr\u00f6m Macroglobulinemia (WM)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Multiple Myeloma (MM): While MM can cause fatigue, weight loss, and anemia, it is less likely in this case due to the absence of lytic bone lesions (holes in the bones) and hypercalcemia (high calcium levels). MM also typically presents with elevated IgG or IgA, not IgM.</li><li>\u2022 Option</li><li>\u2022 A. Multiple Myeloma (MM):</li><li>\u2022 Option C. Monoclonal Gammopathy of Undetermined Significance (MGUS): MGUS is a benign condition where a small amount of monoclonal protein is present in the blood. It usually doesn't cause symptoms and wouldn't explain the patient's fatigue, weight loss, blurred vision, or anemia.</li><li>\u2022 Option C. Monoclonal Gammopathy of Undetermined Significance (MGUS):</li><li>\u2022 Option D. Smoldering Multiple Myeloma (SMM): SMM is a precursor to multiple myeloma. While it shares some similarities with MM, it typically doesn't cause symptoms or organ damage. This patient's presentation with fatigue, weight loss, and blurred vision suggests a more active disease process than SMM.</li><li>\u2022 Option</li><li>\u2022 D. Smoldering Multiple Myeloma (SMM):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 WM often presents with hyperviscosity symptoms and bone marrow infiltration by lymphoplasmacytic cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3c15e57b",
      "audio": ""
    },
    {
      "text": "A patient diagnosed with WM presents with tingling and numbness in their extremities. Which of the following autoantibodies is most likely associated with this finding?",
      "options": [
        {
          "label": "A",
          "text": "Cold agglutinins",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-MAG antibodies",
          "correct": true
        },
        {
          "label": "C",
          "text": "Anti-cardiolipin antibodies",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti-nuclear antibodies (ANA)",
          "correct": false
        }
      ],
      "correct_answer": "B. Anti-MAG antibodies",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Anti-MAG antibodies</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Cold agglutinins: These antibodies are associated with cold agglutinin disease (CAD), a type of autoimmune hemolytic anemia. While CAD can occur in WM, it typically presents with symptoms of anemia like fatigue and shortness of breath, not peripheral neuropathy.</li><li>\u2022 Option</li><li>\u2022 A. Cold agglutinins:</li><li>\u2022 Option C. Anti-cardiolipin antibodies: These antibodies are associated with antiphospholipid syndrome, an autoimmune disorder that can cause blood clots. They are not typically associated with peripheral neuropathy.</li><li>\u2022 Option</li><li>\u2022 C. Anti-cardiolipin antibodies:</li><li>\u2022 Option D. Anti-nuclear antibodies (ANA): ANAs are a group of antibodies that target components of the cell nucleus. They are commonly seen in systemic lupus erythematosus (SLE) and other autoimmune diseases, but not typically in WM-associated neuropathy.</li><li>\u2022 Option</li><li>\u2022 D. Anti-nuclear antibodies (ANA):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Peripheral neuropathy in WM is often associated with anti-MAG antibodies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5e8ce43c",
      "audio": ""
    },
    {
      "text": "A patient with acute myeloid leukemia (AML) in first remission is being evaluated for stem cell transplantation. Which of the following types of transplant is most likely to offer a graft-versus-tumor (GVT) effect?",
      "options": [
        {
          "label": "A",
          "text": "Autologous stem cell transplant (ASCT)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Allogeneic stem cell transplant (allo-SCT) from a matched related donor (MRD)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Allogeneic stem cell transplant (allo-SCT) from an unrelated donor (MUD)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allogeneic stem cell transplant (allo-SCT) from umbilical cord blood (UCB)",
          "correct": false
        }
      ],
      "correct_answer": "B. Allogeneic stem cell transplant (allo-SCT) from a matched related donor (MRD)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Allogeneic stem cell transplant (allo-SCT) from a matched related donor (MRD)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Autologous stem cell transplant (ASCT): In ASCT, the patient receives their own stem cells, which have been previously collected and stored. Since the immune system recognizes these cells as \"self,\" there is no GVT effect. ASCT is mainly used to allow for higher doses of chemotherapy.</li><li>\u2022 Option</li><li>\u2022 A. Autologous stem cell transplant (ASCT):</li><li>\u2022 Option C. Allogeneic stem cell transplant (allo-SCT) from an unrelated donor (MUD): While MUD allo-SCT can also elicit a GVT effect, the risk of graft-versus-host disease (GVHD) is higher than with MRD transplants due to increased immunological disparity. GVHD is a serious complication where the donor's immune cells attack the recipient's tissues.</li><li>\u2022 Option</li><li>\u2022 C. Allogeneic stem cell transplant (allo-SCT) from an unrelated donor (MUD):</li><li>\u2022 Option D. Allogeneic stem cell transplant (allo-SCT) from umbilical cord blood (UCB): UCB transplants also have a GVT effect, but they are often associated with slower engraftment and a higher risk of infection compared to MRD or MUD transplants.</li><li>\u2022 Option</li><li>\u2022 D. Allogeneic stem cell transplant (allo-SCT) from umbilical cord blood (UCB):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Allo-SCT offers the advantage of a GVT effect, but also carries a higher risk of graft-versus-host disease (GVHD).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "97346bf0",
      "audio": ""
    },
    {
      "text": "A patient undergoing allogeneic stem cell transplantation (allo-SCT) develops a maculopapular rash, diarrhea, and elevated liver enzymes. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Acute graft-versus-host disease (GVHD)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Chronic graft-versus-host disease (GVHD)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cytomegalovirus (CMV) reactivation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Engraftment syndrome",
          "correct": false
        }
      ],
      "correct_answer": "A. Acute graft-versus-host disease (GVHD)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Acute graft-versus-host disease (GVHD)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Chronic graft-versus-host disease (GVHD): While chronic GVHD can also affect the skin, gastrointestinal tract, and liver, it typically develops later after transplantation (months to years), and presents with different manifestations like skin thickening, dry eyes/mouth, and lung problems.</li><li>\u2022 Option</li><li>\u2022 B. Chronic graft-versus-host disease (GVHD):</li><li>\u2022 Option C. Cytomegalovirus (CMV) reactivation: CMV reactivation is a common complication of allo-SCT, but it typically presents with fever, fatigue, and less specific gastrointestinal symptoms. It doesn't usually cause the characteristic skin rash seen in GVHD.</li><li>\u2022 Option</li><li>\u2022 C. Cytomegalovirus (CMV) reactivation:</li><li>\u2022 Option D. Engraftment syndrome: This is a non-infectious inflammatory syndrome that can occur shortly after transplant. It may present with fever, rash, and pulmonary edema, but it usually lacks the specific gastrointestinal symptoms of GVHD.</li><li>\u2022 Option</li><li>\u2022 D. Engraftment syndrome:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Acute GVHD is a serious complication of allo-SCT and requires prompt diagnosis and treatment.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4a06e46f",
      "audio": ""
    }
  ]
}